Retrieve available abstracts of 1174 articles: HTML format
Single Articles
July 2025
STOUTEN V, Van Evercooren I, Vernemmen C, Braeye T, et al Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023.
Vaccine. 2025;60:127290. PubMedAbstract available
ANDRAWEERA PH, Wang B, Danchin M, Blyth CC, et al Randomised controlled trials of behavioural nudges delivered through text
messages to increase influenza and COVID-19 vaccine uptake among pregnant women
(EPIC study) in Australia.
Vaccine. 2025;62:127477. PubMedAbstract available
EDDY AC, Speaks S, Roth M, Roettger JE, et al IFITM3-deficient mice as a model for testing influenza virus vaccines via the
intramuscular route.
Vaccine. 2025;62:127458. PubMedAbstract available
JIA M, Cao Y, Mu X, Ren D, et al School-based interventions to increase influenza vaccination in primary school
students.
Vaccine. 2025;62:127442. PubMedAbstract available
LAZARUS R, Kasstan-Dabush B, Ali I, Mounier-Jack S, et al Influenza vaccine delivery models in secondary care (hospital) settings: What
approaches are used to enhance access for clinical risk groups in England?
Vaccine. 2025;62:127445. PubMedAbstract available
GILROY J, O'Leary M, Domegan L, O'Connor L, et al Increasing the uptake of Live Attenuated Influenza Vaccine through a new
school-based vaccination programme in Ireland.
Vaccine. 2025;62:127467. PubMedAbstract available
PIERCE SR, Shi H, Caetano C, Prots DA, et al Self-amplifying mRNA expressing COBRA hemagglutinin elicits long-lasting, broadly
reactive antibodies against seasonal influenza A viruses.
Vaccine. 2025;62:127449. PubMedAbstract available
OSTROWSKY JT, Vestin NC, Mehr AJ, Ulrich AK, et al Accomplishments and challenges in developing improved influenza vaccines: An
evaluation of three years of progress toward the milestones of the influenza
vaccines research and development roadmap.
Vaccine. 2025;61:127431. PubMedAbstract available
RZYMSKI P, Plesniak R, Piekarska A, Sznajder D, et al Tracking clinical severity of influenza in adult hospitalized patients in 2024:
Data from the FluTer registry in Poland.
Vaccine. 2025;61:127443. PubMedAbstract available
AUROUX M, Fabacher T, Sauleau E, Arnaud L, et al Pneumococcal and influenza vaccination coverage and impact on COVID-19 infection
severity in patients with inflammatory rheumatic diseases: A French National
Healthcare Database analysis.
Vaccine. 2025;61:127439. PubMedAbstract available
KAHN KE, Santibanez TA, Jain A, Zhou T, et al Parental reasons for non-receipt of influenza vaccination among children
6 months-17 years and changes over time, 2015-2024.
Vaccine. 2025;61:127415. PubMedAbstract available
June 2025
SONG Z, Ma Y, Jiao L, Yu R, et al Lovastatin enhanced immune response to avian influenza vaccine in chickens and
changed mRNA expression in the bursa of fabricius.
Vaccine. 2025;61:127438. PubMedAbstract available
SHINJOH M, Tamura K, Yamaguchi Y, Fukushima H, et al Influenza vaccination in Japanese children, 2024/25: Effectiveness of inactivated
vaccine and limited use of newly introduced live-attenuated vaccine.
Vaccine. 2025;61:127429. PubMedAbstract available
SAMY A, Alber A, Fife M, Hammond JA, et al IFITM knockout DF1 cells produce higher influenza and newcastle disease viral
yields: a proof of concept for avian origin cell-based vaccine production.
Vaccine. 2025;61:127360. PubMedAbstract available
MISHINA M, Cao W, Ende Z, Sharma SS, et al Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and
HA-specific B cell humoral immune responses among healthcare personnel.
Vaccine. 2025;61:127361. PubMedAbstract available
HANSEN BT, Dahl J, Greve-Isdahl M, Winje BA, et al Low and inequitable influenza and COVID-19 vaccination coverage among pregnant
women in Norway: Nationwide population-based cohort study.
Vaccine. 2025;61:127386. PubMedAbstract available
PUENTE-MASSAGUER E, Vasilev K, Krammer F Combination of recombinant neuraminidase with cHA-based inactivated split
vaccines improves the breadth of cross-reactivity and protection against
influenza viruses in mice.
Vaccine. 2025;61:127388. PubMedAbstract available
KIM C, Lee D, Oh YW, Jung SJ, et al Association between parental and child influenza vaccination: A national health
survey analysis.
Vaccine. 2025;61:127345. PubMedAbstract available
May 2025
STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort
study.
Vaccine. 2025;57:127232. PubMedAbstract available
DAVE E, Culhane JF, Lundsberg LS, Partridge C, et al Trends in Tdap and influenza vaccination in pregnancy relative to the coronavirus
disease-19 pandemic.
Vaccine. 2025;61:127329. PubMedAbstract available
YADAV G, Dandu H, Malhotra HS, Jain A, et al COVID-19 vaccination and utility of booster dose: A community-based
cross-sectional study.
Vaccine. 2025;60:127325. PubMedAbstract available
NASREEN S, Jiang Y, Lu H, Lee A, et al Risk of Guillain-Barre syndrome after COVID-19 vaccination or SARS-CoV-2
infection: A multinational self-controlled case series study.
Vaccine. 2025;60:127291. PubMedAbstract available
SEILER P, Kaplan BS, Brice DC, Duan S, et al Altered germinal center responses in mice vaccinated with highly pathogenic avian
influenza A(H5N1) virus.
Vaccine. 2025;60:127311. PubMedAbstract available
LEE N, Nguyen L, Nasreen S, Austin PC, et al Limited durability of protection conferred by XBB.1.5 vaccines against
omicron-associated severe outcomes among community-dwelling adults, Ontario,
Canada.
Vaccine. 2025;60:127300. PubMedAbstract available
MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al Influenza vaccination during early pregnancy and risk of major birth defects, US
Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
Vaccine. 2025;59:127297. PubMedAbstract available
ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al Understanding the shift in COVID-19 vaccine hesitancy and its associated factors
for primary and booster doses among university students: A cross-sectional study.
Vaccine. 2025;59:127296. PubMedAbstract available
RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al Immunogenicity and adverse effects of pneumococcal vaccines co-administered with
influenza or SARS-CoV-2 vaccines in adults: A systematic review and
Meta-analysis.
Vaccine. 2025;59:127293. PubMedAbstract available
MOHAMED Y, Luey E, Kata ', Tukia O, et al "The only vaccine that we really question is the new vaccine": A qualitative
exploration of the social and behavioural drivers of human papillomavirus (HPV)
vaccination in Tonga.
Vaccine. 2025;59:127280. PubMedAbstract available
GANDHI K, Vijay Y, Page K, Dahari H, et al Challenges in coverage of future hepatitis C vaccines: Review and potential
solutions.
Vaccine. 2025;59:127256. PubMedAbstract available
SURI RK, Maugeais D, Maithal K COVID-19 pandemic: A multidimensional analysis and the strategic role played by
developing countries vaccine manufacturers.
Vaccine. 2025;59:127271. PubMedAbstract available
GIANNINI F, Hogan AB, Cameron E, Le H, et al Estimating the impact of Western Australia's first respiratory syncytial virus
immunisation program for all infants: A mathematical modelling study.
Vaccine. 2025;56:127155. PubMedAbstract available
MANDVIWALA AS, Munje AK, Huckriede ALW, Arankalle VA, et al Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based
virus-like-particles consisting of G and M proteins in mice.
Vaccine. 2025;56:127203. PubMedAbstract available
KISLAYA I, Caserta M, Faye SLB, Dia OK, et al Evaluating the effects of a multisectoral dialogue-based COVID-19
awareness-raising intervention in a limited-resource setting: A
quasi-experimental study in Senegal.
Vaccine. 2025;56:127168. PubMedAbstract available
HASAN Z, Masood KI, Qaiser S, Kanji A, et al Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by
different COVID-19 vaccine types: Insights into protection against wildtype,
Delta and JN.1 omicron strains.
Vaccine. 2025;59:127270. PubMedAbstract available
TIAN X, Zhou Y, Deng P, Xu N, et al Effectiveness and safety of a novel intranasal influenza vaccine in Chinese
children: A phase IV multi-Center, randomized, double-blind, placebo-controlled
clinical trial.
Vaccine. 2025;59:127268. PubMedAbstract available
MYBURGH L, van Loon K, Huijbers EJM, van Beijnum JR, et al Guided design for the development of an evolution-proof influenza vaccine.
Vaccine. 2025;59:127281. PubMedAbstract available
LIAW K, Konrath KM, Trachtman AR, Tursi NJ, et al DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with
chemokine adjuvant CTACK induces potent immunogenicity for heterologous
protection in vivo.
Vaccine. 2025;59:127231. PubMedAbstract available
QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake
Using the National Healthcare data System.
Vaccine. 2025;58:127223. PubMedAbstract available
FITZPATRICK T, Yamoah P, Summerby-Murray D, Cowan J, et al Neurological adverse events following COVID-19 vaccination among Canadians
referred to the special immunization clinic network.
Vaccine. 2025;59:127254. PubMedAbstract available
NHAM E, Song JY, Sohn JW, Choi WS, et al Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis
over nine months.
Vaccine. 2025;59:127275. PubMedAbstract available
SCHAFFER AL, Hulme WJ, Horne E, Parker EPK, et al Effect of the 2022 COVID-19 booster vaccination campaign in people aged 50 years
in England: Regression discontinuity analysis in OpenSAFELY-TPP.
Vaccine. 2025;59:127257. PubMedAbstract available
FURUSE Y, Tabuchi T Impact of COVID-19 vaccination by implementation timing and coverage rate in
relation to misinformation prevalence in Japan.
Vaccine. 2025;59:127273. PubMedAbstract available
LUPTON D, Whitten T, Tay AK, Beek K, et al Mental health and psychosocial factors predicting concerns about the COVID-19
vaccine among refugee background and Australian-born women.
Vaccine. 2025;58:127251. PubMedAbstract available
AVERIN A, Quinn E, Atwood M, Weycker D, et al Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF)
maternal vaccine among infants in the United States.
Vaccine. 2025;58:127191. PubMedAbstract available
SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al Establishment of a novel adjuvant screening system for the development of
intranasal vaccine adjuvants.
Vaccine. 2025;58:127267. PubMedAbstract available
SOBLE A, Malhame M, Malvolti S, Mantel C, et al Identification and sizing of the current use cases for seasonal influenza
vaccines.
Vaccine. 2025 May 15:127233. doi: 10.1016/j.vaccine.2025.127233. PubMedAbstract available
MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al Childhood vaccine hesitancy: The power of metaphors.
Vaccine. 2025;58:127221. PubMedAbstract available
PATTYN J, Hanning N, Valckx S, Claessens T, et al Investigating the state of vaccine confidence among the general public and
parents with children up to 13 years in Flanders (Belgium).
Vaccine. 2025;58:127250. PubMedAbstract available
MERRITT A, Bansal S Prison Vaccination in a pandemic: Geographic disparities and policy insights.
Vaccine. 2025;58:127218. PubMedAbstract available
MOU J, LaSalle G, Pflugeisen C, Sherls-Jones J, et al Practice, beliefs and intent in influenza vaccination among Hispanic patients
during the pandemic: An interventional study.
Vaccine. 2025;58:127207. PubMedAbstract available
PEARCE A, Henery P, Dundas R, Katikireddi SV, et al Socio-economic inequalities in uptake and timing of childhood vaccination: Taking
a life course approach in an administrative cohort in Scotland.
Vaccine. 2025;57:127222. PubMedAbstract available
WANG-LU H, Valerio Mendoza OM, Chen S, Geldsetzer P, et al Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.
Vaccine. 2025;58:127179. PubMedAbstract available
CARTER DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, et al Corrigendum to "Cross-protection against H7N9 influenza strains using a
live-attenuated H7N3 virus vaccine" [Vaccine (2015) 33(1) 108-16].
Vaccine. 2025;57:127174. PubMed
TILMANNE A, Pirson M, Leclercq P, Van Den Bulcke J, et al Evaluation of the costs of care for pediatric patients hospitalized for RSV: A
retrospective cohort study in Belgium.
Vaccine. 2025;55:127065. PubMedAbstract available
GAGNON D, Gubany C, Ouakki M, Malo B, et al Factors influencing acceptance of RSV immunization for newborns among pregnant
individuals: A mixed-methods study.
Vaccine. 2025;55:127062. PubMedAbstract available
HAO T, Ryan GE, Lydeamore MJ, Cromer D, et al Predicting immune protection against outcomes of infectious disease from
population-level effectiveness data with application to COVID-19.
Vaccine. 2025;55:126987. PubMedAbstract available
ADAME BJ, Corman SR, Von Feldt PA, Meneses CM, et al Reactance as a cause of COVID-19 vaccination hesitancy.
Vaccine. 2025;57:127209. PubMedAbstract available
ROULEAU I, Issa Kana KDN, Zafack JG, Viger YB, et al New-onset anesthesia/paresthesia following the administration of COVID-19
vaccines in Quebec, Canada.
Vaccine. 2025;57:127217. PubMedAbstract available
MASHAMBA M, Msibi T, Tshabalala G, Tsotetsi L, et al Factors influencing influenza vaccine uptake among adults in Johannesburg, South
Africa: A qualitative study.
Vaccine. 2025;57:127133. PubMedAbstract available
RAHA JR, Kim KH, Le CTT, Bhatnagar N, et al Intranasal vaccination with multi-neuraminidase and M2e virus-like particle
vaccine results in greater mucosal immunity and protection against influenza than
intramuscular injection.
Vaccine. 2025;57:127206. PubMedAbstract available
PADRON-REGALADO E, Escudero Gonzalez NA, Del Carmen Selvera HN Morbidity of viral vaccine preventable diseases in the Mexican states bordering
the U.S., 2014-2023.
Vaccine. 2025;56:127192. PubMedAbstract available
ASHRAF U, Lee A, Gao Q, Gonzalez JC, et al Impact of age and prior COVID-19 on the response to influenza a components in the
2020-2021 Fluzone vaccine.
Vaccine. 2025;56:127171. PubMedAbstract available
BOUADDI O, Khalis M, Abdellatifi M, Seedat F, et al Behavioural and social drivers of vaccination among child and adult migrants in
Morocco: A qualitative interview study.
Vaccine. 2025;56:127166. PubMedAbstract available
PITTER JG, Mihajlovic J, Nagy D, van der Schans J, et al Underreported influenza mortality in Central and Eastern Europe hinders the
extension of seasonal influenza vaccination programs in older adults.
Vaccine. 2025;56:127184. PubMedAbstract available
AKMATOVA R, Otorbaeva D, Ebama MS Impact of the COVID-19 pandemic on influenza knowledge, attitudes, and
vaccination practices in at-risk groups in the Kyrgyz Republic: A comparative
study.
Vaccine. 2025;56:127159. PubMedAbstract available
SEFAT KMSR, Kulkarni R, Trinh J, Leekha A, et al Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV
(respiratory syncytial virus) replication in cotton rats.
Vaccine. 2025;56:127183. PubMedAbstract available
OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al Corrigendum to "Post-introduction evaluation (PIE) of the seasonal influenza
vaccination program in Kyrgyzstan in 2023" Vaccine 55 (2025) 127052.
Vaccine. 2025;56:127123. PubMed
KANESHITA S, Chambers CD, Johnson D, Kavanaugh A, et al Short-term side effects following COVID-19 vaccination in pregnancies complicated
by autoimmune inflammatory rheumatic diseases: A prospective cohort study.
Vaccine. 2025;56:127194. PubMedAbstract available
April 2025
FUJI N, Gonzalez E, Salamone FN, Bajorski P, et al Comparison of Streptococcus pneumoniae nasopharyngeal colonization,
serotype-specific and protein-specific antibody and cytokine levels in young
children prior to, during and post COVID-19 pandemic.
Vaccine. 2025;54:126954. PubMedAbstract available
MOTTA M, Callaghan T, Ross JC, Gargano L, et al Promoting RSV vaccine confidence through reversal narrative (RN) messaging.
Vaccine. 2025;56:127178. PubMedAbstract available
PAUL MJ, Hudda MT, Pallett S, Groppelli E, et al Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination.
Vaccine. 2025;56:127175. PubMedAbstract available
SHANKER A, Vlaev I The social influence of the corrections of vaccine misinformation on social
media.
Vaccine. 2025;56:127177. PubMedAbstract available
BAYSAC DJ, Guay M, Chen R, Dube E, et al Did inequalities in COVID-19 vaccination resolve over time? Insights from the
Canadian Community Health Survey.
Vaccine. 2025;56:127153. PubMedAbstract available
HANSEN BT, Kristoffersen AB, Stecher M Vaccination readiness among adults in Norway: A cross-sectional survey using the
7C model.
Vaccine. 2025;56:127169. PubMedAbstract available
SINGLETON KL, Post DJ, Augustine AD, Ison MG, et al Collaborative influenza vaccine innovation centers (CIVICs) program.
Vaccine. 2025;54:127118. PubMedAbstract available
ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a
MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine
(aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.
Vaccine. 2025;56:127127. PubMed
FATIMAH MNN, Thian BYZ, Wong CL, Ong HK, et al Chimeric virus-like particles of nodavirus displaying M2e of human and avian
influenza A viruses as a potential dual-use vaccine: Inducing a broader immune
response and protecting mice against viral infections.
Vaccine. 2025;56:127165. PubMedAbstract available
BUSTAMANTE Q, Sparkes D, Findlater L, Munro K, et al Understanding occupational and attitudinal factors influencing UK healthcare
worker decisions for COVID-19 and influenza vaccination: A cross-sectional survey
within SIREN.
Vaccine. 2025;56:127160. PubMedAbstract available
OHNO M, Sekiya T, Obeng-Kyeremeh R, Handabile C, et al Optimization of the preparation method of inactivated intact virus particle
vaccine for COVID-19.
Vaccine. 2025;56:127173. PubMedAbstract available
LANATA CF, Ochoa TJ, Bancalari EM, Baylor NW, et al Testing an experimental vaccine during a public health emergency: Lessons from a
Peruvian case.
Vaccine. 2025;56:127176. PubMedAbstract available
HONDA-OKUBO Y, Sakala IG, Li L, Bielefeldt-Ohmann H, et al Advax(R)-adjuvanted inactivated influenza vaccine provides accelerated protection
of mice via early induction of an influenza-specific IgM response.
Vaccine. 2025;56:127144. PubMedAbstract available
MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al 2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US
states.
Vaccine. 2025;56:127120. PubMedAbstract available
ZHANG X, Shi H, Ross TM Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in
a pre-immune elderly ferret model.
Vaccine. 2025;56:127156. PubMedAbstract available
FINNEY J, Kuraoka M, Song S, Watanabe A, et al Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza
neuraminidases.
Vaccine. 2025;56:127157. PubMedAbstract available
OLESEN SW, Holmdahl I, Ortega-Sanchez IR, Biggerstaff M, et al Projecting maximum potential demand for nirsevimab to protect eligible US infants
and young children against respiratory syncytial virus in the 2024/2025 season.
Vaccine. 2025;53:127109. PubMedAbstract available
KADOI K, Toba J, Uehara A, Isoda N, et al Enhanced sulfate pseudo-affinity chromatography using monolith-like particle
architecture for purifying SARS-CoV-2.
Vaccine. 2025;53:126951. PubMedAbstract available
EYAL N, Wendler D Assessing the risks of current COVID-19 challenge trials systematically.
Vaccine. 2025;53:126877. PubMedAbstract available
TAKEUCHI N, Chang B, Ishiwada N, Cho Y, et al Nationwide population-based surveillance of invasive pneumococcal disease in
children in Japan (2014-2022): Impact of 13-valent pneumococcal conjugate vaccine
and COVID-19 pandemic.
Vaccine. 2025;54:127138. PubMedAbstract available
STONER MCD, Michaels J, Stocks JB, Mancuso N, et al Evaluating concurrency and gaps between self-report and vaccine card data for
COVID-19 vaccination.
Vaccine. 2025;54:127136. PubMedAbstract available
TONG F, Zhou T, Tang L, Wu X, et al Evaluating the impact of influenza vaccine on preventing stroke hospitalization
and death in Chinese elderly hypertensive patients: A retrospective cohort study.
Vaccine. 2025;54:127004. PubMedAbstract available
WEETS CM, Wilson R, Swadley H, Katz R, et al Strengthening health security through routine vaccination policy: A comprehensive
analysis of childhood vaccination laws across 194 countries.
Vaccine. 2025;54:127121. PubMedAbstract available
ENTRICAN G, Bredell H, Charlier J, Cunningham AF, et al Opportunities and challenges for the adoption of novel platform technologies to
develop veterinary bacterial vaccines.
Vaccine. 2025;54:127117. PubMedAbstract available
LEYNS C, McClenaghan E, Rodriguez P, Nguipdop-Djomo P, et al Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional
food markets in Bolivia (2020-2022): A cross-sectional analysis of a serological
survey.
Vaccine. 2025;54:127104. PubMedAbstract available
ZHANG L, Xia Y, Chu L, Sundaram ME, et al Differences in seasonal influenza vaccine hesitancy profiles between clinicians
practicing traditional Chinese medicine and modern Western medicine: A national
cross-sectional survey.
Vaccine. 2025;53:127106. PubMedAbstract available
CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al Regional cooperation on pandemic preparedness and vaccine equity from an
economic, regulatory and legal perspective.
Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107. PubMedAbstract available
BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al Development and validation of a clinical prediction tool for non-receipt of
updated COVID-19 vaccines.
Vaccine. 2025;53:127074. PubMedAbstract available
ZASZTOWT-STERNICKA M, Jagielska A, Rzad M, Szymusik I, et al Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women,
including the level of postvaccination antibodies in umbilical cord blood.
Vaccine. 2025;53:127047. PubMedAbstract available
LLOYD PC, Acharya G, Zhao H, Shah N, et al Safety monitoring of health outcomes following influenza vaccination during the
2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older.
Vaccine. 2025;53:127069. PubMedAbstract available
SASANKAN S, Gathers D, Bellerose A, Pankratz VS, et al Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on
oncology patients in New Mexico with substantial representation of racial
minorities and rural residents.
Vaccine. 2025;53:127091. PubMedAbstract available
LA EM, Sweeney C, Davenport E, Bunniran S, et al Pharmacy and healthcare provider offices as convenient adult vaccination settings
in the US: Patient experiences from a survey of recently-vaccinated adults.
Vaccine. 2025;54:127057. PubMedAbstract available
PRALL S, Lopes A "Better to die trying": Vaccine perceptions and COVID-19 experiences in rural
Namibian pastoralists.
Vaccine. 2025;55:127061. PubMedAbstract available
SHEARN C, Postavaru GI, Hylton L, Morris H, et al COVID-19 vaccine decision-making and the role of institutions across the pandemic
in UK Black African and Black Caribbean communities.
Vaccine. 2025;53:127071. PubMedAbstract available
CHEN PL, Richardson RA, Rovito S, Yang G, et al Live-attenuated pandemic H1N1 influenza vaccines expressing computationally
optimized broadly reactive antigens (COBRAs) are immunogenic and protective in
mice and ferrets.
Vaccine. 2025;53:127090. PubMedAbstract available
BERNARD C, Drouin J, Le Vu S, Botton J, et al COVID-19 vaccination rates among pregnant women in France: A nationwide cohort
study.
Vaccine. 2025;53:127070. PubMedAbstract available
FISHER KA, Goldthwait L, Desrochers O, Zemel M, et al Reasons for COVID-19 vaccination late in the pandemic: A qualitative study.
Vaccine. 2025;53:127084. PubMedAbstract available
FLYNN PM, Stull C, Jain VM, Evans MD, et al A national cross-sectional study of dentists' vaccine hesitancy and intention to
provide HPV vaccines following emergency COVID-19 vaccination authorization.
Vaccine. 2025;53:127035. PubMedAbstract available
FELIX P, Melo AA, Costa JP, Colaco M, et al Exploring TLR agonists as adjuvants for COVID-19 oral vaccines.
Vaccine. 2025;53:127078. PubMedAbstract available
MCCOSKER LK, Dyer B, Sudarmana T, Seale H, et al COVID-19 vaccination uptake in people experiencing homelessness during the first
three years of the global COVID-19 vaccination effort: A systematic review and
meta-analysis.
Vaccine. 2025;53:127050. PubMedAbstract available
PAYNE AB, Novosad S, Sung HM, Zhang Y, et al Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated
hospitalizations among adults aged >/=18 years with end stage kidney disease -
United States, September 2023-April 2024.
Vaccine. 2025;55:127010. PubMedAbstract available
OLIVIERI G, Amodio D, Manno EC, Santilli V, et al Shielding the immunocompromised: COVID-19 prevention strategies for patients with
primary and secondary immunodeficiencies.
Vaccine. 2025;51:126853. PubMedAbstract available
PATRICK R, Mahale P, Ackerson BK, Hong V, et al Respiratory syncytial virus vaccine uptake among adults aged >/=60 years in a
large, integrated healthcare system in Southern California 2023-2024.
Vaccine. 2025;53:127033. PubMedAbstract available
FORAN AM, Jetten J, Muldoon OT Religious group membership and conspiracy beliefs influence vaccine uptake:
Insights from 20 European countries.
Vaccine. 2025;53:127086. PubMedAbstract available
ALVES K, Kouassi A, Plested JS, Kalkeri R, et al Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant
spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive
participants: Primary day-28 analysis of a phase 2/3 open-label study.
Vaccine. 2025;55:127046. PubMedAbstract available
PEREZ MARC G, Coria LM, Ceballos A, Rodriguez JM, et al Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted
RBD-based protein booster vaccines in adults previously immunized with different
vaccine platforms: A phase II/III, randomized clinical trial.
Vaccine. 2025;54:127045. PubMedAbstract available
OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al Post-introduction evaluation (PIE) of the seasonal influenza vaccination program
in Kyrgyzstan in 2023.
Vaccine. 2025;55:127052. PubMedAbstract available
March 2025
KARAN S, Opdensteinen P, Ma Y, De Oliveira JFA, et al A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic
virus-like particles.
Vaccine. 2025;53:127063. PubMedAbstract available
JIANG J, Lam KF, Lau EHY, Yin G, et al Estimation of trajectory of COVID-19 vaccines effectiveness against infection.
Vaccine. 2025;55:127067. PubMedAbstract available
NEWBERN EC, Shoaibi A, Haynes K, Blacketer C, et al A rapid cycle analytics framework for vaccine safety surveillance within a
real-world data network: Experience with enhanced surveillance of the Janssen
COVID-19 vaccine.
Vaccine. 2025;55:127044. PubMedAbstract available
CENAT JM, Moshirian Farahi SMM, Dalexis RD, Xu Y, et al Vaccine hesitancy among racially diverse parents in Canada: The important role of
health literacy, conspiracy beliefs and racial discrimination.
Vaccine. 2025;55:127049. PubMedAbstract available
TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al Sociodemographic and health-related predictors of COVID-19 booster uptake among
fully vaccinated adults.
Vaccine. 2025;54:127048. PubMedAbstract available
FRIVOLD C, Giersing B, Amorij JP, Mvundura M, et al Identification of potential vaccines for use with microarray patches in low- and
middle-income countries: An assessment from the Vaccine Innovation Prioritisation
Strategy Alliance.
Vaccine. 2025;55:126996. PubMedAbstract available
BLACKWELL CK, Bekelman T, Bakre S, Jacobson LP, et al Sociodemographic differences in parental hesitancy to the COVID-19 vaccine.
Vaccine. 2025;55:127041. PubMedAbstract available
HARALAMBIEVA IH, Ratishvili T, Goergen KM, Grill DE, et al Effect of lymphocyte miRNA expression on influenza vaccine-induced immunity.
Vaccine. 2025;55:127023. PubMedAbstract available
FRANCIS MJ A rapid human vaccine process development map outlining lessons learnt from
ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic.
Vaccine. 2025;55:127040. PubMedAbstract available
GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al Adverse events among early caregivers' COVID-19 vaccination correlated inversely
with intention to vaccinate their children.
Vaccine. 2025;55:127001. PubMedAbstract available
VACHON A, Keeshan A, Galipeau Y, Crawley AM, et al Alcohol consumption does not influence SARS-CoV-2 vaccine immunogenicity: A stop
the spread Ottawa cohort analysis.
Vaccine. 2025;55:127034. PubMedAbstract available
KAISER S, Kaiser S, Reis J, Marschalek R, et al Quantification of objective concentrations of DNA impurities in mRNA vaccines.
Vaccine. 2025;55:127022. PubMedAbstract available
HAMID S, Simeone RM, Newhams MM, Halasa N, et al Concordance between parent-reported and documented COVID-19 vaccination status
among hospitalized children and adolescents: Implications for vaccine
effectiveness estimates, May 2021-October 2023.
Vaccine. 2025;54:126891. PubMedAbstract available
SHINO MY, Ibarrondo FJ, Yang OO SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the
spectrum in non-immunocompromised persons.
Vaccine. 2025;50:126851. PubMedAbstract available
THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
Vaccine. 2025;55:126981. PubMedAbstract available
RASKIN N, Hiligsmann M, Luyten J, Tubeuf S, et al Socio-demographic differences in citizen' preferences for distributing a scarce,
lifesaving resource: A case study using COVID-19 vaccine distribution in Belgium.
Vaccine. 2025;55:126997. PubMedAbstract available
CHOI J, Feelemyer J, Choe K, Lynch K, et al Anti-vaccine attitudes and COVID-19 vaccine status at the end of the U.S. public
health emergency.
Vaccine. 2025;55:127003. PubMedAbstract available
HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al A phase I study of the safety, reactogenicity and immunogenicity of two
quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without
one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of
age.
Vaccine. 2025;54:126991. PubMedAbstract available
PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al Factors associated with influenza and COVID-19 vaccination among health workers
in Lao PDR, 2023.
Vaccine. 2025;54:127006. PubMedAbstract available
XU J, Davoudpour S, Phillips G 2nd Applying the health belief model (HBM) to understand COVID-19 vaccine uptake
among youth and young adults: Findings from a 6-month follow-up study in the
United States.
Vaccine. 2025;54:127002. PubMedAbstract available
RICCI L, Fery C, Tubach F, Agrinier N, et al Health care institutions and their physicians are the greatest promoters of
COVID-19 vaccine acceptance among health care workers.
Vaccine. 2025;54:127005. PubMedAbstract available
MYBURGH L, Karsjens H, Blanas A, de Ligt A, et al Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate
vaccine.
Vaccine. 2025;54:126989. PubMedAbstract available
SKOCZYNSKA A, Golebiewska A, Wrobel-Pawelczyk I, Ronkiewicz P, et al The direct impact of mandatory PCV10 vaccination on invasive pneumococcal disease
in Polish children.
Vaccine. 2025;54:126999. PubMedAbstract available
VEDEL JO, Furtado O, Almeida LL, Nehal KR, et al Childhood vaccination coverages in rural Guinea-Bissau before and during the
early COVID-19 pandemic, a cohort study.
Vaccine. 2025;54:127011. PubMedAbstract available
BOLU O, Alo OD, Iwara E, Longley AT, et al Feasibility of cohort event monitoring and assessment of reactogenicity and
adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine
recipients in Nigeria, 2021.
Vaccine. 2025;52:126907. PubMedAbstract available
MEERAUS W, Postema A, Gray CM, Lee A, et al Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase
protection against COVID-19 hospitalization: Final analysis from the
REFORCO-Brazil real-world effectiveness study during Omicron.
Vaccine. 2025;53:126955. PubMedAbstract available
DI CHIARA C, Karimi-Shahrbabak E, Peresin J, Farrar DS, et al A review of Canadian online resources providing information on COVID-19
vaccination for caregivers of children aged 5-11 years.
Vaccine. 2025;54:126990. PubMedAbstract available
KRAMMER F Next-generation seasonal influenza virus vaccines need a neuraminidase component.
Vaccine. 2025;54:126994. PubMed
OTIENO NA, Kalani R, Ayugi J, Nyawanda BO, et al Seasonal influenza vaccination in Kenya: What determines healthcare Workers'
willingness to accept and recommend vaccination?
Vaccine. 2025;54:126963. PubMedAbstract available
DE SOUZA RA, Barreto FR, de Jesus Lima CCO, da Natividade MS, et al Efficacy of BCG vaccination on incidence, severity and clinical progression of
COVID-19: A BCG-REVAC population analysis.
Vaccine. 2025;54:126911. PubMedAbstract available
JI C, Senthinathan A, Apajee J, Dubey V, et al Impact of the COVID-19 pandemic on routine immunization coverage of children and
teenagers in Ontario, Canada.
Vaccine. 2025;49:126811. PubMedAbstract available
DESILVA MB, Vazquez-Benitez G, Seburg EM, Henderson MSG, et al Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota,
2023-2024.
Vaccine. 2025;54:126958. PubMedAbstract available
DOWGIER G, Hobbs A, Greenwood D, Shawe-Taylor M, et al Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1
in the assessment of vaccination and therapeutics.
Vaccine. 2025;54:126960. PubMedAbstract available
LEE DW, Nasir A, Elbashir S, Jani H, et al mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses
against the JN.1 sublineages of SARS-CoV-2 in mice.
Vaccine. 2025;54:126961. PubMedAbstract available
CARROLL M, Fox HB, Tran A, Chellappan G, et al SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect
against evolving variants.
Vaccine. 2025;54:126988. PubMedAbstract available
MOORE M, Anderson L, Schiffer JT, Matrajt L, et al Durability of COVID-19 vaccine and infection induced immunity: A systematic
review and meta-regression analysis.
Vaccine. 2025;54:126966. PubMedAbstract available
RAJA AI, Connor RI, Ashare A, Weiner JA, et al Binding and neutralising antibodies to respiratory syncytial virus and influenza
A virus in serum and bronchoalveolar lavage fluid of healthy adults in the United
States: A cross-sectional study.
Vaccine. 2025;53:126936. PubMedAbstract available
PEIXOTO DE MIRANDA EJF, Calado RT, Boulos FC, de Sousa Moreira JA, et al Safety and immunogenicity of an inactivated recombinant Newcastle disease virus
vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled
phase I ADAPTCOV trial in Brazil.
Vaccine. 2025;52:126680. PubMedAbstract available
CHU CF, Chang TH, Ho JJ Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and
claim approval rates.
Vaccine. 2025;52:126830. PubMedAbstract available
ZHAO T, Xu Q, Cai X, Wang M, et al Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy
between 2020 and 2022: A meta-analysis.
Vaccine. 2025;53:126933. PubMedAbstract available
COTTER LM, Hopkins-Sheets M, Yang S, Passmore SR, et al Increasing confidence for pediatric COVID-19 and influenza vaccines using
messages affirming parental autonomy: A randomized online experiment.
Vaccine. 2025;53:126947. PubMedAbstract available
TENGATTINI S, Bavaro T, Rinaldi F, Temporini C, et al Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy
for good practices.
Vaccine. 2025;53:126932. PubMedAbstract available
NIU Y, Yan Y, Hu Y, Yang X, et al A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector.
Vaccine. 2025;53:126959. PubMedAbstract available
KEELING MJ, Hill EM, Petrou S, Tran PB, et al Cost-effectiveness of routine COVID-19 adult vaccination programmes in England.
Vaccine. 2025;53:126948. PubMedAbstract available
February 2025
RIGAMONTI V, Torri V, Morris SK, Ieva F, et al Real-world effectiveness of influenza vaccination in preventing influenza and
influenza-like illness in children.
Vaccine. 2025;53:126946. PubMedAbstract available
WANG B, Lassi Z, Andraweera P, Chen G, et al Pregnant women's choices for preventing respiratory syncytial virus (RSV).
Vaccine. 2025;48:126790. PubMedAbstract available
ADU P, Popoola T, Iqbal N, Roemer A, et al A cross-country network analysis of disease infodemics: Looking through the lens
of the COVID-19 pandemic.
Vaccine. 2025;48:126733. PubMedAbstract available
SHEERAH HA, Al-Jedai AH, Al-Jerian NA, Al-Otaiby MA, et al COVID-19 and influenza hospitalizations and the role of COVID-19 vaccination in
the post-pandemic period: A cross-sectional study from Saudi Arabia.
Vaccine. 2025;52:126937. PubMedAbstract available
MATHUR I, Ruisch A, Conlin M, Oyatoye I, et al COVID-19 vaccination integration, innovations and key populations: Results from a
global survey.
Vaccine. 2025;52:126863. PubMedAbstract available
DIYA O, Gayed J, Lowry FS, Ma H, et al A phase 2/3 trial to investigate the safety and immunogenicity of monovalent
Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old.
Vaccine. 2025;52:126869. PubMedAbstract available
LEBLANG D, Smith MD, Wesselbaum D Global perspectives on COVID-19 vaccination: Impacts on well-being and
inequality.
Vaccine. 2025;52:126906. PubMedAbstract available
ANDERSEN KM, Allen KE, Nepal RM, Mateus JS, et al Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using
tokenization in two U.S. states.
Vaccine. 2025;52:126881. PubMedAbstract available
FARAH Z, Bazant ES, Basha I, Saleh N, et al Determinants of seasonal influenza vaccination uptake, intention and
recommendations among Lebanese physicians.
Vaccine. 2025;52:126890. PubMedAbstract available
YE Q, Xiao Z, Bai C, Yao H, et al Unveiling the multi-characteristic potential of hyper-productive suspension MDCK
cells for advanced influenza A virus propagation.
Vaccine. 2025;52:126900. PubMedAbstract available
DUDLEY MZ, Zapf AJ, Delamater P, Proveaux TM, et al Attitudes of California school personnel on potential COVID-19 vaccine mandates
and state law SB277 to remove nonmedical vaccine exemptions.
Vaccine. 2025;52:126888. PubMedAbstract available
MACKENZIE LJ, Bousie JA, Newman P, Cunningham J, et al What three years of COVID-19 vaccine administration reveals about the incidence
of shoulder injury related to vaccine administration (SIRVA).
Vaccine. 2025;51:126892. PubMedAbstract available
ATTI A, England A, Sung J, Foulkes S, et al Estimating neutralising antibody responses against emerging SARS-CoV-2 variants
utilising convalescent sera before the roll-out of XBB-lineage vaccines.
Vaccine. 2025;51:126898. PubMedAbstract available
MEYERS E, De Rop L, Deschepper E, Duysburgh E, et al SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and
staff post-primary course vaccination in Belgium between February and December
2021.
Vaccine. 2025;51:126865. PubMedAbstract available
BERGSTROM F, Gunther F, Britton T A counterfactual analysis quantifying the COVID-19 vaccination impact in Sweden.
Vaccine. 2025;52:126870. PubMedAbstract available
ZHAO T, Liu X, Huang X, Wang L, et al Development and evaluation of mosaic VLPs vaccine for enhanced broad-Spectrum
immunity against influenza B virus lineages in mice.
Vaccine. 2025;51:126882. PubMedAbstract available
TAAFFE J, Goldin S, Lambach P, Sparrow E, et al Global production capacity of seasonal and pandemic influenza vaccines in 2023.
Vaccine. 2025;51:126839. PubMedAbstract available
HALL C, Lanning J, Romano CJ, Bukowinski AT, et al COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes
among United States military service members, January-December 2021.
Vaccine. 2025;51:126894. PubMedAbstract available
DARWAR R, Huang X, Abayeneh A, Alemayehu Beshah S, et al Costing approaches for vaccine-preventable disease surveillance: Lessons from
Ethiopia and Nepal.
Vaccine. 2025;50:126776. PubMedAbstract available
APPEL AM, Janbek J, Laursen TM, Gasse C, et al Dementia and influenza vaccination: Time trends and predictors of vaccine uptake
among older adults.
Vaccine. 2025;51:126864. PubMedAbstract available
KEMP M, Capriola A, Schauer S RSV immunization uptake among infants and pregnant persons - Wisconsin, October
1, 2023-March 31, 2024.
Vaccine. 2025;47:126674. PubMedAbstract available
CHANG C, Patel H, Ferrari A, Scalzo T, et al sa-mRNA influenza vaccine raises a higher and more durable immune response than
mRNA vaccine in preclinical models.
Vaccine. 2025;51:126883. PubMedAbstract available
SMITH DS, Postma M, Fisman D, Mould-Quevedo J, et al Cost-effectiveness models assessing COVID-19 booster vaccines across eight
countries: A review of methods and data inputs.
Vaccine. 2025;51:126879. PubMedAbstract available
VAN DIEMEN PM, Lean FZX, Ramsay A, Mollett BC, et al Evaluation of a nanoparticle influenza vaccine in the pig model.
Vaccine. 2025;49:126844. PubMedAbstract available
KIM SY, Song M, Kwon SL Impact of caregiver vaccination status on child influenza vaccination hesitancy:
A time-to-vaccination analysis for 2023-2024 season in the Republic of Korea.
Vaccine. 2025;49:126852. PubMedAbstract available
ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted
quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults
aged 50 years and older.
Vaccine. 2025;51:126791. PubMedAbstract available
WILLIAMS JTB, Johnson D, Weinshenker D, O'Leary ST, et al Co-creation of pediatric influenza digital stories via rapid community
translation.
Vaccine. 2025;51:126866. PubMedAbstract available
COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in
vulnerable groups - The CONVERS project, report from a pediatric tertiary
hospital.
Vaccine. 2025;49:126778. PubMedAbstract available
O'KENNEDY MM, Reedy SE, Abolnik C, Khan A, et al Protective efficacy of a bivalent equine influenza H3N8 virus-like particle
vaccine in horses.
Vaccine. 2025;50:126861. PubMedAbstract available
CAPAO A, Araujo MF, Tort LFL, Toledo TS, et al Impact in the humoral and cellular immune response to SARS-CoV-2 variants after
primary vaccination with AZD1222/COVISHIELD protocol in healthy adults.
Vaccine. 2025;50:126785. PubMedAbstract available
SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al Intention to receive new vaccines post-COVID-19 pandemic among adults and health
workers in Lusaka, Zambia.
Vaccine. 2025;50:126846. PubMedAbstract available
FAUSTINI SE, Backhouse C, Duggal NA, Toellner KM, et al Time of day of vaccination does not influence antibody responses to pneumococcal
and annual influenza vaccination in a cohort of healthy older adults.
Vaccine. 2025;49:126770. PubMedAbstract available
FU Y, Xu Z, Wang Q, Zhang J, et al Effectiveness and coverage of COVID-19 vaccination among the infection-naive
population: A community-based retrospective cohort study in China.
Vaccine. 2025;50:126836. PubMedAbstract available
ABBAD A, Yueh J, Yellin T, Singh G, et al Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads
to enhanced immune responses to influenza virus and reduced immune responses to
SARS-CoV-2 in naive mice.
Vaccine. 2025;50:126825. PubMedAbstract available
SOENS M, Ananworanich J, Hicks B, Lucas KJ, et al A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal
influenza vaccine in adults.
Vaccine. 2025;50:126847. PubMedAbstract available
VAHORA MS, Leao O, da Silveira MF, Domingues MR, et al Impacts of vaccination, school attendance, and nutrition on SARS-CoV-2 antibody
titer in a prospective birth cohort in Brazil.
Vaccine. 2025;49:126838. PubMedAbstract available
MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al Acceptance and preference between respiratory syncytial virus vaccination during
pregnancy and infant monoclonal antibody among pregnant and postpartum persons in
Canada.
Vaccine. 2025;50:126818. PubMedAbstract available
KANG HS, Kim SY, De Gagne JC, Chae SM, et al Pregnant women's experiences of and attitudes toward COVID-19 vaccination: A
qualitative descriptive study.
Vaccine. 2025;50:126835. PubMedAbstract available
HONDA-OKUBO Y, Sajkov D, Wauchope B, Turner JV, et al Immunogenicity and safety study of a single dose of SpikoGen(R) vaccine as a
heterologous or homologous intramuscular booster following a primary course of
mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory
adults.
Vaccine. 2025;49:126744. PubMedAbstract available
DOUA J, Ndembi N, Auerbach J, Kaseya J, et al Advancing local manufacturing capacities for vaccines within Africa -
Opportunities, priorities and challenges.
Vaccine. 2025;50:126829. PubMedAbstract available
KAN AKC, Mak HWF, Chiang V, Yim JSH, et al Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy
delabelling: Effectiveness and impact on quality of life.
Vaccine. 2025;50:126849. PubMedAbstract available
POWELL A, Jones A, Van Hout MC, Montgomery C, et al Influenza vaccine uptake in socially deprived areas: A multilevel retrospective
population-based cross-sectional study using electronic health records in
Liverpool, United Kingdom.
Vaccine. 2025;50:126837. PubMedAbstract available
GE Y, Handel A, Giabbanelli PJ, Lemacks J, et al Exploring bias due to below-limit-of-detection values in influenza vaccine
antibody modeling: A case study and instructional guide for the CIVIC study.
Vaccine. 2025;49:126802. PubMedAbstract available
January 2025
MCGOLDRICK M, Truong TBQ, Campa C, Ali M, et al How to accelerate the supply of vaccines to all populations worldwide? Part III:
Reflections after the pandemic.
Vaccine. 2025;49:126782. PubMedAbstract available
GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in
immunocompromised patients: A targeted literature review.
Vaccine. 2025;49:126777. PubMedAbstract available
GRAILEY K, Crespo RF, Woldmann L, Chisambi M, et al Implementing behavioural science-informed letter interventions to increase
COVID-19 vaccination uptake in London residents. A difference-in-difference study
in London, United Kingdom.
Vaccine. 2025;49:126781. PubMedAbstract available
YILMAZ IC, Ipekoglu EM, Golcuklu BS, Bildik T, et al A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen
carrying virus-like particle COVID-19 vaccine.
Vaccine. 2025;49:126787. PubMedAbstract available
HASHIMOTO M, Tsujii K, Nakajima-Yoshida H, Akiyama N, et al A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune
responses of quadrivalent influenza vaccine in ferrets.
Vaccine. 2025;49:126780. PubMedAbstract available
MWENDA JM, Mandomando I, Worwui AK, Gacic-Dobo M, et al A decade of rotavirus vaccination in the World Health Organization African
Region: An in-depth analysis of vaccine coverage from 2012 to 2023.
Vaccine. 2025 Jan 30:126768. doi: 10.1016/j.vaccine.2025.126768. PubMedAbstract available
WIEGAND RE, Devine O, Wallace M, Ortega-Sanchez IR, et al Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital
deaths averted in the United States by 2023-2024 COVID-19 vaccination: A
conditional probability, causal inference, and multiplier-based approach.
Vaccine. 2025;49:126808. PubMedAbstract available
KHAN A, Zhu Y, Babcock HM, Busse LW, et al COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United
States, 2019-2022.
Vaccine. 2025 Jan 29:126806. doi: 10.1016/j.vaccine.2025.126806. PubMedAbstract available
ITO S, Tsuchida N, Kusunoki S, Kaneko Y, et al Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca
AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe
acute respiratory syndrome coronavirus 2 vaccination in Japan.
Vaccine. 2025;49:126754. PubMedAbstract available
LAO G, Feng J, Wu L, Su W, et al Development of a genetically modified full-length human respiratory syncytial
virus preF protein vaccine.
Vaccine. 2025;49:126799. PubMedAbstract available
ROPER LE, Link-Gelles R, Surie D, DeCuir J, et al A framework for monitoring RSV prevention product effectiveness in the United
States.
Vaccine. 2025;45:126633. PubMedAbstract available
GEBRECHERKOS Y, Hodgson D Cost-effectiveness of anti-viral treatment for infants with RSV disease in the
United Kingdom.
Vaccine. 2025;45:126647. PubMedAbstract available
MYEMBA DT, Smets L, Sunguya BF, Vandaele N, et al Challenges and strategies for sustainable and resilient immunization systems in
sub-Saharan Africa: A comprehensive scoping review.
Vaccine. 2025;45:126639. PubMedAbstract available
EURICH DT, Weaver O, McDermott C, Soprovich A, et al Describing COVID-19 immunizations for First Nations people on-reserve in Alberta
using real-time integration of point of care and provincial data.
Vaccine. 2025;45:126614. PubMedAbstract available
CONLIN K, Jenkin D, de Whalley P, Weckx LY, et al Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a
randomised controlled trial.
Vaccine. 2025;45:126582. PubMedAbstract available
OKA E, Ueda Y, Yagi A, Machida M, et al Challenges to promoting maternal respiratory syncytial virus vaccination in
Japan.
Vaccine. 2025;48:126767. PubMedAbstract available
PROSSER LA, Perroud J, Chung GS, Gebremariam A, et al The cost-effectiveness of vaccination against COVID-19 illness during the initial
year of vaccination.
Vaccine. 2025;48:126725. PubMedAbstract available
LIAO Z, Deng L, Luo J, Shi M, et al Association between adults' vaccine literacy and their intention to recommend
older family members for influenza vaccine.
Vaccine. 2025;48:126757. PubMedAbstract available
CLAESSENS T, Eagan RL, Hendrickx G, Van Damme P, et al Navigating vaccine confidence: A mixed methods study investigating healthcare
providers' perspectives across four non-EU European regions.
Vaccine. 2025;47:126694. PubMedAbstract available
RAINERI D, Mazzucca CB, Moia R, Bruna R, et al Impairment of the T cell memory response in chronic lymphocytic leukemia patients
after SARS-CoV-2 vaccination.
Vaccine. 2025;48:126723. PubMedAbstract available
TRANTER I, Judd D, Stickley M, Vasant B, et al Promoting aged care COVID-19 and influenza vaccination through education of
Australian residential aged care staff: A mixed methods project evaluation.
Vaccine. 2025;48:126742. PubMedAbstract available
SHAH RM, Parzen-Johnson S, Sun S, Patel SJ, et al Childhood opportunity index and vaccine uptake in pediatric COVID-19
hospitalizations.
Vaccine. 2025;48:126734. PubMedAbstract available
DOS SANTOS CVB, Coelho LE, de Noronha TG, Goedert GT, et al The impact of vaccination on the length of stay of hospitalized COVID-19 patients
in Brazil.
Vaccine. 2025;48:126735. PubMedAbstract available
DE OLIVEIRA PMN, Hartmann K, Bhamare C, Lucchesi MBB, et al Active vaccine safety surveillance in low- and middle-income countries:
Challenges for vaccine manufacturers from emerging countries.
Vaccine. 2025;48:126727. PubMedAbstract available
ZHANG Y, Li X, Yang Y, Yin Y, et al Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant
breakthrough infection.
Vaccine. 2025;48:126722. PubMedAbstract available
COROMINAS J, Garriga C, Prenafeta A, Moros A, et al Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2
booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Vaccine. 2025;47:126685. PubMedAbstract available
MARCHESE AM, Beyhaghi H, Rousculp MD, Huang V, et al Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines
compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2
trial (COV-BOOST).
Vaccine. 2025;44:126569. PubMedAbstract available
FILIMONOVIC J, Stosic M, Gazibara T, Dotlic J, et al The trend in national childhood immunization program coverage throughout Serbian
communities in Kosovo and Metohija from 2003 to 2022: pre-COVID-19 period vs.
COVID-19 pandemic.
Vaccine. 2025;44:126576. PubMedAbstract available
HARTEVELD LM, van Leeuwen LM, Euser SM, Smit LJ, et al Respiratory syncytial virus (RSV) prevention: Perception and willingness of
expectant parents in the Netherlands.
Vaccine. 2025;44:126541. PubMedAbstract available
DE LIMA EDS, Antunes MOB, de Souza JS, Jones MH, et al Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes
among children and adolescents: A Brazilian nationwide cohort study.
Vaccine. 2025;44:126550. PubMedAbstract available
FREY SE, Brady R, Jackson L, Goepfert P, et al Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated
vaccine with or without MF59(R).
Vaccine. 2025;47:126702. PubMedAbstract available
HONDA-OKUBO Y, Vaghasiya U, Petrovsky N Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted
recombinant hemagglutinin seasonal quadrivalent influenza vaccine.
Vaccine. 2025;47:126707. PubMedAbstract available
SHIELDS T, King KD, Cripps S, Edwards SA, et al Perspectives on vaccination among unvaccinated members of a Canadian indigenous
population.
Vaccine. 2025;47:126665. PubMedAbstract available
CASPERSEN IH, Skodvin SN, Blix K, Robertson AH, et al Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster
vaccination: A population-based cohort study.
Vaccine. 2025;47:126664. PubMedAbstract available
LE N, McMann TJ, Wenzel C, Li Z, et al COVID-19 pediatric vaccine Hesitancy: Themes and interactions with verified
twitter accounts.
Vaccine. 2025;47:126688. PubMedAbstract available
EL SAHLY HM, Anderson EJ, Jackson LA, Neuzil KM, et al Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza
a(H7N9) vaccine regimens.
Vaccine. 2025;47:126689. PubMedAbstract available
DUAN Y, Suo L, Li X, Bai C, et al Association between underlying conditions, multimorbidity, and COVID-19
vaccination status of adults aged >/=80 years old in Beijing, China.
Vaccine. 2025;47:126677. PubMedAbstract available
ALVARADO-FACUNDO E, Herrup R, Wang W, Colombo RE, et al Comparison of neuraminidase inhibiting antibody responses elicited by egg- and
cell-derived influenza vaccines.
Vaccine. 2025;46:126669. PubMedAbstract available
ANSELEM O, Charlier C, Viaud M, Lelong N, et al Barriers to influenza vaccination during pregnancy in France: A national
population-based study.
Vaccine. 2025;47:126671. PubMedAbstract available
GIERSING B, Mo AX, Hwang A, Baqar S, et al Meeting summary: Global vaccine and immunization research forum, 2023.
Vaccine. 2025;46:126686. PubMedAbstract available
HAEBERER M, Lopez-Ibanez de Aldecoa A, Seabroke S, Ramirez Agudelo JL, et al Economic burden of children hospitalized with respiratory syncytial virus
infection in Spain, 2016-2019.
Vaccine. 2025;43. PubMedAbstract available
DERMENCHYAN A, Choi KR, Bokhoor PR, Cho DJ, et al Receipt of respiratory vaccines among patients with heart failure in a
multicenter health system registry.
Vaccine. 2025;46:126682. PubMedAbstract available
December 2024
PILAPITIYA D, Lee WS, Vu MN, Kelly A, et al Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses
delivering self-assembling nanoparticles.
Vaccine. 2024;46:126668. PubMedAbstract available
CHOI YJ, Jung J, Kang M, Choi MJ, et al Corrigendum to The risk of pregnancy-related adverse outcomes after COVID-19
vaccination: propensity score-matched analysis with influenza vaccination.
Vaccine. 2024;46:126676. PubMed
NAZARENO AL, Wood JG, Muscatello DJ, Homaira N, et al Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV)
vaccination in Australia: A dynamic and economic modelling analysis.
Vaccine. 2024;46:126651. PubMedAbstract available
MALTEZOU HC, Poland GA, de Lejarazu RO Influenza vaccination for children in Europe: The health of every child matters.
Vaccine. 2024 Dec 27:126675. doi: 10.1016/j.vaccine.2024.126675. PubMed
ZHANG J, Zhang L, Li J, Ma J, et al Moderate effectiveness of influenza vaccine in outpatient settings: A
test-negative study in Beijing, China, 2023/24 season.
Vaccine. 2024;46:126662. PubMedAbstract available
MA Y, Dong C, Kim JK, Zhu W, et al Impact of influenza immune imprinting on immune responses to subsequent
vaccinations in mice.
Vaccine. 2024;46:126670. PubMedAbstract available
HAEBERER M, Lopez-Ibanez de Aldecoa A, Seabroke S, Ramirez Agudelo JL, et al Hospitalization cost estimates of respiratory syncytial virus and influenza
infections in adults in Spain, 2016-2019.
Vaccine. 2024;46:126683. PubMedAbstract available
AI L, Gao Z, Lv H, Zhang J, et al Immunogenicity and safety of live attenuated influenza vaccine in children aged
3-17 years in China.
Vaccine. 2024;46:126653. PubMedAbstract available
GRIMES DR Tortured confessions? Potentially erroneous statistical inferences may underpin
misleading claims of harms in reanalyses of COVID-19 and HPV vaccines.
Vaccine. 2024 Dec 25:126657. doi: 10.1016/j.vaccine.2024.126657. PubMedAbstract available
SAVULESCU C, Prats-Uribe A, Brolin K, Uuskula A, et al Relative effectiveness of the second booster COVID-19 vaccines against laboratory
confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study
(1 October 2022-2 May 2023).
Vaccine. 2024;45:126615. PubMedAbstract available
SHELDENKAR A, Ling TP, Schulz PJ, Chen MI, et al Trust in government vaccine recommendations during the Covid-19 pandemic in
Singapore: A longitudinal survey study.
Vaccine. 2024;45:126643. PubMedAbstract available
CAMPANELLA S, Volpe T, Safar Y, Lunsky Y, et al "They need to speak a language everyone can understand": Accessibility of
COVID-19 vaccine information for Canadian adults with intellectual and
developmental disabilities.
Vaccine. 2024;45:126618. PubMedAbstract available
WERTHNER Q, Faehrmann L, Och K, Bragazzi NL, et al Client satisfaction, safety, and insights from a three-season survey on influenza
vaccinations delivered at community pharmacies in Germany.
Vaccine. 2024;45:126650. PubMedAbstract available
FRAIHA ALS, da Silva Santos BSA, Aguilar NR, Gallinari GC, et al Immunization and challenge trials in a murine model using different inactivated
recombinant vaccines against H1N1 swine influenza virus circulating in Brazil.
Vaccine. 2024;45:126638. PubMedAbstract available
WANG J, Tonnies T, Brinks R Seasonal influenza vaccination coverage and the social determinants of influenza
vaccination among people over 50 with diabetes in Europe: Analyzing
population-based SHARE data for the 2019-2020 and 2021-2022 influenza seasons.
Vaccine. 2024;45:126646. PubMedAbstract available
YANG J, Yao YL, Lv XY, Geng LH, et al The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing
assisted reproductive technology: A prospective cohort study.
Vaccine. 2024;45:126635. PubMedAbstract available
SUN JW, Dodge LE, Kim EJ, Zhou L, et al Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in
the United States.
Vaccine. 2024;45:126629. PubMedAbstract available
PERRIER Q, Noble J, Bonadona A, Augier C, et al Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of
solid organ transplants.
Vaccine. 2024;45:126617. PubMedAbstract available
MOGHTADERI A, Callaghan T, Luo Q, Motta M, et al Evidence on trends in uptake of childhood vaccines and association with COVID-19
vaccination rates.
Vaccine. 2024;45:126631. PubMedAbstract available
WILLIAMS JTB, Ritger C, Holliman BD, Huebschmann AG, et al Staff and caregivers' perceptions of digital storytelling to increase influenza
vaccine confidence in an urban safety-net healthcare system.
Vaccine. 2024;45:126572. PubMedAbstract available
KARACHALIOU M, Espinosa A, Farre X, Blay N, et al Mental illness and antibody responses after COVID-19 vaccination in a prospective
population-based study in Catalonia.
Vaccine. 2024;45:126591. PubMedAbstract available
SLAMANIG S, Lemus N, Lai TY, Singh G, et al A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5
variant vaccine reduces disease and transmission in animals against
matched-variant challenge.
Vaccine. 2024;45:126586. PubMedAbstract available
XIA M, Huang P, Vago FS, Jiang W, et al Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza
viruses elicited high HA1-specific antibody responses and protected mice against
mortality caused by influenza virus challenges.
Vaccine. 2024 Dec 7:126585. doi: 10.1016/j.vaccine.2024.126585. PubMedAbstract available
BODY A, Lal L, Srihari S, MacIntyre CR, et al Comprehensive humoral and cellular immune responses to COVID-19 vaccination in
adults with cancer.
Vaccine. 2024 Dec 7:126547. doi: 10.1016/j.vaccine.2024.126547. PubMedAbstract available
CUNNINGHAM-ERVES J, Sanderson M, Jin SW, Davis J, et al Predictors of HPV vaccination coverage among adolescents in Tennessee during the
COVID-19 pandemic: A cross-sectional study.
Vaccine. 2024 Dec 7:126581. doi: 10.1016/j.vaccine.2024.126581. PubMedAbstract available
KAPLAN BS, Souza CK, Kimble JB, Brand MW, et al A neuraminidase-based inactivated influenza virus vaccine significantly reduced
virus replication and pathology following homologous challenge in swine.
Vaccine. 2024 Dec 6:126574. doi: 10.1016/j.vaccine.2024.126574. PubMedAbstract available
SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al Vaccine safety surveillance in South Africa through COVID-19: A journey to
systems strengthening.
Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535. PubMedAbstract available
HODGSON D, Sanchez-Ovando S, Carolan L, Liu Y, et al Quantifying the impact of pre-vaccination titre and vaccination history on
influenza vaccine immunogenicity.
Vaccine. 2024 Dec 4:126579. doi: 10.1016/j.vaccine.2024.126579. PubMedAbstract available
VYSE A, Wright H, Begier E Estimating adult accident and emergency attendances in English hospitals
attributed to respiratory syncytial virus.
Vaccine. 2024;42:126412. PubMedAbstract available
AVERIN A, Sato R, Begier E, Gessner BD, et al Annual public health and economic burden of medically attended respiratory
syncytial virus illnesses among US adults.
Vaccine. 2024;42:126323. PubMedAbstract available
FOTAKIS EA, Picasso E, Sacco C, Petrone D, et al Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in
preventing severe COVID-19 cases in Italy (October 2023-March 2024).
Vaccine. 2024;42:126375. PubMedAbstract available
PRY JM, McCullough K, Lai KW, Lim E, et al Defining long COVID using a population-based SARS-CoV-2 survey in California.
Vaccine. 2024;42:126358. PubMedAbstract available
CHUN J, Yoon D, Nowakowska A, Lee HD, et al Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector
enhance the immune breadth against SARS-CoV-2 variants of concern.
Vaccine. 2024;42:126355. PubMedAbstract available
CANETTI M, Barda N, Lustig Y, Weiss-Ottolenghi Y, et al Risk factors and correlates of protection against XBB SARS-CoV-2 infection among
health care workers.
Vaccine. 2024;42:126308. PubMedAbstract available
November 2024
GONG S, Beukema M, De Vries-Idema J, Huckriede A, et al Assessing human B cell responses to influenza virus vaccines and adjuvants in a
PBMC-derived in vitro culture system.
Vaccine. 2024;44:126563. PubMedAbstract available
PICHE-RENAUD PP, Drover SSM, Austin PC, Morris SK, et al COVID-19 vaccine effectiveness against severe omicron-related outcomes in
children aged 5 to 11 years in Ontario: A Canadian immunization research network
(CIRN) study.
Vaccine. 2024 Nov 30:126539. doi: 10.1016/j.vaccine.2024.126539. PubMedAbstract available
COSMA C, Radi A, Cattano R, Zanobini P, et al Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A
scoping review of the literature.
Vaccine. 2024;44:126559. PubMedAbstract available
FLORES D, Luna EM The effectiveness of vaccines against COVID-19 in Mexico: A time series approach.
Vaccine. 2024;44:126565. PubMedAbstract available
THIEM VD, Anh DD, Ha VH, Van Thom N, et al Safety and immunogenicity of an inactivated recombinant Newcastle disease virus
vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2
trial.
Vaccine. 2024;44:126542. PubMedAbstract available
WANG Q, Yang L, Li L, Xiu S, et al Investigating parental perceptions of respiratory syncytial virus (RSV) and
attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.
Vaccine. 2024;44:126570. PubMedAbstract available
GEMANDER N, Kemlin D, Depickere S, Kelkar NS, et al COVID-19 vaccine responses are influenced by distinct risk factors in naive and
SARS-CoV-2 experienced hemodialysis recipients.
Vaccine. 2024;44:126544. PubMedAbstract available
BLUKACZ A, Obach A, Vasquez P, Campana C, et al Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and
middle-income countries: A systematic review of qualitative evidence and thematic
synthesis.
Vaccine. 2024;44:126546. PubMedAbstract available
AMODIO D, Angelidou A, Cotugno N, Sherman AC, et al Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from
the fourth international precision vaccines conference.
Vaccine. 2024;43. PubMedAbstract available
CHOI YJ, Jung J, Kang M, Choi MJ, et al The risk of pregnancy-related adverse outcomes after COVID-19 vaccination:
Propensity score-matched analysis with influenza vaccination.
Vaccine. 2024;44:126506. PubMedAbstract available
DEAN NE, Halloran ME, Zarnitsyna VI Poor vaccine responders mask the true trend in vaccine effectiveness against
progression to severe disease.
Vaccine. 2024;43. PubMedAbstract available
LEE M, Qin C, Lee Y, Deng J, et al COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron
surge in South Korea and China.
Vaccine. 2024;43. PubMedAbstract available
DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian
indigenous adolescents.
Vaccine. 2024;43. PubMedAbstract available
MEELDIJK A, Vandeberg L, Akkermans R, Hautvast J, et al How text message reminders increase COVID-19 booster vaccine uptake: Two
randomized controlled trials.
Vaccine. 2024;43. PubMedAbstract available
MAO J, Kang HJ, Eom GD, Yoon KW, et al Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like
particles co-expressing M2e5x or N2.
Vaccine. 2024;43. PubMedAbstract available
VASQUEZ WF, Trudeau JM Americans' willingness to give to global immunization programs: Political
heterogeneity in preferences for program management and response to priming
communications.
Vaccine. 2024;42:126126. PubMedAbstract available
KIRK B, Bush C, Toyip A, Mues KE, et al Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2
among adults aged >/= 65 years in the United States.
Vaccine. 2024;42:126113. PubMedAbstract available
BONNIN FA, Talarico LB, Ferolla FM, Acosta PL, et al Antibody levels against respiratory syncytial virus fusion protein conformations
and lack of association with life-threatening infection in previously healthy
infants.
Vaccine. 2024;42:126119. PubMedAbstract available
LOCKMAN A, Callaghan T, Blackburn CC, Colwell B, et al Vaccine spillover effects in Africa: A cross-national study of vaccine spillover
and confidence in Kenya, Nigeria, and South Africa.
Vaccine. 2024;43. PubMedAbstract available
JASTORFF A, Gymnopoulou E, Salas J, Merrall E, et al Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18
to 59 years with and without at-risk comorbidities for severe respiratory
syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
Vaccine. 2024;43. PubMedAbstract available
REGAN AK, Couture MC, Callaghan T, Agnew B, et al Modification and validation of a vaccine hesitancy scale for adolescent COVID-19
vaccination.
Vaccine. 2024;43. PubMedAbstract available
LOPEZ-MACIAS C, Torres M, Armenta-Copca B, Wacher NH, et al Phase II study on the safety and immunogenicity of single-dose intramuscular or
intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle
disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
Vaccine. 2024;43. PubMedAbstract available
GWAK E, Choe SA, Bolormaa E, Choe YJ, et al Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19
vaccinations in South Korea.
Vaccine. 2024;43. PubMedAbstract available
MATTES F, Dratva J, Schmelzer S, Wagner A, et al The association between service experience in vaccination centers and expectation
confirmation as a driver of future vaccination intentions: Results from a survey
among users of a Swiss mass COVID-19 vaccination center.
Vaccine. 2024;43. PubMedAbstract available
AGUIRRE-CAMACHO A, Hidalgo B, Rash JA Exposure to objective/sensationalist information moderates associations between
psychological factors and COVID-19 anti-vaccination attitudes: An experimental
study.
Vaccine. 2024;43. PubMedAbstract available
LEWIS NM, Harker EJ, Leis A, Zhu Y, et al Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness
analyses - IVY Network, September 1, 2022-March 30, 2023.
Vaccine. 2024;43. PubMedAbstract available
WILLIAMS E, Echeverri Tribin F, Carreno JM, Krammer F, et al Proteomic signatures of vaccine-induced and breakthrough infection-induced host
responses to SARS-CoV-2.
Vaccine. 2024;43. PubMedAbstract available
DENG Y, Hayes KN, Zhao Y, Chachlani P, et al Variation in the time to complete the primary COVID-19 vaccine series by race,
ethnicity, and geography among older US adults.
Vaccine. 2024;43. PubMedAbstract available
STEFFENS MS, Bolsewicz KT, King C, Bullivant B, et al Australian parents' experiences with adolescent age-based vaccinations during the
COVID-19 pandemic.
Vaccine. 2024;43. PubMedAbstract available
LE MARCHAND C, Singson JRC, Clark A, Shah D, et al Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status
in California.
Vaccine. 2024;43. PubMedAbstract available
DELARUELLE K, Lermytte E, Bockstal M, Vuolanto P, et al Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of
preventive practices.
Vaccine. 2024;43. PubMedAbstract available
KIM SA, Maeda M, Murata F, Fukuda H, et al Effect of COVID-19 vaccination on the risk of developing post-COVID conditions:
The VENUS study.
Vaccine. 2024;43. PubMedAbstract available
CHARLAND K, Quach C, Papenburg J, Pierce L, et al Parental decisions regarding the vaccination of children and adolescents against
SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and
children in Montreal, Canada.
Vaccine. 2024;43. PubMedAbstract available
October 2024
KASAMATSU A, Yahata Y, Fukushima W, Sakamoto H, et al Estimating influenza vaccine effectiveness among older adults using an integrated
administrative database and the implications of potential bias: A
population-based cohort study in Japan.
Vaccine. 2024;42:126488. PubMedAbstract available
SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens
and induce dual immunity in mice.
Vaccine. 2024;42:126463. PubMedAbstract available
HOFSTETTER AM, Klein EJ, Strelitz B, Selvarangan R, et al On-time childhood vaccination before and during the COVID-19 pandemic in seven
communities: Findings from the New Vaccine Surveillance Network.
Vaccine. 2024;42:126455. PubMedAbstract available
MACINTYRE CR, Akhtar Z, Moa A Corrigendum to "Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine
42/26 (2024) 126450]".
Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486. PubMed
LEIS AM, Wagner A, Flannery B, Chung JR, et al Evaluation of test-negative design estimates of influenza vaccine effectiveness
in the context of multiple, co-circulating, vaccine preventable respiratory
viruses.
Vaccine. 2024;42:126493. PubMedAbstract available
WHITE TM, Lazarus JV, Rabin KH, Ratzan SC, et al Emerging global patterns of COVID-19 vaccine information fatigue in 23 countries
in 2023.
Vaccine. 2024;42:126475. PubMedAbstract available
EBERHARDT J, Al-Qerem W, Ling J Comparing COVID-19 booster vaccine acceptance in the United Kingdom, Germany,
Austria, and Jordan: The role of protection motivation theory, conspiracy
beliefs, social media use and religiosity.
Vaccine. 2024;42:126474. PubMedAbstract available
MCGREGOR R, Paterson A, Lavender B, Hooker C, et al The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023:
Impact of vaccination and infection.
Vaccine. 2024;42:126482. PubMedAbstract available
LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al Exploring the delivery of adult vaccination outside of primary care settings: A
mixed methods scoping review.
Vaccine. 2024;42:126458. PubMedAbstract available
HO TC, Chuang SC, Hung KC, Chang CC, et al Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination.
Vaccine. 2024;42:126470. PubMedAbstract available
LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al Exploring the attitudes and practices of adult service users and providers
towards vaccination in non-primary care settings: A mixed methods scoping review.
Vaccine. 2024;42:126472. PubMedAbstract available
MOHD HISHAM AA, Mat Yassim AS, Suppian R, Azlan M, et al Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2
homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month
prospective study in Malaysia.
Vaccine. 2024;42:126471. PubMedAbstract available
JORDAN E, Jenkins V, Silbernagl G, Chavez MPV, et al A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows
moderate protection against disease caused by RSV in older adults in a phase 3
clinical study.
Vaccine. 2024;42:126427. PubMedAbstract available
TUFFY KM, Ahani B, Domachowske JB, Furuno K, et al Molecular and phenotypic characteristics of respiratory syncytial virus isolates
recovered from medically vulnerable children: An exploratory analysis of a phase
2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab
(MEDLEY).
Vaccine. 2024;42:126276. PubMedAbstract available
ROWE M, Collier AY, Barouch DH Insights from an observational translational research program during the COVID-19
pandemic: Four years of experience.
Vaccine. 2024;42:126306. PubMedAbstract available
PHAM-HUY A, Bowes J, Russell K, Amira A, et al Short- and long-term outcomes of cardiac adverse events following COVID-19
immunization managed in a Canadian pediatric center.
Vaccine. 2024;42:126090. PubMedAbstract available
SINTAYEHU K, Shaum A, Bonger ZT, Dagnachew Zeleke E, et al Applicability of selected Brighton Collaboration case definitions in low-resource
settings: A prospective hospital-based active surveillance in Addis Ababa,
Ethiopia.
Vaccine. 2024;42:126079. PubMedAbstract available
GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al The 2020 immunization programme landscape: Piloting an assessment metric to
evaluate the maturity of national immunization programmes across the life course.
Vaccine. 2024;42 Suppl 4:125541. PubMedAbstract available
NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A
population-based study using electronic health records in Singapore.
Vaccine. 2024;42:126462. PubMedAbstract available
DARKO DM, Seaneke SK, Karikari-Boateng E, Nkansah E, et al Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A
cohort event monitoring study.
Vaccine. 2024;42:126460. PubMedAbstract available
AB RAHMAN N, King TL, Peariasamy KM, Sivasampu S, et al Risk of major adverse cerebro-cardiovascular events following BNT162b2,
CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled
case-series study.
Vaccine. 2024;42:126465. PubMedAbstract available
SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an
integrated health system.
Vaccine. 2024;42:126440. PubMedAbstract available
WICKLINE MM, Carpenter PA, Harris JR, Iribarren SJ, et al Vaccine hesitancy and routine revaccination among adult HCT survivors in the
United States: A convergent mixed methods analysis.
Vaccine. 2024;42:126374. PubMedAbstract available
HARRACHE A, Saker K, Mokdad B, Generenaz L, et al Anti-RBD IgG dynamics following infection or vaccination.
Vaccine. 2024;42:126464. PubMedAbstract available
MACINTYRE CR, Akhtar Z, Moa A Influenza B/Yamagata cannot currently be declared extinct.
Vaccine. 2024 Oct 18:126450. doi: 10.1016/j.vaccine.2024.126450. PubMed
MA SH, Chen TL, Ou WF, Chao WC, et al The risk of postherpetic neuralgia in COVID-19 vaccination-associated herpes
zoster: A retrospective cohort study using TriNetX.
Vaccine. 2024;42:126451. PubMedAbstract available
EVIATAR T, Ziv A, Oved A, Miller-Barmak A, et al Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in
children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic
diseases: A prospective multicenter study.
Vaccine. 2024;42:126426. PubMedAbstract available
NAZARENO AL, Newall AT, Muscatello DJ, Hogan AB, et al Modelling the epidemiological impact of maternal respiratory syncytial virus
(RSV) vaccination in Australia.
Vaccine. 2024;42:126418. PubMedAbstract available
SANO K, Kurosawa T, Horikawa K, Kimura Y, et al Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5
monovalent vaccination in Japan.
Vaccine. 2024;42:126452. PubMedAbstract available
NUZHATH T, Colwell B, Callaghan T, Hotez P, et al Pediatric COVID-19 vaccine hesitancy among pregnant and post-partum women: A
mixed-method study.
Vaccine. 2024;42:126420. PubMedAbstract available
EIDEN AL, Drakeley S, Modi K, Mackie D, et al Attitudes and beliefs of healthcare providers toward vaccination in the United
States: A cross-sectional online survey.
Vaccine. 2024;42:126437. PubMedAbstract available
COCKERILL R, Horney JA, Penta SC, Silver A, et al Factors associated with COVID-19 vaccination or intent to be vaccinated across
three U.S. states.
Vaccine. 2024;42:126457. PubMedAbstract available
TOP KA, Shulha HP, Muller MP, Valiquette L, et al Participant-reported neurological events following immunization in the Canadian
National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study.
Vaccine. 2024;42:126445. PubMedAbstract available
HSIEH HC, Chen CC, Liu WC, Wu SC, et al Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a
subunit after primary mRNA vaccination in mice.
Vaccine. 2024;42:126448. PubMedAbstract available
SEDAGHAT M, Karami B, Najafi F, Shadmani FK, et al Gender differences in adverse effects following the second dose of AstraZeneca
COVID-19 vaccine: a cross-sectional study among healthcare workers.
Vaccine. 2024;42:126424. PubMedAbstract available
LITAO L, Feng C, Hongyu Z, Wenbin C, et al Field production efficiency investigation of broilers immunized with a turkey
herpesvirus vector vaccine expressing hemagglutinin from H9N2 subtype avian
influenza virus.
Vaccine. 2024;42:126436. PubMedAbstract available
DOYON-PLOURDE P, Farley R, Krishnan R, Tunis M, et al Direct quantitative comparison of benefits and risks of COVID-19 vaccines used in
National Immunization Technical Advisory Groups Guidance during the first two
years of the pandemic.
Vaccine. 2024;42:126406. PubMedAbstract available
TAAFFE J, Ostrowsky JT, Mott J, Goldin S, et al Advancing influenza vaccines: A review of next-generation candidates and their
potential for global health impact.
Vaccine. 2024;42:126408. PubMedAbstract available
MWAMBA G, Gibson EM, Toko C, Tunda C, et al Effective integration of COVID-19 vaccination with routine immunization: A case
study from Kinshasa, DRC.
Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392. PubMedAbstract available
PASCOE KM, Bishop S, Ci X, Ramirez M, et al Factors that shape COVID-19 pediatric vaccine decision-making in rural
agricultural communities: A qualitative study.
Vaccine. 2024;42:126389. PubMedAbstract available
HOJO-SOUZA NS, de Castro JT, Rivelli GG, Azevedo PO, et al SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows
high efficacy in experimental models challenged with SARS-CoV-2 variants of
concern.
Vaccine. 2024;42:126394. PubMedAbstract available
ALANSARI KDH, Buhl C, Thabit AK, Badr AF, et al Validation of the Arabic translation of the vaccination attitudes examination
(VAX) scale.
Vaccine. 2024;42:126411. PubMedAbstract available
EARP M, Meng L, Black CL, Carter RJ, et al Using regression tree analysis to examine demographic and geographic
characteristics of COVID-19 vaccination trends over time, United States, May
2021-April 2022, National Immunization Survey Adult COVID Module.
Vaccine. 2024;42:126372. PubMedAbstract available
REN J, Gao Q, Zhou X, Chen L, et al Identification of gene and protein signatures associated with long-term effects
of COVID-19 on the immune system after patient recovery by analyzing single-cell
multi-omics data using a machine learning approach.
Vaccine. 2024;42:126253. PubMedAbstract available
RAMIREZ MA, Loaiza RA, Martinez-Balboa Y, Bruneau N, et al Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust
antiviral immunity.
Vaccine. 2024;42:126203. PubMedAbstract available
GALLANT AJ, Steenbeek A, Halperin SA, Parsons Leigh J, et al Operationalizing the Behaviour Change Wheel and APEASE criteria to co-develop
recommendations with stakeholders to address barriers to school-based
immunization programs.
Vaccine. 2024;42:126226. PubMedAbstract available
MENG Q, Wang B, Du Q, Zhang X, et al Seroprevalence of B. pertussis infection and the changes of specific antibody
levels in health care workers during the first two years of COVID-19 in Wuhu,
China.
Vaccine. 2024;42:126239. PubMedAbstract available
GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al Evaluation of the potential impact and cost-effectiveness of respiratory
syncytial virus (RSV) prevention strategies for infants in Argentina.
Vaccine. 2024;42:126234. PubMedAbstract available
LANGER S, Holzapfel S, August L, Badura A, et al Parental knowledge and attitudes to infant immunization in the context of RSV:
All about confidence?
Vaccine. 2024;42:126050. PubMedAbstract available
CHOI YJ, Song JY, Wie SH, Choi WS, et al Real-world effectiveness of influenza vaccine over a decade during the 2011-2021
seasons-Implications of vaccine mismatch.
Vaccine. 2024;42:126381. PubMedAbstract available
PATRICK-SMITH M, Emary K, Hodgson SH, Thomas TM, et al Roles and responsibilities of participants, researchers, and the media in the
communication of vaccine trials: Experience from the United Kingdom's first
COVID-19 vaccine trial.
Vaccine. 2024;42:126391. PubMedAbstract available
September 2024
LYU X, Liu X, Hong H Validation of the Chinese version of the vaccine conspiracy beliefs scale during
COVID-19 pandemic and its correlates.
Vaccine. 2024;42:126395. PubMedAbstract available
SOTOODEH A, Hedberg P, Granath F, Alfven T, et al Sociodemographic determinants of COVID-19 vaccination in adolescents in
Stockholm, Sweden.
Vaccine. 2024;42:126388. PubMedAbstract available
ENGLAND A, Sung J, Deulofeu M, Soler LF, et al Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2
vaccine (Bimervax(R)) by HIPRA.
Vaccine. 2024;42:126386. PubMedAbstract available
LAZARUS R, Harris R, Thirard R, Baos S, et al Comparison of assays used to detect antibody response in COVID-19 vaccine trials:
Results from of a UK multi-Centre randomised controlled trial to determine the
immunogenicity responses of COVID-19 vaccines administered concomitantly with
seasonal inf
Vaccine. 2024;42:126369. PubMedAbstract available
AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al The impact of coronavirus pandemic shutdowns on immunization completion in
Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering
healthcare system.
Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383. PubMedAbstract available
BERNADIN O, Cochin M, Driouich JS, Laprie C, et al Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate
AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer
Programme.
Vaccine. 2024;42:126378. PubMedAbstract available
LAEMMLE-RUFF I, Fryk JJ, Shenton P, Clothier HJ, et al Detailed review of mortality reported following COVID-19 vaccination in Victoria,
Australia: 2021-2023.
Vaccine. 2024;42:126368. PubMedAbstract available
GOLDIN S, Brooks D, Jorgensen P, Wijesinghe P, et al Seasonal influenza vaccination: A global review of national policies in 194 WHO
member states in 2022.
Vaccine. 2024;42:126274. PubMedAbstract available
IMRAN M, Mills C, McDermott KW, Dean A, et al Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in
older adults with risk factors for influenza complications during the
2019-2020 U.S. influenza season.
Vaccine. 2024;42:126316. PubMedAbstract available
WEE LE, Malek MIBA, Tan J, Chiew C, et al Risk of death and cardiovascular events following COVID-19 vaccination or
positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.
Vaccine. 2024;42:126356. PubMedAbstract available
ROELS S, Bruckner M, Sadoff J, Cardenas V, et al Pre- and post-Ad26.COV2.S booster dose antibody levels predict COVID-19 disease
risk.
Vaccine. 2024;42:126159. PubMedAbstract available
ESTRELLA-PORTER P, Blanco-Calvo C, Lameiras-Azevedo AS, Juaneda J, et al Effectiveness of nirsevimab introduction against respiratory syncytial virus in
the Valencian Community: A preliminary assessment.
Vaccine. 2024;42:126030. PubMedAbstract available
REICHERZ F, Li S, Watts AA, Goldfarb DM, et al Bordetella pertussis infection following relaxation of COVID-19
non-pharmaceutical interventions in 2021-2023 in Vancouver metropolitan area,
British Columbia, Canada.
Vaccine. 2024;42:126004. PubMedAbstract available
SHEN AK, Gutu V, Druc A, Ebama M, et al An evaluation of the National Influenza Vaccination Program in the Republic of
Moldova, 2023-2024.
Vaccine. 2024;42:126322. PubMedAbstract available
MEANEY-DELMAN D, Carroll S, Polen K, Jatlaoui TC, et al Planning for the future of maternal immunization: Building on lessons learned
from the COVID-19 pandemic.
Vaccine. 2024;42 Suppl 3. PubMedAbstract available
JONES-JACK N, El Kalach R, Yassanye D, Link-Gelles R, et al Advancing public health informatics during the COVID-19 pandemic: Lessons learned
from a public-private partnership with pharmacies.
Vaccine. 2024;42 Suppl 3:125667. PubMedAbstract available
HEINS MJ, Spreeuwenberg P, Caini S, Hooiveld M, et al Measuring the impact of influenza vaccination in the Netherlands using
retrospective observational primary care, hospitalisation and mortality data.
Vaccine. 2024;42:126244. PubMedAbstract available
KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax
study.
Vaccine. 2024;42:126320. PubMedAbstract available
SHIU EYC, Cheng SMS, Martin-Sanchez M, Au NYM, et al Durability for 12 months of antibody response to a booster dose of monovalent
BNT162b2 in adults who had initially received 2 doses of inactivated vaccine.
Vaccine. 2024;42:126317. PubMedAbstract available
VAN HEESBEEN R, Bastian AR, Omoruyi E, Rosen J, et al Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF
protein vaccine in adults aged 60 years and older: A randomized, double-blind,
placebo-controlled, phase 2a study.
Vaccine. 2024;42:126273. PubMedAbstract available
BAFFOUR AWUAH G, Tanaka LF, Eberl M, Donnachie E, et al Analysis of health claims data on vaccination coverage in older adults in
Bavaria, Germany: Influenza, pneumococcus and herpes zoster.
Vaccine. 2024;42:126354. PubMedAbstract available
CHANG JY, Chang M, Huang S, Bosco J, et al COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during
the early pandemic in New York City.
Vaccine. 2024;42:126260. PubMedAbstract available
GAUDOUEN H, Tattevin P, Thibault V, Menard G, et al Determinants of influenza and COVID vaccine uptake in healthcare workers: A
cross-sectional survey during the post-pandemic era in a network of academic
hospitals in France.
Vaccine. 2024;42:126272. PubMedAbstract available
REGAN AK, Sullivan SG, Arah OA Maternal influenza vaccination and associated risk of fetal loss: A claims-based
prospective cohort study.
Vaccine. 2024;42:126256. PubMedAbstract available
BLASCO A, Royuela A, Garcia-Gomez S, Gomez-Lozano N, et al Association of SARS-CoV-2 immunoserology and vaccination status with myocardial
infarction severity and outcome.
Vaccine. 2024;42:126305. PubMedAbstract available
WOO EJ, Miller ER, Stroud E Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse
Event Reporting System (2003-2024).
Vaccine. 2024;42:126290. PubMedAbstract available
HOXIE I, Vasilev K, Clark JJ, Bushfield K, et al A recombinant N2 neuraminidase-based CpG 1018(R) adjuvanted vaccine provides
protection against challenge with heterologous influenza viruses in mice and
hamsters.
Vaccine. 2024;42:126269. PubMedAbstract available
GROOM HC, Biel FM, Crane B, Sun E, et al Disparities in COVID-19 vaccination receipt by race, ethnicity, and social
determinants of health among a large patient population in a network of
community-based healthcare centers.
Vaccine. 2024;42:126288. PubMedAbstract available
HUTTON DW, Prosser LA, Rose AM, Mercon K, et al Cost-effectiveness of vaccinating adults aged 60 years and older against
respiratory syncytial virus.
Vaccine. 2024;42:126294. PubMedAbstract available
POH XY, Torres-Ruesta A, Yoong T, Wong N, et al Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants:
Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Vaccine. 2024;42:126275. PubMedAbstract available
KIM C, Dunphy C, Duggar C, Pike J, et al Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program
in the United States, December 20, 2020-May 31, 2021.
Vaccine. 2024;42:126287. PubMedAbstract available
BONNER C, Taba M, Fajardo MA, Batcup C, et al Using health literacy principles to improve understanding of evolving evidence in
health emergencies: Optimisation and evaluation of a COVID-19 vaccination
risk-benefit calculator.
Vaccine. 2024;42:126296. PubMedAbstract available
LIU S, van Dijk LLA, den Hartog Y, Hoek R, et al mRNA-based COVID-19 vaccination of lung transplant recipients with prior
SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
Vaccine. 2024;42:126250. PubMedAbstract available
BOTTON J, Bertrand M, Jabagi MJ, Duranteau L, et al Risk of heavy menstrual bleeding following COVID-19 vaccination: A nationwide
case-control study.
Vaccine. 2024;42:126252. PubMedAbstract available
COLEMAN BL, Gutmanis I, Bondy SJ, Harrison R, et al Canadian health care providers' and education workers' hesitance to receive
original and bivalent COVID-19 vaccines.
Vaccine. 2024;42:126271. PubMedAbstract available
August 2024
MACKAY H, Gretton JD, Chyderiotis S, Elliott S, et al Confidence and barriers: Analysis of factors associated with timely routine
childhood vaccination in Canada during the COVID-19 pandemic.
Vaccine. 2024;42:126236. PubMedAbstract available
GUARNIERI V, Macucci C, Mollo A, Trapani S, et al Impact of respiratory syncytial virus on older children: Exploring the potential
for preventive strategies beyond the age of 2 years.
Vaccine. 2024;42:126170. PubMedAbstract available
AIZAWA Y, Sato I, Abe Y, Sasagawa F, et al Impact of the emergence of severe acute respiratory syndrome coronavirus 2
omicron variants on routine childhood immunization in Japan.
Vaccine. 2024;42:126137. PubMedAbstract available
MAI W, Shen J, Ma F, Zhu J, et al Specific humoral immune response and XBB variants re-infection risk of
hemodialysis patients after Omicron BA.5 infection in China.
Vaccine. 2024;42:126108. PubMedAbstract available
EYAWO O, Ugoji UC, Pan S, Oyibo P, et al Predictors of the willingness to accept a free COVID-19 vaccine among households
in Nigeria.
Vaccine. 2024;42:126225. PubMedAbstract available
BRESEE JS, Lafond KE The partnership for international vaccine initiatives: The importance and
opportunity to develop influenza vaccination programs in low- and middle-income
countries.
Vaccine. 2024 Aug 29:126255. doi: 10.1016/j.vaccine.2024.126255. PubMed
HARADA Y, Takahashi H, Fujimoto T, Horikoshi F, et al Evaluation of a qualified MDCK cell line for virus isolation to develop
cell-based influenza vaccine viruses with appropriate antigenicity.
Vaccine. 2024;42:126242. PubMedAbstract available
LLABRE MM, Timpano KR, Broos HC, Leite RO, et al Lessons from a longitudinal community-based investigation of adherence to
guidelines and intent to vaccinate during the COVID-19 pandemic.
Vaccine. 2024;42:126265. PubMedAbstract available
PATHER S, Charpentier N, van den Ouweland F, Rizzi R, et al A Brighton Collaboration standardized template with key considerations for a
benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
Vaccine. 2024;42:126165. PubMedAbstract available
FERREIRA-SILVA SN, Soares MEM, Vasconcelos R, Barbieri C, et al COVID-19 vaccine hesitancy: Meaning relations between responses in an
epidemiological study and twitter messages.
Vaccine. 2024;42:126247. PubMedAbstract available
SINGH D, Damasevicius R, Kumar V, Bagnoli F, et al Editorial: ML-driven vaccine against COVID-19: Developmental challenges and
foresight.
Vaccine. 2024;42:126267. PubMed
VIELOT NA, Kelly NK, Ludema C, Rosenberg M, et al Patterns and predictors of COVID-19 vaccination among young adults at 44 US
sites: Secondary analysis of a randomized, controlled, open-label trial, March -
December 2021.
Vaccine. 2024;42:126237. PubMedAbstract available
UNAGAMI K, Yoshikawa M, Egawa H, Ohfuji S, et al Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid
organ transplant recipients: Prospective cohort study.
Vaccine. 2024;42:126221. PubMedAbstract available
SHINJOH M, Yaginuma M, Yamaguchi Y, Tamura K, et al Effectiveness of inactivated influenza vaccine in children during the 2023/24
season: The first season after relaxation of intensive COVID-19 measures.
Vaccine. 2024;42:126241. PubMedAbstract available
ADAMS L, Prasinou AK, Hadley L, Ramsay M, et al Estimating the potential number of cases prevented by infant/ toddler
immunisation with a MenACWY vaccine.
Vaccine. 2024;42:126240. PubMedAbstract available
OGAR CK, Gilbert HN, Bloem LT, Leopold C, et al Patient-reported outcomes of adverse events after COVID-19 vaccination in
Nigeria: A mixed methods study.
Vaccine. 2024;42:126196. PubMedAbstract available
ESPOSITO GL, Fassio F, Girardi D, Picasso E, et al "REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis
against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised
patients (REALISE).
Vaccine. 2024;42:126208. PubMedAbstract available
SANFTENBERG L, Bader F, Rottenkolber M, Sebastiao M, et al Associations of mental health with vaccination readiness in informal caregivers
and the vaccination status of their care recipients during the Covid-19 pandemic
- A cross sectional analysis.
Vaccine. 2024;42:126218. PubMedAbstract available
HERNANDEZ-BERNAL F, Noa-Romero E, Quintana-Guerra J, Chavez-Chong CO, et al Efficacy and safety of Abdala COVID-19 subunit vaccine in children and
adolescents: An open-label, single-arm, phase 2 trial (MENIQUE).
Vaccine. 2024;42:126223. PubMedAbstract available
IHENETU G, Aylin P, Novov V, Skirrow H, et al Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19
in pregnancy: Retrospective cohort study.
Vaccine. 2024 Aug 13:126214. doi: 10.1016/j.vaccine.2024.126214. PubMedAbstract available
WALDEN J, Stanek JR, Young J, Griffith MM, et al Influenza vaccine uptake among youth with sickle cell disease who are seen in
clinic before and after the COVID-19 pandemic.
Vaccine. 2024;42:126212. PubMedAbstract available
GRAF DD, Westphal L, Hallgreen CE The life cycle of vaccines evaluated by the European Medicines Agency.
Vaccine. 2024;42:126186. PubMedAbstract available
GOMEZ-ACEBO I, Barquin-Ruiz A, Llorente S, Alonso-Molero J, et al The impact of the COVID-19 pandemic on childhood vaccination rates and the role
of sociodemographic factors: A cohort study.
Vaccine. 2024;42:126207. PubMedAbstract available
BAJPAI D, Bose S, Saxena N, Kulkarni B, et al Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients.
Vaccine. 2024 Aug 8:126206. doi: 10.1016/j.vaccine.2024.126206. PubMedAbstract available
GAO Y, Yang X, Li X, Chen H, et al Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion
inactivated influenza vaccine in healthy population aged 9-59 years: A
randomized, double-blind, controlled, phase IV clinical trial.
Vaccine. 2024;42:126182. PubMedAbstract available
D'SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al Understanding structural inequities in Covid-19 vaccine access and uptake among
disability, transgender and gender-diverse communities in India.
Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174. PubMedAbstract available
GEORGE G, Strauss M, Lansdell E, Nota P, et al Factors associated with COVID-19 vaccine uptake among south African health care
workers.
Vaccine. 2024;42:126181. PubMedAbstract available
BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al Identifying psychological predictors of SARS-CoV-2 vaccination: A machine
learning study.
Vaccine. 2024;42:126198. PubMedAbstract available
BOKEL J, Martins-Goncalves R, Grinsztejn E, Mendes-de-Almeida DP, et al Anti-PF4 positivity and platelet activation after Ad26.COV2.S vaccination in
Brazil.
Vaccine. 2024 Aug 5:126175. doi: 10.1016/j.vaccine.2024.126175. PubMedAbstract available
MCCARRON M, Marcenac P, Yau TS, Lafond KE, et al Healthcare personnel acceptance and recommendations for influenza vaccine in
twelve low- and middle-income countries: A pooled analysis from 2018 to 2020.
Vaccine. 2024 Aug 2:125670. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
AUGELLO M, Wagenhauser I, Krone M, Dauby N, et al Should SARS-CoV-2 serological testing be used in the decision to deliver a
COVID-19 vaccine booster? A pro-con assessment.
Vaccine. 2024 Aug 2:126184. doi: 10.1016/j.vaccine.2024.126184. PubMedAbstract available
JIANG M, Zhang H, Yao X, Wang Y, et al Immunization-related stress and stress-related responses of mucosal versus
intramuscular COVID-19 vaccination among adults in China.
Vaccine. 2024 Aug 1:126150. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WOOLFORK MN, Haire K, Farinu O, Ruffin J, et al A health equity science approach to assessing drivers of COVID-19 vaccination
coverage disparities over the course of the COVID-19 pandemic, United States,
December 2020-December 2022.
Vaccine. 2024 Aug 1:126158. doi: 10.1016/j.vaccine.2024.126158. PubMedAbstract available
July 2024
MATSUMOTO N, Sasaki A, Kadowaki T, Mitsuhashi T, et al Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an
Omicron surge in Japan.
Vaccine. 2024;42:126156. PubMedAbstract available
ASUPOTO O, Li X, Hemberg JL, Emerson A, et al COVID-19 and influenza vaccine uptake in women with criminal-legal system
involvement.
Vaccine. 2024 Jul 30:126176. doi: 10.1016/j.vaccine.2024.126176. PubMedAbstract available
GE Y, Lu Y, Allen JD, Einav T, et al Pre-existing immunity to influenza aids ferrets in developing stronger and
broader H3 vaccine-induced antibody responses.
Vaccine. 2024 Jul 29:126149. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ELYASS J, Desalegn A, Trinh NTH, Orangzeb S, et al Individual and familial factors associated with mRNA COVID-19 vaccine uptake in
pregnancy: A large-scale registry-based linkage study.
Vaccine. 2024 Jul 29:126171. doi: 10.1016/j.vaccine.2024.126171. PubMedAbstract available
TAHSIN A, Bhattacharjee P, Al Saba A, Yasmin T, et al Genetic and epigenetic analyses of IFN-gamma gene proximal promoter region underlying
positive correlation between persistently high anti-SARS-CoV-2 IgG and IFN-gamma
among COVID-19 vaccinated Bangladeshi adults.
Vaccine. 2024 Jul 29:126157. doi: 10.1016/j.vaccine.2024.126157. PubMedAbstract available
GEBRETEKLE GB, Yeung MW, Ximenes R, Cernat A, et al Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of
respiratory syncytial virus disease in Canadian infants.
Vaccine. 2024 Jul 29:126164. doi: 10.1016/j.vaccine.2024.126164. PubMedAbstract available
MOTAGHI S, Pullenayegum E, Morgan RL, Loeb M, et al The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator
in children.
Vaccine. 2024 Jul 28:126122. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SULEMAN A, Vicente P COVID-19 vaccination reluctance across Europe: Lessons for the future.
Vaccine. 2024 Jul 27:126168. doi: 10.1016/j.vaccine.2024.126168. PubMedAbstract available
KHANAFER N, Oudot S, Maligeay M, Planckaert C, et al A quick access to information on influenza burden and prevention in Lyon
university hospital: A prospective QR code-based information campaign in
2022-2023.
Vaccine. 2024 Jul 26:126160. doi: 10.1016/j.vaccine.2024.126160. PubMedAbstract available
JENA D, Ghosh A, Jha A, Prasad P, et al Impact of vaccination on SARS-CoV-2 evolution and immune escape variants.
Vaccine. 2024 Jul 26:126153. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WILLIAMS LR, Emary KRW, Phillips DJ, Hay J, et al Implementation and adherence to regular asymptomatic testing in a COVID-19
vaccine trial.
Vaccine. 2024 Jul 26:126167. doi: 10.1016/j.vaccine.2024.126167. PubMedAbstract available
BILGIN GM, Munira SL, Lokuge K, Glass K, et al Mathematical modelling of the 100-day target for vaccine availability after the
detection of a novel pathogen: A case study in Indonesia.
Vaccine. 2024 Jul 26:126163. doi: 10.1016/j.vaccine.2024.126163. PubMedAbstract available
ATAULLAHJAN A, Piche-Renaud PP, Shahrbabak EK, Fadaleh SA, et al Weighing the risks and benefits: Parental perspectives on COVID-19 vaccines for
5- to 11-year-old children.
Vaccine. 2024 Jul 26:126154. doi: 10.1016/j.vaccine.2024.126154. PubMedAbstract available
JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al Effectiveness of mRNA booster doses in preventing infections and hospitalizations
due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare
workers, Spain.
Vaccine. 2024;42:4011-4021. PubMedAbstract available
WAGENHAUSER I, Almanzar G, Forg FB, Stein A, et al Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of
basic immunity show similar immunogenicity regarding long-term spike-specific
cellular immunity in healthcare workers.
Vaccine. 2024 Jul 20:126132. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZOU GQ, Li K, Yan C, Li YQ, et al Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for
enhanced COVID-19 subunit vaccine immunogenicity.
Vaccine. 2024 Jul 20:126145. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SANADA T, Honda T, Kohara M Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2
mRNA vaccination.
Vaccine. 2024 Jul 19:126146. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ANDERSON S, Kuter BJ, Brien K, Bauerle Bass S, et al Perceptions of vaccine requirements among students at four Pennsylvania
universities.
Vaccine. 2024 Jul 17:S0264-410X(24)00801-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JIN CHOI S, Lee W, Cheol Kim S, Jo HY, et al Longitudinal multiomic profiling and corticosteroid modulation of the immediate
innate immune response to an adenovirus-vector vaccine.
Vaccine. 2024 Jul 17:S0264-410X(24)00774-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SANTIBANEZ TA, Black CL, Zhou T, Srivastav A, et al Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.
Vaccine. 2024 Jul 16:S0264-410X(24)00802-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LIU G, Pang Y, Lv M, Lu M, et al Effectiveness of influenza vaccination on hospitalization outcomes among older
patients with diabetes.
Vaccine. 2024 Jul 16:S0264-410X(24)00806-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ERIKSSON M, Nylen S, Gronvik KO Passive immunization of mice with IgY anti-H5N1 protects against experimental
influenza virus infection and allows development of protective immunity.
Vaccine. 2024 Jul 16:S0264-410X(24)00796-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
STEENACKERS K, Hanning N, Bruckers L, Desombere I, et al Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine
schedules in healthy adults: The IMCOVAS randomized clinical trial.
Vaccine. 2024 Jul 16:S0264-410X(24)00773-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LUNA-MUSCHI A, Carmo Borges I, Dos Santos Barboza A, de Faria E, et al Duration of vaccine protection against breakthrough infections during five
COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac.
Vaccine. 2024 Jul 16:S0264-410X(24)00752-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TAKAHASHI Y, Tanaka H, Taniguchi C, Ogata T, et al Efficiency of indirect protection of COVID-19 vaccination and interactions
between indirect and direct protection on household transmission.
Vaccine. 2024 Jul 16:S0264-410X(24)00749-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HATFIELD K, Wiegand R, Reddy S, Patel A, et al Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among
residents of US nursing homes, November 2022 - March 2023.
Vaccine. 2024 Jul 16:S0264-410X(24)00754-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
STEFANIZZI P, Di Lorenzo A, Capodiferro L, Moscara L, et al Increasing vaccination coverage among healthcare workers: Active call and
mandatory laws. Data from a large general hospital in Southern Italy.
Vaccine. 2024 Jul 15:S0264-410X(24)00739-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FISMAN DN, Simmons AE, Tuite AR Case-cohort design as an efficient approach to evaluating COVID-19 vaccine
effectiveness, waning, heterologous immune effect and optimal dosing interval.
Vaccine. 2024 Jul 13:S0264-410X(24)00797-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JAJOU R, Lieber T, van Puijenbroek EP, Mulder E, et al GP consultations for menstrual disorders after COVID-19 vaccination - A
self-controlled cohort study based on routine healthcare data from the
Netherlands.
Vaccine. 2024 Jul 13:S0264-410X(24)00793-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LE BAGOUSSE-BERNARD A, Dussart C, Pin P, Tazarourte K, et al Mass COVID-19 vaccination center: Optimizing the vaccination pathway during a
12 month timeframe.
Vaccine. 2024 Jul 12:S0264-410X(24)00742-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HUANG WT, Law B, Tran H, Schonborn L, et al Validation of the newly proposed Brighton Collaboration case definition for
vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LI J, Gong L, Li J, Gong Z, et al Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in
response to breakthrough infection by booster.
Vaccine. 2024;42:3751-3755. PubMedAbstract available
HOEVE CE, Huiberts AJ, de Gier B, Andeweg SP, et al COVID-19 vaccination-induced antibody responses and waning by age and comorbidity
status in a large population-based prospective cohort study.
Vaccine. 2024 Jul 11:S0264-410X(24)00783-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GARCIA S, Shin M, Gill M, He Z, et al Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to
inform health messaging interventions in community-based settings.
Vaccine. 2024 Jul 11:S0264-410X(24)00792-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SARTORI AL, Buffarini R, Machado da Silva A, Amaral de Andrade Leao O, et al Child COVID-19 vaccine uptake among participants of the 2015 Pelotas (Brazil)
Birth Cohort Study.
Vaccine. 2024 Jul 11:S0264-410X(24)00746-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KOUASSI KS, Chisupa E, Clarke A, Massenon I, et al Pandemic-related resilience in HPV vaccination programmes - Perspectives from
selected countries in Africa on what it will take to vaccinate 90 % of girls by
2030.
Vaccine. 2024;42 Suppl 2:S33-S36. PubMedAbstract available
BANG JY, Kim YJ, Seo YJ, Hong SH, et al Reduced cell-mediated immune response in hyperglycemic NOD mice following
influenza vaccination.
Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JITENDER, Vikram Kumar B, Singh S, Verma G, et al Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine
antigen and confers near-complete protection against SARS-CoV-2 infection in
Hamster.
Vaccine. 2024 Jul 8:S0264-410X(24)00740-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KORCHINSKI I, Marquez C, McClymont E, Av-Gay G, et al Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in
pregnancy: A prospective cohort study.
Vaccine. 2024 Jul 8:S0264-410X(24)00785-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WACHINGER J, Renosa MDC, Endoma V, Landicho-Guevarra J, et al Routines, disruptions, revised decisions: A biographical analysis of vaccination
trajectories among Filipino caregivers.
Vaccine. 2024 Jul 6:S0264-410X(24)00736-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ARAUJO-CHAVERON L, Olivier C, Pellissier G, Bouvet E, et al Analyzing the 7C psychological antecedents of vaccine acceptance throughout the
COVID-19 pandemic among healthcare sector workers in France: A repeated
cross-sectional study (CappVac-Cov).
Vaccine. 2024 Jul 6:S0264-410X(24)00744-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al Cost-effectiveness of recombinant influenza vaccine compared with standard dose
influenza vaccine in adults 18-64 years of age.
Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KAFADAR AH, Sabatini S, Jones KA, Dening T, et al Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy
in the United Kingdom: A systematic review and meta-analysis.
Vaccine. 2024 Jul 2:S0264-410X(24)00733-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HOULE SKD, Waite NM, Vernon-Wilson E, Dolovich L, et al Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A
study among community pharmacists.
Vaccine. 2024 Jul 1:S0264-410X(24)00737-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
June 2024
PLEY C, Kampmann B Opportunities and challenges to the development and deployment of vaccines for
pregnant women in Germany.
Vaccine. 2024 Jun 28:S0264-410X(24)00735-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ROOZEN GVT, Granger A, van Binnendijk RS, den Hartog G, et al Intradermal fractional dose vaccination as a method to vaccinate individuals with
suspected allergy to mRNA COVID-19 vaccines.
Vaccine. 2024 Jun 28:S0264-410X(24)00734-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BHELLA S, Wilkin AM, Hueniken K, Vijenthira A, et al COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent
vaccine doses in patients with hematologic malignancies.
Vaccine. 2024 Jun 28:S0264-410X(24)00715-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KELLY JA, Walsh JL, Quinn K, Amirkhanian YA, et al Factors predicting primary and booster COVID-19 vaccination in a community sample
of African American men and women in the United States Midwest.
Vaccine. 2024 Jun 27:S0264-410X(24)00729-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
COULIBALY D, Douba A, N'Guessan K, N'Gattia AK, et al Intent to receive flu vaccine and influenza vaccination coverage among health
professionals during 2019, 2020 and 2021 campaigns in Cote d'Ivoire.
Vaccine. 2024 Jun 25:S0264-410X(24)00717-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YOO YM, Katz MA, Greenberg D, Marcenac P, et al Knowledge, attitudes, and practices associated with influenza vaccine uptake
among healthcare personnel in Israel during three influenza seasons, 2016-2019.
Vaccine. 2024 Jun 25:S0264-410X(24)00705-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHATZILENA A, Hyams C, Challen R, Marlow R, et al Winter 2022-23 influenza vaccine effectiveness against influenza-related
hospitalised aLRTD: A test-negative, case-control study.
Vaccine. 2024 Jun 24:S0264-410X(24)00713-8. doi: 10.1016/j.vaccine.2024. PubMed
LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or
heterologous COVID-19 booster vaccination: Results of a randomized, double-blind,
phase 2 trial.
Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HELARY A, Botelho-Nevers E, Bonneton M, Khennouf L, et al Factors, motivations and barriers associated with eagerness to volunteer in
COVID-19 vaccine clinical trials in France: A mixed-method study.
Vaccine. 2024 Jun 22:S0264-410X(24)00662-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FITZPATRICK T, Yamoah P, Lacuesta G, Sadarangani M, et al Revaccination outcomes among adolescents and adults with suspected
hypersensitivity reactions following COVID-19 vaccination: A Canadian
immunization research network study.
Vaccine. 2024 Jun 22:S0264-410X(24)00719-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RIMAL RN, Ganjoo R, Jamison A, Parida M, et al Social norms, vaccine confidence, and interpersonal communication as predictors
of vaccination intentions: Findings from slum areas in Varanasi, India.
Vaccine. 2024 Jun 21:S0264-410X(24)00666-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MCDERMID P, Abdi I, Mustafa K, Blazek K, et al Examining the influence of community leaders and other community actors on
immunisation practices in Australia: A national cross-sectional study.
Vaccine. 2024;42:3647-3654. PubMedAbstract available
ZHANG X, Monnat SM Watchful, skeptics, and system distrusters: Characteristics associated with
different types of COVID-19 vaccine hesitancy among U.S. working-age adults.
Vaccine. 2024 Jun 19:S0264-410X(24)00721-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHENG TM, Chen YS, Wei KC, Chang YC, et al Assessment of the herpes zoster risk among renal transplant recipients
administered the influenza vaccine.
Vaccine. 2024 Jun 18:S0264-410X(24)00716-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YAZDAN PANAH M, Vaheb S, Mokary Y, Afshari-Safavi A, et al Comparing the consequences of COVID-19 vaccination between central nervous system
(CNS) demyelinating diseases and other neurological disorders.
Vaccine. 2024 Jun 16:S0264-410X(24)00702-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DESLAURIERS F, Hoq M, Kaufman J, Enticott J, et al Comparison of parent-reported motivators of non-vaccination for children
5-11 years old in Australia and Canada: Results of the iCARE study.
Vaccine. 2024 Jun 15:S0264-410X(24)00698-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JIANG X, Wang J, Li C, Yeoh EK, et al Relationship between parental acceptance of the COVID-19 vaccine and attitudes
towards measles vaccination for children: A cross-sectional study.
Vaccine. 2024 Jun 15:S0264-410X(24)00708-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TING DK, Rosychuk RJ, Hau JP, Righolt CH, et al Leveraging a clinical emergency department dataset to estimate two-dose COVID-19
vaccine effectiveness and duration of protection in Canada.
Vaccine. 2024 Jun 14:S0264-410X(24)00699-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DAVEY SA, Hampson C, Christodoulaki ME, Gaffiero D, et al Investigating the predictors of COVID-19 vaccine decision-making among parents of
children aged 5-11 in the UK.
Vaccine. 2024 Jun 13:S0264-410X(24)00646-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
QUIROGA R, Gastellu S, Fernandez B, Ottaviani R, et al The impact of COVID-19 childhood and adolescent vaccination on mortality in
Argentina.
Vaccine. 2024 Jun 12:S0264-410X(24)00665-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind,
placebo-controlled Phase 2a dose-finding study.
Vaccine. 2024;42:3536-3546. PubMedAbstract available
SHERMAN AC, van Haren SD, Borberg E, Swank Z, et al Heterologous SARS-CoV-2 booster vaccine for individuals with hematological
malignancies after a primary SARS-CoV-2 mRNA vaccine series.
Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MANANDHAR P, Katz J, Lama TP, Khatry SK, et al COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
OTSUKI T, Akada S, Anami A, Kosaka K, et al Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV
illness in Japanese infants: Subset analysis from the pivotal randomized phase 3
MATISSE trial.
Vaccine. 2024 Jun 8:S0264-410X(24)00668-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BADLIS S, Yu H, Klusaritz H, S L Tan A, et al Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in
Philadelphia: Lessons from the VaxUpPhillyFamilies program.
Vaccine. 2024 Jun 8:S0264-410X(24)00664-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BRADY K, Lee A, Bassler J, Young Pierce J, et al Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release
among mothers in Alabama.
Vaccine. 2024 Jun 8:S0264-410X(24)00673-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al Immunogenicity during 6 months after SARS-CoV-2 infection is significantly
different depending on previous COVID-19 vaccine regimens and a booster dose
received.
Vaccine. 2024 Jun 7:S0264-410X(24)00652-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VILLENA R, Izquierdo G, Wilhelm J, Garcia C, et al Dynamics of multisystem inflammatory syndrome in children associated to COVID-19
in Chile: Epidemiologic trends during pandemic, before and after children
vaccination.
Vaccine. 2024 Jun 7:S0264-410X(24)00640-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JAYAWARDANA S, Esquivel M, Oreskovic T, Mossialos E, et al Gender differences in COVID-19 preventative measures and vaccination rates in the
United States: A longitudinal survey analysis.
Vaccine. 2024 Jun 7:S0264-410X(24)00671-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
R MUGALI R, Ip H, Zikusooka A, Vong L, et al Striving for equitable vaccination coverage: Leveraging rapid coverage and
community assessments during the COVID-19 pandemic to reach missed populations in
Cambodia.
Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YOUNES S, Nicolai E, Younes N, Pieri M, et al Comparable antibody levels in heterologous and homologous mRNA COVID-19
vaccination, with superior neutralizing and IgA antibody responses in mRNA
homologous boosting.
Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al Costs of in- and outpatient respiratory disease and the seasonal influenza
vaccination program in Armenia - 2020-2021.
Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in
Europe: Results from the VEBIS primary care test-negative design study, September
2023-January 2024.
Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KAWASUJI H, Morinaga Y, Tani H, Yamada H, et al Low pre-infection levels of neutralizing antibody in breakthrough infections
after bivalent BA.4-5 vaccine and practical application of dried blood spots.
Vaccine. 2024 Jun 4:S0264-410X(24)00656-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FENG J, Du Y, Chen L, Su W, et al A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong
protective immune responses in animal models.
Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FABIANI M, Mateo-Urdiales A, Sacco C, Fotakis EA, et al Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent
(original/Omicron BA.4-5) mRNA vaccines in persons aged >/=60 years: Estimates over
calendar time and by time since administration during prevalent circulation of
different O
Vaccine. 2024 Jun 3:S0264-410X(24)00653-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BEJKO D, Ernst C, Vergison A, Stranges S, et al High vaccine effectiveness against severe COVID-19 outcomes and population
preventable fraction during the Omicron era in Luxembourg: A nationwide
retrospective risk factor analysis.
Vaccine. 2024 Jun 1:S0264-410X(24)00636-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
May 2024
KUPEK E Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
Vaccine. 2024;42:3437-3444. PubMedAbstract available
EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
Vaccine. 2024 May 31:S0264-410X(24)00595-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VASHIST K, Yankey D, Elam-Evans LD, Mu Y, et al Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years,
National Immunization Surveys, 2019-2022.
Vaccine. 2024 May 27:S0264-410X(24)00596-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BEGUM T, Efstathiou N, Bailey C, Guo P, et al Cultural and social attitudes towards COVID-19 vaccination and factors associated
with vaccine acceptance in adults across the globe: A systematic review.
Vaccine. 2024 May 27:S0264-410X(24)00600-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LUSTIG Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and
BA.5 mRNA COVID-19 vaccines.
Vaccine. 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TREHARNE A, Patel Murthy B, Zell ER, Jones-Jack N, et al Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S.
jurisdictions.
Vaccine. 2024 May 25:S0264-410X(24)00603-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine
in multiple sclerosis patients under disease modifying therapies: A single-center
prospective study.
Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BAK J, Hasan Q, Kissa J, Mere MO, et al Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23:
How do we switch to a life course approach?
Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LYNETTE EJEZIE C, Cuccaro P, Savas LS, Shegog R, et al Regional differences in provider recommendation of HPV vaccines among
13-to-17 year old adolescents from 2019 to 2021.
Vaccine. 2024 May 24:S0264-410X(24)00581-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BENEDICT KPOZEHOUEN E, Raina Macintyre C, Tan TC Coverage of influenza, pneumococcal and zoster vaccination and determinants of
influenza and pneumococcal vaccination among adults with cardiovascular diseases
in community.
Vaccine. 2024 May 23:S0264-410X(24)00619-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EIBERG MF, Rezahosseini O, Bukan KB, Charlotte Arp B, et al Changes in vaccination uptake against pneumococcal disease, influenza, and
coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer
diagnosis.
Vaccine. 2024 May 23:S0264-410X(24)00566-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TSAMPALIEROS A, Zemek R, Barrowman N, Langlois MA, et al Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5
to 11 years.
Vaccine. 2024 May 23:S0264-410X(24)00588-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CARNALLA M, Stern D, Arantxa Colchero M, Rangel-Moreno K, et al Who is getting COVID-19 boosters? A latent class analysis in a nationally
representative sample of Mexican adults 60 years and over.
Vaccine. 2024;42:3273-3276. PubMedAbstract available
RAMOS-DUARTE VA, Orlowski A, Jaquenod de Giusti C, Corigliano MG, et al Safe plant Hsp90 adjuvants elicit an effective immune response against
SARS-CoV2-derived RBD antigen.
Vaccine. 2024;42:3355-3364. PubMedAbstract available
ZHANG WX, Zhang Y, Du J, Shi W, et al Effectiveness of momentary intervention on influenza vaccination among the
elderly in China: From willingness to action.
Vaccine. 2024 May 22:S0264-410X(24)00591-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PROSPER P, Rodriguez Puertas R, Guerin DMA, Branda MM, et al Computational method for designing vaccines applied to virus-like particles
(VLPs) as epitope carriers.
Vaccine. 2024 May 22:S0264-410X(24)00584-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZHOU H, Zhao W, Ma R, Zheng Y, et al Mixed methods examination of risk perception on vaccination intentions: The
perspective of doctor-patient communication.
Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VAN DER PLAS JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, et al Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza
vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A
randomized, double-blind, controlled, ascending dose study in healthy adults and
elderly.
Vaccine. 2024 May 20:S0264-410X(24)00370-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al COVID-19 vaccine acceptance and uptake among caregivers of children aged
5-11?years in Ontario, Canada: A cross-sectional survey.
Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MACHIDA M, Fukushima S, Saitoh A, Inoue S, et al Uptake among four indicated vaccines by adults aged 65 years and older in Japan,
2023.
Vaccine. 2024 May 20:S0264-410X(24)00592-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GARG R, Liu Q, Van Kessel J, Asavajaru A, et al Efficacy of a stable broadly protective subunit vaccine platform against
SARS-CoV-2 variants of concern.
Vaccine. 2024 May 19:S0264-410X(24)00586-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YANG T, Tong F, Tang L, Li P, et al Repeated vaccination does not appear to significantly weaken the protective
effect of influenza vaccine in the elderly: A test-negative case-control study in
China.
Vaccine. 2024 May 17:S0264-410X(24)00593-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al Interchangeability of different COVID-19 vaccine platforms as booster doses: A
phase 3 study mimicking real-world practice.
Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
URQUIDI C, Sepulveda-Penaloza A, Valenzuela MT, Ponce A, et al Vaccine effectiveness in reducing COVID-19-related hospitalization after a
risk-age-based mass vaccination program in a Chilean municipality: A comparison
of observational study designs.
Vaccine. 2024 May 14:S0264-410X(24)00538-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against
SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EJNAR HANSEN M, David Pickering S The role of religion and COVID-19 vaccine uptake in England.
Vaccine. 2024;42:3215-3219. PubMedAbstract available
DINH THIEM V, Van Anh PT, Van Men C, Hung DT, et al A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19
prevention during the Omicron-dominant period: A phase 3, randomised,
placebo-controlled clinical trial.
Vaccine. 2024 May 10:S0264-410X(24)00523-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among
healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and
BA.2 subvariants.
Vaccine. 2024 May 9:S0264-410X(24)00522-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHANI M, Hermesh I, Feldhamer I, Reges O, et al The association between BNT162b2 vaccinations and incidence of immune-mediated
comorbidities.
Vaccine. 2024 May 9:S0264-410X(24)00536-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LEE KY, Song KH, Lee KH, Baek JY, et al Persistent differences in the immunogenicity of the two COVID-19 primary vaccines
series, modulated by booster mRNA vaccination and breakthrough infection.
Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KIM DH, Lee SH, Kim J, Lee J, et al Efficacy of live and inactivated recombinant Newcastle disease virus vaccines
expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian
influenza in SPF chickens, Broilers, and domestic ducks.
Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TIPPINS A, Acevedo JC, Palomeque FS, Coy KC, et al Strategies to strengthen COVID-19 vaccine uptake and improve vaccine equity in
U.S. Territories and Freely Associated States during the first six months of
vaccine rollout.
Vaccine. 2024 May 7:S0264-410X(24)00541-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KIM J, Chang J Cross-protective efficacy and safety of an adenovirus-based universal influenza
vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix
protein 2.
Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CAO A, Ueta M, Uchibori M, Murakami M, et al Trust in governments, public health institutions, and other information sources
as determinants of COVID-19 vaccine uptake behavior in Japan.
Vaccine. 2024 May 6:S0264-410X(24)00520-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JEARANAIWITAYAKUL T, Sunintaboon P, Kittiayuwat A, Limthongkul J, et al Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects
mice from nasal infection and completely inhibits disease development.
Vaccine. 2024 May 6:S0264-410X(24)00519-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SOE P, Wong H, Naus M, Muller MP, et al mRNA COVID-19 vaccine safety among older adults from the Canadian National
Vaccine Safety Network.
Vaccine. 2024 May 6:S0264-410X(24)00535-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHI XC, Gruber JF, Ondari M, Lloyd PC, et al Assessment of potential adverse events following the 2022-2023 seasonal influenza
vaccines among U.S. adults aged 65 years and older.
Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al Exploring the effect of clinical case definitions on influenza vaccine
effectiveness estimation at primary care level: Results from the end-of-season
2022-23 VEBIS multicentre study in Europe.
Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients
with cardiovascular diseases.
Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HU H, Ma F, Gong L, Wang Y, et al Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine
ZF2202-A in Chinese adults.
Vaccine. 2024 May 3:S0264-410X(24)00495-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ADINUGROHO I, Stafford T, Bentall RP The correlation between conspiracy mentality and vaccine intentions is moderated
by social events: Evidence from longitudinal data during COVID-19 pandemic in the
UK.
Vaccine. 2024 May 3:S0264-410X(24)00510-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHRISTOU-ERGOS M, Bleicher K, Leask J Factors associated with vaccination intention and uptake over time in a sample of
older Australians.
Vaccine. 2024 May 3:S0264-410X(24)00508-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BAGLIVO F, De Angelis L, Magri M, De Nicola I, et al The impact of COVID-19 vaccination campaign on pediatric vaccine uptake based on
parents' attitudes towards mandatory and recommended vaccination in Southern
Italy.
Vaccine. 2024 May 3:S0264-410X(24)00513-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MARINTHE G, Brown G, Cristea M, Kutlaca M, et al Predicting vaccination hesitancy: The role of basic needs satisfaction and
institutional trust.
Vaccine. 2024 May 3:S0264-410X(24)00507-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al Changes in depressive symptoms and antibody production following influenza
vaccination in adolescents and adults.
Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
April 2024
FLEARY SA, Shahn Z, Teasdale CA Effects of parental childhood cultural health environment on children's influenza
and COVID-19 vaccination status.
Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NIESSEN FA, Bruijning-Verhagen PCJL, Bonten MJM, Knol MJ, et al Vaccine effectiveness against COVID-19 related hospital admission in the
Netherlands by medical risk condition: A test-negative case-control study.
Vaccine. 2024 Apr 29:S0264-410X(24)00432-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GUDOORU K, Nguyen K, Le K, Sarabu V, et al Collective good and individual choice: Perceptions on COVID-19 vaccine mandate
among COVID-19 vaccinated individuals.
Vaccine. 2024 Apr 27:S0264-410X(24)00479-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DORJEE K, Namdon T, Topgyal S, Gyatso U, et al Association between Covishield vaccine and menstrual disturbance. Findings from a
cross-sectional study among participants of Zero TB cohort in India.
Vaccine. 2024 Apr 27:S0264-410X(24)00500-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al Authors' reply: Excess mortality in Cyprus during the COVID-19 vaccination
campaign.
Vaccine. 2024 Apr 25:S0264-410X(24)00506-1. doi: 10.1016/j.vaccine.2024. PubMed
XIE Z, Stallings-Smith S, Patel S, Case S, et al COVID-19 booster vaccine uptake and reduced risks for long-COVID: A
cross-sectional study of a U.S. adult population.
Vaccine. 2024 Apr 25:S0264-410X(24)00509-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PIASECKI AM, Hall DM, Zajac J, Miller SA, et al A programmatic update on COVID-19 vaccination in rural communities in the United
States.
Vaccine. 2024 Apr 25:S0264-410X(24)00469-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FUJITA DM, da Silva Nali LH, da Costa RR, de Andrade Junior HF, et al Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.
Vaccine. 2024 Apr 24:S0264-410X(24)00435-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al Non-specific effects of the inactivated influenza vaccine. A test-negative study:
The inactivated influenza vaccine and SARS-CoV-2 infections.
Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SONG S, Madewell ZJ, Liu M, Miao Y, et al A systematic review and meta-analysis on the effectiveness of bivalent mRNA
booster vaccines against Omicron variants.
Vaccine. 2024 Apr 22:S0264-410X(24)00476-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MUSA S, Merdrignac L, Skocibusic S, Nedic R, et al BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and
older during the Delta-dominant period in the Federation of Bosnia and
Herzegovina, a test-negative case-control study.
Vaccine. 2024 Apr 20:S0264-410X(24)00471-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LIEVRE G, Sicsic J, Galmiche S, Charmet T, et al Are the 7C psychological antecedents associated with COVID-19 vaccine behaviours
beyond intentions? A cross-sectional study on at-least-one-dose and up-to-date
vaccination status, and uptake speed among adults in France.
Vaccine. 2024 Apr 19:S0264-410X(24)00438-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al Immunogenicity and protective efficacy of a multivalent herpesvirus vectored
vaccine against H9N2 low pathogenic avian influenza in chicken.
Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WON H, Kim JA, Jeong NY, Choi NK, et al Safety of concomitant administration of 23-valent polysaccharide pneumococcal
vaccine and influenza vaccine among the elderly.
Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines
among a convenience sample in Minnesota.
Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive
registry-based cohort study of over 800,000 individuals.
Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show
improved immunogenicity and neutralizing response in mice.
Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al Cost-effectiveness of high-dose influenza vaccination in the Netherlands:
Incorporating the impact on both respiratory and cardiovascular hospitalizations.
Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BEITARI S, Yi S, Sharma S, Yung R, et al Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in
inner city Vancouver, Canada: Insights into characteristics and clinical
outcomes.
Vaccine. 2024 Apr 17:S0264-410X(24)00477-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PEREIRA ET, Iasulaitis S, Greco BC Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and
ideological orientations in Brazil.
Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LEE N, Hong Y, Kirkpatrick CE, Hu S, et al COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and
message framing among black and white participants.
Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al Understanding the views of adult migrants around catch-up vaccination for missed
routine immunisations to define strategies to improve coverage: A UK in-depth
interview study.
Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GEE J, Shimabukuro TT, Su JR, Shay D, et al Overview of U.S. COVID-19 vaccine safety surveillance systems.
Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MARTINEZ JL, Lemus N, Lai TY, Mishra M, et al The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin
increases with high immunoglobulin titers of the cohorts and with young age, but
not sex.
Vaccine. 2024 Apr 15:S0264-410X(24)00451-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MELNIKOW J, Padovani A, Zhang J, Miller M, et al Patient concerns and physician strategies for addressing COVID-19 vaccine
hesitancy.
Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WONG IOL, Wong C, Mak N, Dai A, et al Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy
and uptake among Chinese adults in Hong Kong.
Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BAKER J, Aliabadi N, Munjal I, Jiang Q, et al Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults
18-49 years of age: Results of a randomized phase 3 study.
Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection,
symptoms, and severity in the pre-omicron era: A time-dependent gradient.
Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NOLAN MB, Chrenka E, Walker P, Steiner A, et al COVID-19 vaccine uptake among non-US-born populations in the United States,
2020-2022.
Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al Despite mandated primary series, health care personnel still hesitant about
COVID-19 vaccine and immunizing children.
Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LEE JS, Choi H, Shin SH, Hwang MJ, et al Characterization of Brighton Collaboration criteria for myocarditis and
pericarditis following COVID-19 vaccine in Korean adolescents.
Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PITTS PJ, Poland GA Addressing vaccine hesitancy: Learning from the successes and failures of the
COVID-19 pandemic.
Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024. PubMed
AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al A comparative analysis of knowledge, attitude, and practice (KAP) towards
influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior
to and during the COVID-19 pandemic.
Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
THAI H, Audet EC, Koestner R Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory
Perspective to a Global Health Crisis.
Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
Immunization agenda 2030: A global strategy to leave no one behind.
Vaccine. 2024;42 Suppl 1:S5-S14. PubMed
ZHU J, Cole CB, Fihman J, Adjagba A, et al Opportunities to accelerate immunization progress in middle-income countries.
Vaccine. 2024;42 Suppl 1:S98-S106. PubMedAbstract available
BLANC DC, Grundy J, Sodha SV, O'Connell TS, et al Immunization programs to support primary health care and achieve universal health
coverage.
Vaccine. 2024;42 Suppl 1:S38-S42. PubMedAbstract available
SAXENIAN H, Alkenbrack S, Freitas Attaran M, Barcarolo J, et al Sustainable financing for Immunization Agenda 2030.
Vaccine. 2024;42 Suppl 1:S73-S81. PubMedAbstract available
CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al The quest for more effective vaccine markets - Opportunities, challenges, and
what has changed with the SARS-CoV-2 pandemic.
Vaccine. 2024;42 Suppl 1:S64-S72. PubMedAbstract available
KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al A survey of state and local practices encouraging pediatric COVID-19 vaccination
of children ages 6 months through 11 years.
Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al Estimating averted illnesses from influenza vaccination for children and pregnant
women - El Salvador, Panama, and Peru, 2011-2018.
Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ARCHER H, McCoy SI, Sears D, Kwan A, et al Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a
California state Prison, May 2021.
Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SCHULTZE A, Martin I, Messina D, Bots S, et al A comparison of four self-controlled study designs in an analysis of COVID-19
vaccines and myocarditis using five European databases.
Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BAUM HE, Thirard R, Halliday A, Baos S, et al Detection of SARS-CoV-2-specific mucosal antibodies in saliva following
concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine
(IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3,
randomized, active-controlled, multicenter trial.
Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WU CY, Kao SE, Tseng YC, Hou JT, et al Pilot-scale production of a highly efficacious and stable monoglycosylated
influenza split virus vaccine.
Vaccine. 2024;42:2220-2228. PubMedAbstract available
LASRADO N, Rossler A, Rowe M, Collier AY, et al Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
Vaccine. 2024;42:2117-2121. PubMedAbstract available
March 2024
GONG JD, Barnboym E, O'Mara M, Gurevich N, et al Self-reported determinants of COVID-19 vaccine acceptance among persons with and
without autoimmune disease.
Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al Effectiveness of COVID-19 vaccination against school absenteeism in children and
adolescents hospitalized with COVID-19.
Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HUF SW, Grailey K, Crespo RF, Woldmann L, et al Testing the impact of differing behavioural science informed text message content
in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical
trial.
Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al Influenza vaccination accuracy among adults: Self-report compared with electronic
health record data.
Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al The early safety profile of simultaneous vaccination against influenza and
Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al Leveraging seasonal influenza health worker vaccination programmes for COVID-19
vaccine Introduction: A global qualitative analysis.
Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DAHL BA, Tritter B, Butryn D, Dahlke M, et al Global VAX: A U.S. contribution to global COVID-19 vaccination efforts,
2021-2023.
Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MORGAN G, Casalino S, Chowdhary S, Frangione E, et al COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CONDIE J, Northstone K, Major-Smith D, Halstead I, et al Exploring associations between the Big Five personality traits and cognitive
ability with COVID-19 vaccination hesitancy and uptake among mothers and
offspring in a UK prospective cohort study.
Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al Higher educational attainment associated with higher confidence in influenza
vaccination in Norway.
Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PRICE O, Dietze P, Maher L, Dore GJ, et al High COVID-19 vaccine uptake following initial hesitancy among people in
Australia who inject drugs.
Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al Differences in social media use by COVID-19 vaccination status.
Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SASI A, Dandotiya J, Kaushal J, Ganguly S, et al Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA
vaccines in adolescent/young adults with cancer: A prospective cohort study.
Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al Mucosal immunization with dual influenza/COVID-19 single-replication virus vector
protects hamsters from SARS-CoV-2 challenge.
Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al Transformative vaccination: A pentavalent shield against COVID-19 and influenza
with betulin-based adjuvant for enhanced immunity.
Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults
in United States commercial and Medicare claims databases, 2017-2020.
Vaccine. 2024;42:2004-2010. PubMedAbstract available
LANG JC, Kura K, Garba SM, Elbasha EH, et al Comparison of a static cohort model and dynamic transmission model for
respiratory syncytial virus intervention programs for infants in England and
Wales.
Vaccine. 2024;42:1918-1927. PubMedAbstract available
SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al CHO cells for virus-like particle and subunit vaccine manufacturing.
Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al COVID-19 vaccination in cancer patients: Immune responses one year after the
third dose.
Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FIX J, Christopher Mast T, Smith K, Baker N, et al Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
COTTON SA, Subramanian A, Hughes TD, Huang Y, et al The effect of SARS-COV-2 variant on non-respiratory features and mortality among
vaccinated and non-fully vaccinated patients.
Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CAMERON DB, Grage L, Van Wyck R, Edwards A, et al Identifying trusted local sources and predicting behavior change pathways
according to COVID-19 vaccination status: Results of a 2022 statewide survey of
Alaskan adults.
Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al Predicting intention to vaccinate against COVID-19 in older Syrian refugees in
Lebanon: Findings from a multi-wave study.
Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al The effect of a financial incentive on COVID-19 vaccination uptake, and
predictors of uptake, in people experiencing homelessness: A randomized
controlled trial.
Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RUSS S, Myers C, Licherdell E, Bowden A, et al Sociodemographic and Occupational Characteristics Associated with Early and
Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHIJIA YAN A, Jay Sehgal N Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among
Parents/Guardians and vaccine uptake among children in the U.S.
Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MORO PL, Carlock G, Fifadara N, Habenicht T, et al Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the
vaccine adverse event reporting System - United States, September 1, 2022 - March
31, 2023.
Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LUISI M, Geana MV, Pei J Pandemic antecedents - Exploring predictivity and relationships between COVID-19
vaccine uptake and influenza, shingles, and HPV vaccination.
Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli
filaments and the highly conserved M2e epitope confers protection against
influenza a virus in mice.
Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SU YW, Qiu YZ, Wang YH, Xu Y, et al Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2
mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A
randomised, double-blinded, active-controlled phase 1 trial.
Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
Expression of Concern: "Cross-protection against H7N9 influenza strains using a
live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages
108-116].
Vaccine. 2024;42:1851. PubMed
MENG L, Harris L, Shaw L, Lymon H, et al Social and demographic factors associated with receipt of a COVID-19 vaccine
initial booster dose and with interval between primary series completion and
initial booster dose uptake among persons aged >/= 12 years, United States, August
2021-October 2
Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KARRAS J, Harrison M, Steffens M, Abdi I, et al "COVID is a huge jigsaw puzzle that I am trying to make sense of myself":
Exploring the perceptions towards the COVID-19 vaccine communication strategy in
Australia amongst unvaccinated Australian adults.
Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WONG WHS, Leung DL, Yip KM, So HK, et al Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less
than 3 years old during Omicron wave in Hong Kong.
Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country
cohort event monitoring study.
Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al Association of COVID-19 vaccination with duration of hospitalization in older
adults in Hong Kong.
Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy
at point of care.
Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
February 2024
YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al Immunogenicity and safety of a quadrivalent recombinant influenza vaccine
manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind,
non-inferiority, randomized controlled trial.
Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KOHLI M, Maschio M, Lee A, Igarashi A, et al Projections of the incidence of COVID-19 in Japan and the potential impact of a
Fall 2023 COVID-19 vaccine.
Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al An overview of the COVID-19 pediatric vaccine program - The U.S. experience
vaccinating children ages 6 months through 17 years.
Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GUO J, Chen X, Guo Y, Liu M, et al Real-world effectiveness of seasonal influenza vaccination and age as effect
modifier: A systematic review, meta-analysis and meta-regression of test-negative
design studies.
Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MARINDA E, Mathentamo Q, Coulson N, Parker S, et al Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake
in Kwazulu-Natal, South Africa.
Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YANG XY, Liu T, Jiang SC, Zhang ZW, et al Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human
muscle cells and neuroglial cells.
Vaccine. 2024;42:1259-1267. PubMedAbstract available
JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al Intensification of integrated immunization services to recover routine
vaccination coverage and bring COVID-19 vaccine to the population of Iraq in
2022.
Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KRISTINSDOTTIR I, Haraldsson A, Thors V Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of
influenza in pregnant women and their infants.
Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MUNDO ORTIZ A, Nasri B Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring
differences across the Health Region model.
Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al The association between influenza vaccination uptake and influenza and
pneumonia-associated deaths in the United States.
Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al Influenza vaccine effectiveness against hospitalizations associated with
influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November
2023.
Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al Audiovestibular adverse events following COVID-19 vaccinations.
Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
XU S, Sy LS, Hong V, Farrington P, et al Mortality risk after COVID-19 vaccination: A self-controlled case series study.
Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al Impact and cost-effectiveness analyses of vaccination for prevention of
respiratory syncytial virus disease among older adults in Ontario: A Canadian
Immunization Research Network (CIRN) study.
Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHERRY N, Adisesh A, Burstyn I, Charlton C, et al Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers:
A prospective cohort study.
Vaccine. 2024;42:1168-1178. PubMedAbstract available
JIN F, Qiu Y, Wu Z, Wang YH, et al Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy
Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2
clinical trial.
Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al Vaccine effectiveness against COVID-19: A test negative case-control study in
Tunisia, August 2021.
Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al Trend of measles-rubella vaccination coverage and impact on measles epidemiology
in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KIM HK, Park SK, Choe SA, Gwak ES, et al Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2
vaccinations in Korean Adults: A population-based observational study.
Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KUTER BJ, Brien K, Anderson S, Bass SB, et al COVID-19 vaccine perspectives and uptake among university students three years
into the pandemic.
Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al A population-based, province-wide, record-linkage interrupted time series
analysis of impact of the universal seasonal influenza vaccination policy on
seasonal influenza vaccine uptake among 5-64-year-olds in the province of
Manitoba, Canada.
Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BATHEJA A, Balkrishnan R Rhode Island as a model for promoting flu vaccination in the United States.
Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024. PubMed
KLASSEN AC, Lee G, Chiang S, Murray R, et al Did the COVID-19 experience change U.S. parents' attitudes towards HPV
vaccination? Results from a national survey.
Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DUGGAR C, Santoli JM, Noblit C, Moore LB, et al U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons
learned, December 2020 - May 2023.
Vaccine. 2024 Feb 14:S0264-410X(24)00167-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DONATO F, Pilotto A, Foca E, Tresoldi M, et al The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on
COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HEARN EB, Kehinde G, Sambamoorthi U Food insecurity and COVID-19 vaccine hesitancy among adults in the United States
(US).
Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al The coverage of influenza vaccination and predictors of influenza non-vaccination
in Danish cancer patients: A nationwide register-based cohort study.
Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al Protection conferred by an H5 DNA vaccine against highly pathogenic avian
influenza in chickens: The effect of vaccination schedules.
Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al Acute disseminated encephalomyelitis and transverse myelitis following COVID-19
vaccination - A self-controlled case series analysis.
Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al COVID-19 vaccines and adverse events of special interest: A multinational Global
Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WHITAKER HJ, Hassell K, Hoschler K, Power L, et al Influenza vaccination during the 2021/22 season: A data-linkage test-negative
case-control study of effectiveness against influenza requiring emergency care in
England and serological analysis of primary care patients.
Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose:
Homologous versus heterologous boost.
Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WEI J, Tan TC, Moa AM, MacIntyre CR, et al Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst
Australian adults.
Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al Safe in pregnancy: A global living systematic review and meta-analysis of
COVID-19 vaccines in pregnancy.
Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024. PubMed
MARKOWITZ LE, Hopkins RH Jr, Broder KR, Lee GM, et al COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety
monitoring during the pandemic.
Vaccine. 2024 Feb 9:S0264-410X(23)01505-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WADAPURKAR R, Singh S, Singh A Leveraging the immunoinformatics approach for designing the SARS-CoV-2
omicron-specific antigenic cassette of mRNA vaccine.
Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RANDELL M, Sheel M, Dynes M, Li M, et al Influence of the COVID-19 pandemic on caregiver beliefs and experiences of
routine childhood immunisation in Indonesia.
Vaccine. 2024;42:812-818. PubMedAbstract available
KOLANDAI K, Milne B, von Randow M, Bullen C, et al Public opinion on global COVID-19 vaccine procurement and distribution policies:
A nationally representative survey in Aotearoa New Zealand 2022.
Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MAEDA M, Murata F, Fukuda H The age-specific impact of COVID-19 vaccination on medical expenditures and
hospitalization duration after breakthrough infection: The Vaccine Effectiveness,
Networking, and Universal Safety (VENUS) Study.
Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MIYAMOTO S, Suzuki T Infection-mediated immune response in SARS-CoV-2 breakthrough infection and
implications for next-generation COVID-19 vaccine development.
Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RIVERS P, Porter C, LeClair LB, Jeddy Z, et al Longitudinal parental perception of COVID-19 vaccines for children in a
multi-site, cohort study.
Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al Utilizing a university testing program to estimate relative effectiveness of
monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against
symptomatic SARS-CoV-2 infection.
Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DATTA S, Vattiato G, Maclaren OJ, Hua N, et al The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
January 2024
SOOD S, Matar MM, Kim J, Kinsella M, et al Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine
formulated with a functional polymer.
Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HUANG Y, Shi H, Forgacs D, Ross TM, et al Flu-COVID combo recombinant protein vaccines elicited protective immune responses
against both influenza and SARS-CoV-2 viruses infection.
Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
JI Y, Sui X, Miao W, Wang C, et al Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type
SARS-CoV-2 and Omicron variants in a murine model.
Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children
aged 5-11 years, a nationwide parental survey.
Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BALSELLS E, Vicente M, Reyes S, Figueroa M, et al Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage
in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
OKPANI AI, Adu P, Paetkau T, Lockhart K, et al Are COVID-19 vaccination mandates for healthcare workers effective? A systematic
review of the impact of mandates on increasing vaccination, alleviating staff
shortages and decreasing staff illness.
Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FILIPAS DK, Labban M, Beatrici E, Stone BV, et al Exploring preventive care practices among unvaccinated individuals in the United
States during the COVID-19 pandemic.
Vaccine. 2024;42:441-447. PubMedAbstract available
TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the
phase 3b implementation Sisonke study in South Africa.
Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RUSS S, Bennett N, van Wijngaarden E, Hill E, et al Influence of Community Determinants on Barriers and Facilitators to COVID-19
Vaccine Uptake: Regional Stakeholders' Perspectives.
Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LIU R, Fan Y, Patel A, Liu H, et al The association between influenza vaccination, cardiovascular mortality and
hospitalization: A living systematic review and prospective meta-analysis.
Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RATTAY K, Thierry JM, Yeargin-Allsopp M, Griffin-Blake S, et al Lessons learned: COVID-19 vaccinations and people with disabilities.
Vaccine. 2024 Jan 23:S0264-410X(24)00028-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ABAD N, Bonner KE, Kolis J, Brookmeyer KA, et al Strengthening COVID-19 vaccine confidence & demand during the US COVID-19
emergency response.
Vaccine. 2024 Jan 23:S0264-410X(24)00029-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA
vaccination in patients with pediatric rheumatic diseases: A prospective cohort
study.
Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al Study of immunogenicity and efficacy against Omicron BA.5 of recombinant
protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in
nonhuman primates.
Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation
oncology patients.
Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HILL PL, Morstead T, Pfund GN, Burrow AL, et al Examining changes in sense of purpose before, during, and after COVID-19
vaccination.
Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MITCHELL MM, Klott A, Scholtes J, Braden BB, et al Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines
among parents of children with autism and autistic adults.
Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HICKEN A, Jones P, Menon A, Rozek LS, et al Can endorsement by religious leaders move the needle on vaccine hesitancy?
Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al Social network risk factors and COVID-19 vaccination: A cross-sectional survey
study.
Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GRIMA AA, Kwong JC, Richard L, Reid J, et al The safety of seasonal influenza vaccination among adults prescribed immune
checkpoint inhibitors: A self-controlled case series study using administrative
data.
Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LEMMER Y, Chapman R, Abolnik C, Smith T, et al Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in
golden Syrian hamsters.
Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FIEBELKORN AP, Adelsberg S, Anthony R, Ashenafi S, et al The role of funded partnerships in working towards decreasing COVID-19
vaccination disparities, United States, March 2021-December 2022.
Vaccine. 2024 Jan 17:S0264-410X(23)01507-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FAN J, Song Y, Cong S, Millman AJ, et al Assessing interventions to encourage primary care health workers to recommend
influenza vaccination and the impact on vaccination uptake for persons with
Non-Communicable diseases in China.
Vaccine. 2024 Jan 16:S0264-410X(24)00011-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd
dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KING ML How manufacturing won or lost the COVID-19 vaccine race.
Vaccine. 2024 Jan 15:S0264-410X(23)01477-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MCADAM E, Hayashi K, Barker B, Reddon H, et al COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NAUTA J Estimand for non-inferiority influenza vaccine immunogenicity trials.
Vaccine. 2024 Jan 13:S0264-410X(24)00014-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RATISHVILI T, Quach HQ, Haralambieva IH, Suryawanshi YR, et al A multifaceted approach for identification, validation, and immunogenicity of
naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.
Vaccine. 2024;42:162-174. PubMedAbstract available
VAN ROEKEL C, Labuschagne L, Pijpers J, van Roon A, et al Factors associated with COVID-19 autumn 2022 booster uptake in the Netherlands
among older adults aged >/= 60 years and younger adults with chronic conditions.
Vaccine. 2024;42:146-155. PubMedAbstract available
PARK SI, Park S, Lee K, Kwak HW, et al Intranasal immunization with the recombinant measles virus encoding the spike
protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
Vaccine. 2024;42:69-74. PubMedAbstract available
REN S, Chen Q, Zhang Y, Yi L, et al Modeling the optimal seasonal monoclonal antibody administration strategy for
respiratory syncytial virus (RSV) prevention based on age-season specific
hospitalization rate of RSV in Suzhou, China, 2016-2022.
Vaccine. 2024;42:352-361. PubMedAbstract available
GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al Assessing the relationship between existing childhood, adolescent and adult
immunization programmes and national COVID-19 vaccination capacities in 2021.
Vaccine. 2024 Jan 11:S0264-410X(23)01484-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
QURESHI NS, Miller LG, Judge SP, Tran NDT, et al Characterizing predictors of COVID-19 vaccine refusal in an urban southern
California jail population.
Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HINSON-ENSLIN AM, Espinoza LE The mental health symptoms of individuals with sensory disabilities and the
reasons that lead to COVID-19 vaccine refusal and hesitancy.
Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHARP M, Lozano P, Southworth A, Peters A, et al Mixed methods approach to understanding COVID-19 vaccine hesitancy among
immigrants in the Chicago.
Vaccine. 2024 Jan 9:S0264-410X(23)01508-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al Parental concerns and vaccine hesitancy against COVID-19 vaccination for children
in Greece: A cross-sectional survey.
Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
STONE ND, Parker Fiebelkorn A, Guo A, Mothershed E, et al Challenges and opportunities during the COVID-19 vaccination efforts in long-term
care.
Vaccine. 2024 Jan 5:S0264-410X(23)01510-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al Racial and ethnic differences in COVID-19 vaccine readiness among adults in the
United States, January 2021-April 2023.
Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with
thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A
cross-sectional study in six EU member states.
Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHARPIGNON ML, Gupta S, Shahnaz Majumder M Massachusetts companion program bolsters COVID-19 vaccine rates among seniors.
Vaccine. 2024 Jan 3:S0264-410X(23)01494-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DAVIDSON AM, Burns S, White LA, Perlman M, et al "I shall not poison my child with your human experiment": Investigating
predictors of parents' hesitancy about vaccinating younger children (<12) in
Canada.
Vaccine. 2024 Jan 2:S0264-410X(23)01519-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
AGASSE E, Rodriguez GF, Vilarino V, Galli JH, et al Social determinants of health and vaccine uptake in pregnancy: Disparities in a
diverse, predominately foreign-born population.
Vaccine. 2024 Jan 2:S0264-410X(23)01515-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
VASHI MD, Watkins M Missed opportunities: Reducing zero dose children amongthe urban poor after
COVID, Mumbai India, 2022.
Vaccine. 2024;42:59-63. PubMedAbstract available
December 2023
RUBIO-CASILLAS A, Rodriguez-Quintero CM, Redwan EM, Gupta MN, et al Do vaccines increase or decrease susceptibility to diseases other than those they
protect against?
Vaccine. 2023 Dec 28:S0264-410X(23)01506-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BARZEN G, Rieber F, Stangl K, Hahn K, et al mRNA vaccines for COVID-19 are safe and clinically effective in patients with
cardiac amyloidosis.
Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
OLIVER SE, Wallace M, Twentyman E, Moulia DL, et al Development of COVID-19 vaccine policy - United States, 2020-2023.
Vaccine. 2023 Dec 28:S0264-410X(23)01466-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GHARPURE R, Akumu AO, Dawa J, Gobin S, et al Costs of seasonal influenza vaccine delivery in a pediatric demonstration project
for children aged 6-23 months - Nakuru and Mombasa Counties, Kenya, 2019-2021.
Vaccine. 2023 Dec 27:S0264-410X(23)01475-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FONSECA HAR, Zimerman A, Monfardini F, Guimaraes HP, et al In-Hospital influenza vaccination to prevent cardiorespiratory events in the
first 45 days after acute coronary syndrome: A prespecified analysis of the
VIP-ACS trial.
Vaccine. 2023 Dec 27:S0264-410X(23)01531-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SHENTON P, Schrader S, Smith J, Alafaci A, et al Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in
Victoria, Australia: A clinical surveillance study.
Vaccine. 2023 Dec 27:S0264-410X(23)01516-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SURTEES TC, Granade CJ, Wells C, Banks M, et al CDC COVID-19 vaccination program: Healthcare provider compliance with COVID-19
vaccine requirements and recommendations.
Vaccine. 2023 Dec 27:S0264-410X(23)01467-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NGUYEN KH, Coy KC, Black CL, Scanlon P, et al Comparison of adult hesitancy towards COVID-19 vaccines and vaccines in general
in the USA.
Vaccine. 2023 Dec 23:S0264-410X(23)01488-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SEPPALA E, Dahl J, Veneti L, Rydland KM, et al Covid-19 and influenza vaccine effectiveness against associated hospital
admission and death among individuals over 65 years in Norway: A population-based
cohort study, 3 October 2022 to 20 June 2023.
Vaccine. 2023 Dec 22:S0264-410X(23)01496-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KACHKO A, Selvaraj P, Liu S, Kim J, et al Vaccine-associated respiratory pathology correlates with viral clearance and
protective immunity after immunization with self-amplifying RNA expressing the
spike (S) protein of SARS-CoV-2 in mouse models.
Vaccine. 2023 Dec 22:S0264-410X(23)01498-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LO E, Brousseau N, Defay F, Fortin E, et al Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in
Quebec, Canada, during the Delta and early Omicron periods.
Vaccine. 2023 Dec 22:S0264-410X(23)01489-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373
(TAK-019) in healthy Japanese adults who had previously received a primary series
of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
Vaccine. 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LINK-GELLES R, Britton A, Fleming-Dutra KE Building the U.S. COVID-19 vaccine effectiveness program: Past successes and
future directions.
Vaccine. 2023 Dec 20:S0264-410X(23)01435-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WOLFF M, Charpentier P, Canals A, Vial C, et al Humoral immune response in people living with HIV after administration of
SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence:
A cross-sectional study.
Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MIRIERI H, Nasimiyu C, Dawa J, Mburu C, et al Resilience of routine childhood immunization services in two counties in Kenya in
the face of the COVID-19 pandemic.
Vaccine. 2023;41:7695-7704. PubMedAbstract available
STUMPF J, Anders L, Siepmann T, Schwobel J, et al 9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2
immunity in dialysis and kidney transplant patients.
Vaccine. 2023 Dec 18:S0264-410X(23)01479-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ARASHIRO T, Miwa M, Nakagawa H, Takamatsu J, et al COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy,
invasive mechanical ventilation, and death in Japan: A multicenter case-control
study (MOTIVATE study).
Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DAWA J, Jalang'o R, Mirieri H, Kalani R, et al Comparing performance of year-round and campaign-mode influenza vaccination
strategies among children aged 6-23 months in Kenya: 2019-2021.
Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
JACKSON LA, Stapleton JT, Walter EB, Chen WH, et al Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9
inactivated vaccine given with and without AS03 adjuvant in healthy adults.
Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
JIANG W, Lu C, Yan X, Tucker JD, et al Vaccine confidence mediates the association between a pro-social pay-it-forward
intervention and improved influenza vaccine uptake in China: A mediation
analysis.
Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ZHAN XY, Chen Y, Zhang X, Shi Q, et al Characterization of SARS-CoV-2-specific humoral immunity and associated factors
in the healthy population post-vaccination.
Vaccine. 2023 Dec 15:S0264-410X(23)01465-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BAJRACHARYA D, Jansen RJ Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19
outbreak: An American ecological study.
Vaccine. 2023 Dec 15:S0264-410X(23)01441-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BURNS KE, Dube E, Godinho Nascimento H, Meyer SB, et al Examining vaccine hesitancy among a diverse sample of Canadian adults.
Vaccine. 2023 Dec 15:S0264-410X(23)01476-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DONG C, Ma Y, Zhu W, Wang Y, et al Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection
against heterosubtypic infection in mice.
Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FERRONI E, Gennaro N, Maifredi G, Leoni O, et al Access to SARS-CoV-2 vaccination in immigrants in Italy, by geographical area of
origin.
Vaccine. 2023 Dec 13:S0264-410X(23)01387-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CAO Z, Yu R, Yuan Q, Ji W, et al Impact of the COVID-19 pandemic on routine vaccination coverage under varying
prevalence Conditions: A cohort study in Beijing, China.
Vaccine. 2023 Dec 13:S0264-410X(23)01447-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SCHARF LG, Adeniyi K, Augustini E, Boyd D, et al Monitoring and reporting the US COVID-19 vaccination effort.
Vaccine. 2023 Dec 13:S0264-410X(23)01438-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
O'NEIL SS, Pendl-Robinson EL, Carosella EA, Sullivan BD, et al The importance of community-specific survey data in understanding behavioral and
social drivers of COVID-19 vaccination: Lessons learned from urban neighborhoods
in four United States cities.
Vaccine. 2023 Dec 12:S0264-410X(23)01450-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
OPRIESSNIG T, Gauger PC, Filippsen Favaro P, Rawal G, et al An experimental universal swine influenza a virus (IAV) vaccine candidate based
on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV
challenge in pigs.
Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LYTRAS T, Di Gregorio AAA, Apostolopoulos D, Naziris D, et al Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the
elderly and general population in Europe: Controlled interrupted time series
analysis.
Vaccine. 2023 Dec 11:S0264-410X(23)01472-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
AKMATOVA R, Dzhangaziev B, Ebama MS, Otorbaeva D, et al Knowledge, attitudes, and practices (KAP) towards seasonal influenza and
influenza vaccine among pregnant women in Kyrgyzstan: A cross-sectional study.
Vaccine. 2023 Dec 9:S0264-410X(23)01453-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MESIDOR M, Liu Y, Talbot D, Skowronski DM, et al Test negative design for vaccine effectiveness estimation in the context of the
COVID-19 pandemic: A systematic methodology review.
Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SUI Y, Andersen H, Li J, Hoang T, et al SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in
efficacy.
Vaccine. 2023 Dec 8:S0264-410X(23)01426-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DI CHIARA C, Cantarutti A, Raffaella Petrara M, Bonfante F, et al Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years
old children with prior COVID-19.
Vaccine. 2023 Dec 8:S0264-410X(23)01439-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHENG DR, Reimer H, Le D, Crawford NW, et al Analyzing an immunization resource website: User browsing trends.
Vaccine. 2023;41:7498-7502. PubMedAbstract available
YU Y, Zhang X, Lau MMC, Lau JTF, et al The intention to get COVID-19 booster vaccination and its association with
cognitive and emotional factors: A survey of Chinese COVID-19 infected people in
Hong Kong.
Vaccine. 2023 Dec 7:S0264-410X(23)01448-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GRAMACHO W, Turgeon M, Santos Mundim P, Pereira I, et al Why did Brazil fail to vaccinate children against COVID-19 during the pandemic?
An assessment of attitudinal and behavioral determinants.
Vaccine. 2023 Dec 6:S0264-410X(23)01432-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CANEVARI JT, Cheng AC, Wu L, Rowe SL, et al The relative effectiveness of three and four doses of COVID-19 vaccine in
Victoria, Australia: A data linkage study.
Vaccine. 2023 Dec 5:S0264-410X(23)01393-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates,
and cohort description.
Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PRASERT K, Praphasiri P, Lerdsamran H, Nakphook S, et al Safety and immunogenicity of locally produced trivalent inactivated influenza
vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A
Phase III double blinded, three-arm, randomized, controlled trial.
Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GASHTI AB, Agbayani G, Hrapovic S, Nassoury N, et al Production, purification and immunogenicity of Gag virus-like particles carrying
SARS-CoV-2 components.
Vaccine. 2023 Dec 1:S0264-410X(23)01394-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
November 2023
WANG Y, Hu Y, Ma Y, Li P, et al RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity
against SARS-CoV-2 virus following boosting with inactivated virus vaccine.
Vaccine. 2023 Nov 27:S0264-410X(23)01381-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NISHIYAMA T, Miyamatsu Y, Park H, Nakamura N, et al Modeling COVID-19 vaccine booster-elicited antibody response and impact of
infection history.
Vaccine. 2023 Nov 25:S0264-410X(23)01384-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DUCASA N, Benencio P, Mauro E, Anders M, et al Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in
liver transplant recipients.
Vaccine. 2023 Nov 24:S0264-410X(23)01383-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PAYNE AB, Ciesla AA, Rowley EAK, Weber ZA, et al Impact of accounting for correlation between COVID-19 and influenza vaccination
in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
Vaccine. 2023 Nov 23:S0264-410X(23)01337-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FITZPATRICK MC, Laufer RS, Baral R, Driscoll AJ, et al Report of the WHO technical consultation on the evaluation of respiratory
syncytial virus prevention cost effectiveness in low- and middle-income
countries, April 7-8, 2022.
Vaccine. 2023;41:7047-7059. PubMedAbstract available
WANG B, McDonough J, Chen G, Ong JJ, et al Sociodemographic factors and attitudes associated with Australian parental
acceptance of paediatric COVID-19 vaccination.
Vaccine. 2023 Nov 22:S0264-410X(23)01336-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NEELY SR, Hao F Breakthrough COVID-19 infections and perceived vaccine effectiveness.
Vaccine. 2023 Nov 22:S0264-410X(23)01365-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al Childhood vaccination coverage and regional differences in Swiss birth cohorts
2012-2021: Are we on track?
Vaccine. 2023;41:7226-7233. PubMedAbstract available
ECONOMIDOU EC, Soteriades ES Excess mortality in Cyprus during the COVID-19 vaccination campaign.
Vaccine. 2023 Nov 22:S0264-410X(23)01361-0. doi: 10.1016/j.vaccine.2023. PubMed
LAW AW, Judy J, Atwell JE, Willis S, et al Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States:
Implications for maternal RSV vaccine uptake in the future.
Vaccine. 2023 Nov 21:S0264-410X(23)01307-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NAUGLE D, Tibbels N, Dosso A, Benie W, et al "I'd do it for my baby": Lessons learned from qualitative research on COVID-19
vaccination among pregnant women in Cote d'Ivoire.
Vaccine. 2023 Nov 19:S0264-410X(23)01333-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HAEDER SF Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in
the United States in late 2023.
Vaccine. 2023 Nov 15:S0264-410X(23)01303-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
AMITAI N, Wertheimer R, Prais D, Wertheimer KO, et al Influenza vaccination in children with pulmonary disease during the COVID-19
pandemic.
Vaccine. 2023 Nov 15:S0264-410X(23)01338-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHOI Y, Park S, Lee J, Kim Y, et al Who gets COVID-19 booster vaccination? Trust in public health institutions and
promotion strategies post-pandemic in the Republic of Korea.
Vaccine. 2023 Nov 15:S0264-410X(23)01294-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SARAFIAN JT, Eucker SA, Gillman M, DeLaroche AM, et al Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to
vaccinate children: Exploring school-related concerns and vaccination
decision-making.
Vaccine. 2023 Nov 14:S0264-410X(23)01334-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PLUMB ID, Briggs Hagen M, Wiegand R, Dumyati G, et al Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2
infection among U.S. Healthcare personnel, September 2022-May 2023.
Vaccine. 2023 Nov 14:S0264-410X(23)01287-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GUBERNOT D, Menis M, Whitaker B Background rates for severe cutaneous reactions in the US: Contextual support for
safety assessment of COVID-19 vaccines and novel biologics.
Vaccine. 2023;41:6922-6929. PubMedAbstract available
LASRADO N, Collier AY, Hachmann NP, Miller J, et al Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
Vaccine. 2023;41:6904-6909. PubMedAbstract available
GOTO T, Chong Y, Tani N, Susai N, et al Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough
infection.
Vaccine. 2023;41:7019-7025. PubMedAbstract available
CUBIZOLLES C, Barjat T, Chauleur C, Bruel S, et al Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis
and to get a future vaccine against respiratory syncytial virus in pregnant
women.
Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
JIANG X, Wang J, Li C, Yeoh EK, et al Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal
influenza vaccination in Hong Kong: A cross-sectional study.
Vaccine. 2023 Nov 11:S0264-410X(23)01304-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GRABENSTEIN JD, Ferrara P, Mantovani LG, McGovern I, et al Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of
adjuvanted influenza vaccine.
Vaccine. 2023 Nov 10:S0264-410X(23)01302-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HERZIG VAN WEES S, Stalgren M, Viberg N, Puranen B, et al "Who is Anders Tegnell?" Unanswered questions hamper COVID-19 vaccine uptake: A
qualitative study among ethnic minorities in Sweden.
Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BRUXVOORT KJ, Sy LS, Hong V, Lewin B, et al Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US
health care system.
Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DUDLEY MZ, Schwartz B, Brewer J, Kan L, et al COVID-19 vaccination attitudes, values, intentions: US parents for their
children, September 2021.
Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ANDERSON EC, Blair PS, Finn A, Ingram J, et al Maternal vaccination provision in NHS maternity trusts across England.
Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
YANG C, Zheng Z, Zheng P, Chen J, et al Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for
both pregnant women and neonates.
Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
INOUE Y, Li Y, Yamamoto S, Fukunaga A, et al The association between antipyretic analgesics use and SARS-CoV-2 antibody titers
following the second dose of the BNT162b2 mRNA vaccine: An observational study.
Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SPACKMAN E, Suarez DL, Lee CW, Pantin-Jackwood MJ, et al Efficacy of inactivated and RNA particle vaccines against a North American Clade
2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
Vaccine. 2023 Nov 4:S0264-410X(23)01285-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HANSEN LG, Larsen LE, Rasmussen TB, Miar Y, et al Investigation of the SARS-CoV-2 post-vaccination antibody response in Canadian
farmed mink.
Vaccine. 2023 Nov 4:S0264-410X(23)01288-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
JONES G, Perry M, Bailey R, Arumugam S, et al Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A
multivariable linked data population analysis.
Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
AKHTAR Z, Gotberg M, Erlinge D, Christiansen EH, et al Optimal timing of influenza vaccination among patients with acute myocardial
infarction - Findings from the IAMI trial.
Vaccine. 2023 Nov 2:S0264-410X(23)01211-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHEN GL, Yu XY, Luo LP, Zhang F, et al Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
Vaccine. 2023 Nov 2:S0264-410X(23)01278-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BOLOTIN S, Osman S, Halperin S, Severini A, et al Immunity of Canadians and risk of epidemics workshop - Conference report.
Vaccine. 2023;41:6775-6781. PubMedAbstract available
DO LAH, Le NTN, Mahmud S, Mulholland K, et al Impact and cost-effectiveness of strategies to prevent respiratory syncytial
virus (RSV) disease in Vietnam: A modelling study.
Vaccine. 2023;41:6782-6790. PubMedAbstract available
ALIZADEH M, Raj S, Shojadoost B, Matsuyama-Kato A, et al In ovo administration of retinoic acid enhances cell-mediated immune responses
against an inactivated H9N2 avian influenza virus vaccine.
Vaccine. 2023 Nov 1:S0264-410X(23)01261-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
JAMES WG, Stanberry LR, LaRussa PS, Grodman MD, et al Vaccines and global health: COVID-19 vaccine development, strategy, and
implementation symposium - Summary of the meeting at Vagelos College of
Physicians and Surgeons (February 22-26, 2021, New York).
Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023. PubMed
October 2023
RAMSAY JA, Jones M, Vande More AM, Hunt SL, et al A single blinded, phase IV, adaptive randomised control trial to evaluate the
safety of coadministration of seasonal influenza and COVID-19 vaccines (The
FluVID study).
Vaccine. 2023 Oct 28:S0264-410X(23)01250-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SALLOUM M, Paviotti A, Bastiaens H, Van Geertruyden JP, et al The inclusion of pregnant women in vaccine clinical trials: An overview of
late-stage clinical trials' records between 2018 and 2023.
Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LIU Y, Sanchez-Ovando S, Carolan L, Dowson L, et al Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines
reflects B cell dynamics independent of anti-vector immunity: Implications for
future pandemic vaccines.
Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NYAMBAYO PPM, Gold MS, Mehta UC, Clarke S, et al Efficacy and feasibility of SMS m-Health for the detection of adverse events
following immunisation (AEFIs) in resource-limited setting-The Zimbabwe
stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised
control trial.
Vaccine. 2023;41:6700-6709. PubMedAbstract available
TANI N, Ikematsu H, Goto T, Kondo S, et al Correlation between specific antibody response to wild-type BNT162b2 booster and
the risk of breakthrough infection with omicron variants: Impact of household
exposure in hospital healthcare workers.
Vaccine. 2023;41:6672-6678. PubMedAbstract available
WALLIAR T, Khan B, Newstead S, Al-Assadi G, et al "Fighting the pandemic!" Western Australian pharmacists' perspectives on COVID-19
vaccines: A qualitative study.
Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ANASTASSOPOULOU C, Boufidou F, Hatziantoniou S, Vasileiou K, et al Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after
COVID-19 vaccination.
Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al The state of COVID-19 vaccine confidence and need in Black individuals in Canada:
Understanding the role of sociodemographic factors, health literacy, conspiracy
theories, traumatic stressors and racial discrimination.
Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KITIKOON P, Knetter SM, Mogler MA, Morgan CL, et al Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous
and heterologous strains of swine influenza virus infection.
Vaccine. 2023 Oct 24:S0264-410X(23)01175-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FLOR N, Garcia MI, Molineri A, Bottasso O, et al Antibodies to SARS-CoV2 induced by vaccination and infection correlate with
protection against the infection.
Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BRESEE J, Koh M, Chadwick C, Jit M, et al The need and ongoing efforts to understand the full value of improved influenza
vaccines.
Vaccine. 2023 Oct 21:S0264-410X(23)01245-8. doi: 10.1016/j.vaccine.2023. PubMed
WANGCHUK S, Prabhakaran AO, Dhakal GP, Zangmo C, et al Introducing seasonal influenza vaccine in Bhutan: Country experience and
achievements.
Vaccine. 2023 Oct 20:S0264-410X(23)01255-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
IRVING SA, Groom HC, Belongia EA, Crane B, et al Influenza vaccination coverage among persons ages six months and older in the
Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.
Vaccine. 2023 Oct 20:S0264-410X(23)01206-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
TUNIS M, Deeks S, Harrison R, Quach C, et al Canada's National Advisory Committee on immunization: Adaptations and challenges
during the COVID-19 pandemic.
Vaccine. 2023;41:6538-6547. PubMedAbstract available
MORI Y, Uchida N, Wake A, Miyawaki K, et al Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell
transplant recipients: A Japanese multicenter observational study.
Vaccine. 2023 Oct 20:S0264-410X(23)01022-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HART R, Feygin Y, Kluthe T, Quinn KG, et al Emergency departments: An underutilized resource to address pediatric influenza
vaccine coverage.
Vaccine. 2023 Oct 19:S0264-410X(23)01222-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MCCLYMONT E, Atkinson A, Albert A, Av-Gay G, et al Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19
vaccination during pregnancy in Canada: A national prospective cohort study.
Vaccine. 2023 Oct 19:S0264-410X(23)01215-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HONDA-OKUBO Y, Bowen R, Barker M, Bielefeldt-Ohmann H, et al Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike
protein vaccine protects hamsters against heterologous infection with Beta or
Delta variants.
Vaccine. 2023 Oct 18:S0264-410X(23)01190-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
RIEFOLO F, Castillo-Cano B, Martin-Perez M, Messina D, et al Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules
against severe illness in general population and clinical subgroups in three
European countries.
Vaccine. 2023 Oct 17:S0264-410X(23)01181-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HAEDER SF U.S. public support and opposition to vaccination mandates in K-12 education in
light of the COVID-19 pandemic.
Vaccine. 2023 Oct 17:S0264-410X(23)01188-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
YANG H, Wang Z, Zhang Y, Xu M, et al Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron
subvariant BF.7 among outpatients in Beijing, China.
Vaccine. 2023 Oct 17:S0264-410X(23)01219-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PLATENBURG PPLI, Deschamps F, Jung J, Leonard C, et al Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose
seasonal influenza vaccines.
Vaccine. 2023 Oct 16:S0264-410X(23)01189-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LOPEZ-GOMEZ A, Pelaez-Prestel HF, Juarez I Approaches to evaluate the specific immune responses to SARS-CoV-2.
Vaccine. 2023;41:6434-6443. PubMedAbstract available
MOSCA S, Lin Q, Stokes R, Bharucha T, et al Innovative method for rapid detection of falsified COVID-19 vaccines through
unopened vials using handheld Spatially Offset Raman Spectroscopy (SORS).
Vaccine. 2023 Oct 13:S0264-410X(23)01182-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ARASHIRO T, Arima Y, Kuramochi J, Muraoka H, et al Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against
symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
Vaccine. 2023 Oct 13:S0264-410X(23)01194-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PARK H, Jang MS, Choi JA, Kim W, et al Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine
for SARS-CoV-2 in rabbits.
Vaccine. 2023 Oct 9:S0264-410X(23)01178-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MO C, Li X, Wu Q, Fan Y, et al SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.
Vaccine. 2023 Oct 9:S0264-410X(23)01156-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SATHE N, Shaikh S, Bhavsar M, Parte L, et al Safety, immunogenicity and efficacy of Relcovax(R), a dual receptor binding domain
(RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2
virus.
Vaccine. 2023 Oct 8:S0264-410X(23)01176-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LOPEZ-ZAMBRANO MA, Pita CC, Escribano MF, Galan Melendez IM, et al Factors associated to influenza vaccination among hospital's healthcare workers
in the Autonomous Community of Madrid, Spain 2021-2022.
Vaccine. 2023 Oct 6:S0264-410X(23)01117-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PROCTER TD, Ogasawara H, Spruin S, Wijayasri S, et al Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector
COVID-19 vaccination in Canada.
Vaccine. 2023 Oct 6:S0264-410X(23)01159-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
OZAWA S, Schuh HB, Nakamura T, Yemeke TT, et al How to increase and maintain high immunization coverage: Vaccination Demand
Resilience (VDR) framework.
Vaccine. 2023 Oct 3:S0264-410X(23)01097-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ZACHRESON C, Tobin R, Szanyi J, Walker C, et al Individual variation in vaccine immune response can produce bimodal distributions
of protection.
Vaccine. 2023 Oct 2:S0264-410X(23)01095-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
September 2023
OKOLI GN, Righolt CH, Zhang G, Alessi-Severini S, et al Impact of the universal seasonal influenza vaccination policy in the province of
Manitoba, Canada: A population-based, province-wide record-linkage study.
Vaccine. 2023 Sep 29:S0264-410X(23)01133-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DIONNE M, Sauvageau C, Kiely M, Rathwell M, et al "The problem is not lack of information": A qualitative study of parents and
school nurses' perceptions of barriers and potential solutions for HPV
vaccination in schools.
Vaccine. 2023 Sep 28:S0264-410X(23)01140-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HARBOE ZB, Hald A, Ekenberg C, Ete Wareham N, et al Implementation of a vaccination clinic for adult solid organ transplant
candidates: A single-center experience.
Vaccine. 2023 Sep 27:S0264-410X(23)01106-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al 25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune
response following SARS-CoV-2 mRNA vaccinations.
Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SHEN X, Hao Y, Wang S, Li D, et al Sequential heterologous immunization with COVID-19 vaccines induces broader
neutralizing responses against SARS-CoV-2 variants in comparison with homologous
boosters.
Vaccine. 2023 Sep 26:S0264-410X(23)01100-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CASSARINO N, Ahnger-Pier KK, Wurcel A Trends in COVID-19 and influenza vaccine ordering and distribution in
Massachusetts jails.
Vaccine. 2023 Sep 25:S0264-410X(23)01115-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SANA S, Merkelbach I, Magnee T, Kollmann J, et al Identifying barriers to vaccination intention at walk-in vaccination facilities
in deprived neighbourhoods: A cross-sectional survey.
Vaccine. 2023 Sep 25:S0264-410X(23)01038-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GOLOVKINA MI, Ertz SC, Lechnir SS, Hayney MS, et al Providing influenza vaccines at endoscopy visits increases influenza vaccine
uptake.
Vaccine. 2023 Sep 23:S0264-410X(23)01108-8. doi: 10.1016/j.vaccine.2023. PubMed
RAISER F, Davis M, Adelglass J, Cai MR, et al Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized
clinical trial in adults.
Vaccine. 2023;41:5965-5973. PubMedAbstract available
HAO F, Shao W Social network, political climate, income inequality, and Americans uptake of
monovalent COVID-19 booster.
Vaccine. 2023;41:6077-6082. PubMedAbstract available
NGAMCHALIEW P, Kaewkuea N, Nonthasorn N, Vonnasrichan T, et al Acceptance of COVID-19 vaccination and vaccine confidence levels in Thailand: A
cross-sectional study.
Vaccine. 2023 Sep 22:S0264-410X(23)01088-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HOMAIRA N, He WQ, McRae J, Macartney K, et al Coverage and predictors of influenza and pertussis vaccination during pregnancy:
a whole of population-based study.
Vaccine. 2023 Sep 21:S0264-410X(23)01062-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FU Y, Wu K, Wang Z, Yang H, et al Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients
from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods
- United States, 11 December 2020 to 30 June 2022.
Vaccine. 2023 Sep 21:S0264-410X(23)01025-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WILKINSON B, Patel KS, Smith K, Walker R, et al A Brighton Collaboration standardized template with key considerations for a
benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a
recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease
caused by SARS-CoV-2 vir
Vaccine. 2023 Sep 20:S0264-410X(23)00871-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ALHARBI HS Review: Factors influencing parents' decisions to vaccinate children against
COVID-19.
Vaccine. 2023 Sep 19:S0264-410X(23)01090-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HAN C, Zhao ZZ, Chan P, Li F, et al A large survey on COVID-19 vaccination in patients with Parkinson's disease and
healthy population.
Vaccine. 2023 Sep 17:S0264-410X(23)01056-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NELSON CB, Brady BL, Richards M, Lew CR, et al Optimal site of care for administration of extended half-life respiratory
syncytial virus (RSV) antibodies to infants in the United States (US).
Vaccine. 2023;41:5820-5824. PubMedAbstract available
SHAVER N, Katz M, Darko Asamoah G, Linkins LA, et al Protocol for a living evidence synthesis on variants of concern and COVID-19
vaccine effectiveness.
Vaccine. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
IRALA S, Hamid S, Penayo E, Michel F, et al COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May
2021-April 2022: A test-negative design.
Vaccine. 2023 Sep 14:S0264-410X(23)01069-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SURYAWANSHI YR An overview of protein-based SARS-CoV-2 vaccines.
Vaccine. 2023 Sep 10:S0264-410X(23)01067-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
POTT H, Andrew MK, Shaffelburg Z, Nichols MK, et al Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated
influenza vaccines in the prevention of influenza-related hospitalization in
older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS)
Network of the Canad
Vaccine. 2023 Sep 9:S0264-410X(23)01026-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
YU J, Sreenivasan C, Sheng Z, Zhai SL, et al A recombinant chimeric influenza virus vaccine expressing the consensus H3
hemagglutinin elicits broad hemagglutination inhibition antibodies against
divergent swine H3N2 influenza viruses.
Vaccine. 2023 Sep 7:S0264-410X(23)01060-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MONTEIRO HS, Lima Neto AS, Kahn R, Sousa GS, et al Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and
socially unequal Brazilian city: A target trial emulation study.
Vaccine. 2023;41:5742-5751. PubMedAbstract available
PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac,
BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and
hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
Vaccine. 2023 Sep 5:S0264-410X(23)01028-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
YUE PHR, Lau HPB, Ng SM, Chan LWC, et al When to be vaccinated? What to consider? Modelling decision-making and time
preference for COVID-19 vaccine through a conjoint experiment.
Vaccine. 2023 Sep 5:S0264-410X(23)01024-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PHILLIPS A, Jiang Y, Walsh D, Andrews N, et al Background rates of adverse events of special interest for COVID-19 vaccines: A
multinational Global Vaccine Data Network (GVDN) analysis.
Vaccine. 2023 Sep 5:S0264-410X(23)01045-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ALSAIF F, Twigg M, Scott S, Blyth A, et al A systematic review of barriers and enablers associated with uptake of influenza
vaccine among care home staff.
Vaccine. 2023 Sep 4:S0264-410X(23)01048-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CLAESSENS T, Krouwer S, Vandebosch H, Poels K, et al Pathways to informed choices: The impact of freedom of choice and two-sided
messages on psychological reactance and vaccination intentions among individuals
who express concerns.
Vaccine. 2023 Sep 3:S0264-410X(23)00948-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WILLIS DE, Moore R, Andersen JA, Li J, et al Correlates of COVID-19 vaccine coverage in Arkansas: Results from a weighted
random sample survey.
Vaccine. 2023 Sep 1:S0264-410X(23)01039-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PORRAS-RAMIREZ A, Sanchez-Paris R, Lopez-Devia W, Moreno-Perilla Z, et al Confirmed cases of COVID-19 after vaccination against COVID in health personnel
in Bogota, Colombia.
Vaccine. 2023 Sep 1:S0264-410X(23)00924-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
August 2023
SAKALA IG, Honda-Okubo Y, Petrovsky N Developmental and reproductive safety of Advax-CpG55.2 adjuvanted COVID-19 and
influenza vaccines in mice.
Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GRILLS LA, Wagner AL The impact of the COVID-19 pandemic on parental vaccine hesitancy: A
cross-sectional survey.
Vaccine. 2023 Aug 31:S0264-410X(23)00977-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DUDLEY HM, O'Mara M, Auma A, Gong J, et al Rheumatoid arthritis and older age are associated with lower humoral and cellular
immune response to primary series COVID-19 mRNA vaccine.
Vaccine. 2023 Aug 31:S0264-410X(23)00965-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
REGAN AK, Fell DB, Wise LA, Vazquez-Benitez G, et al Challenges & opportunities for the epidemiological evaluation of the effects of
COVID-19 vaccination on reproduction and pregnancy.
Vaccine. 2023 Aug 31:S0264-410X(23)00964-7. doi: 10.1016/j.vaccine.2023. PubMed
PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control
study.
Vaccine. 2023 Aug 27:S0264-410X(23)00994-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
YANG J, Li B, Yang D, Wu J, et al The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
Vaccine. 2023 Aug 26:S0264-410X(23)01017-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
JANSSEN ERC, van Montfoort AZ, Hollman F, Lambers Heerspink FO, et al The prevalence and clinical course of shoulder injury related to vaccine
administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers.
Vaccine. 2023 Aug 25:S0264-410X(23)00975-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al Recombinant spike protein vaccines coupled with adjuvants that have different
modes of action induce protective immunity against SARS-CoV-2.
Vaccine. 2023 Aug 25:S0264-410X(23)01008-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHEN IR, Wang GJ, Hsueh PR, Chou CH, et al Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic
syndrome patients in Taiwan.
Vaccine. 2023 Aug 25:S0264-410X(23)00952-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WATERLOW NR, Procter SR, van Leeuwen E, Radhakrishnan S, et al The potential cost-effectiveness of next generation influenza vaccines in England
and Wales: A modelling analysis.
Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MOHAMMED IS, Widome R, Searle KM COVID-19 vaccine decision-making among Black women: A qualitative study.
Vaccine. 2023 Aug 24:S0264-410X(23)00920-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DENG L, Tapper K, Thosar D, Goeman E, et al Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination:
An Australian retrospective cohort study.
Vaccine. 2023 Aug 24:S0264-410X(23)00956-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GOULD S, Wrzesinski C, Stebbings R, Segal L, et al Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry,
regulatory and CRO perspectives.
Vaccine. 2023 Aug 24:S0264-410X(23)00972-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
STRUYF F, Hardt K, Van Rampelbergh R, Shukarev G, et al Thrombosis with thrombocytopenia syndrome: A database review of clinical trial
and post-marketing experience with Ad26.COV2.S.
Vaccine. 2023;41:5351-5359. PubMedAbstract available
KUMRU OS, Sanyal M, Friedland N, Hickey JM, et al Formulation development and comparability studies with an aluminum-salt
adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from
two different cell lines.
Vaccine. 2023 Aug 22:S0264-410X(23)00969-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SU Y, Guo Z, Gu X, Sun S, et al Influenza vaccine effectiveness against influenza A during the delayed 2022/23
epidemic in Shihezi, China.
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
YAO T, Guo Y, Xu X, Zhang X, et al Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in
high-risk occupational population.
Vaccine. 2023 Aug 19:S0264-410X(23)00974-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KENIGSBERG TA, Goddard K, Hanson KE, Lewis N, et al Simultaneous administration of mRNA COVID-19 bivalent booster and influenza
vaccines.
Vaccine. 2023 Aug 18:S0264-410X(23)00955-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHAIWONG W, Takheaw N, Pata S, Laopajon W, et al Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by
heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic
obstructive pulmonary disease.
Vaccine. 2023 Aug 18:S0264-410X(23)00966-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PALACHE A, Billingsley JK, MacLaren K, Morgan L, et al Lessons learned from the COVID-19 pandemic for improved influenza control.
Vaccine. 2023 Aug 17:S0264-410X(23)00960-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MORRISON K, Cullen L, James AB, Chua V, et al Predictors of incomplete COVID-19 vaccine schedule among adults in Scotland: Two
retrospective cohort analyses of the primary schedule and third dose.
Vaccine. 2023 Aug 17:S0264-410X(23)00916-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ZUR M, Shelef L, Glassberg E, Fink N, et al Are intelligent people more likely to get vaccinated? The association between
COVID-19 vaccine adherence and cognitive profiles.
Vaccine. 2023 Aug 15:S0264-410X(23)00951-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SARNA M, Gebremedhin A, Richmond P, Levy A, et al Determining the true incidence of seasonal respiratory syncytial virus-confirmed
hospitalizations in preterm and term infants in Western Australia.
Vaccine. 2023;41:5216-5220. PubMedAbstract available
TOYAMA K, Eto T, Takazawa K, Shimizu S, et al DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe
acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
Vaccine. 2023 Aug 14:S0264-410X(23)00824-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WITTAWATMONGKOL O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, et al Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19
vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A
multicenter, prospective, double-blind, randomized control trial.
Vaccine. 2023 Aug 14:S0264-410X(23)00953-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BERTHELEMY C, Bouche P, Lamiral Z, Boivin JM, et al Parental acceptability of vaccinating young children against influenza and
COVID-19.
Vaccine. 2023 Aug 12:S0264-410X(23)00929-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HONDA-OKUBO Y, Bart Tarbet E, Hurst BL, Petrovsky N, et al An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice
against lethal influenza infection.
Vaccine. 2023 Aug 9:S0264-410X(23)00941-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BAGLIVO F, Magri M, De Angelis L, Aprile V, et al Performance comparison between heterologous and homologous COVID19 vaccine
schedules on Omicron variant incidence: A real-world retrospective cohort study
in Southern Italy.
Vaccine. 2023 Aug 9:S0264-410X(23)00886-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MAC S, Shi S, Millson B, Tehrani A, et al Burden of illness associated with Respiratory Syncytial Virus (RSV)-related
hospitalizations among adults in Ontario, Canada: A retrospective
population-based study.
Vaccine. 2023;41:5141-5149. PubMedAbstract available
CHICOYE A, Crepey P, Nguyen VH, Marquez-Pelaez S, et al Contributions of cost-effectiveness analyses (CEA) to influenza vaccination
policy for older adults in Europe.
Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SIMMS AJ, King KD, Tsui N, Edwards SA, et al COVID-19 vaccine behaviour among citizens of the Metis Nation of Ontario: A
qualitative study.
Vaccine. 2023 Aug 5:S0264-410X(23)00891-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
VERJOVSKY M, Barreto MP, Carmo I, Coutinho B, et al Political quarrel overshadows vaccination advocacy: How the vaccine debate on
Brazilian Twitter was framed by anti-vaxxers during Bolsonaro administration.
Vaccine. 2023 Aug 5:S0264-410X(23)00921-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CAMPBELL J, Kaur A, Gamino D, Benoit E, et al Individual and structural determinants of COVID-19 vaccine uptake in a
marginalized community in the United States.
Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MOSCARA L, Venerito V, Martinelli A, Di Lorenzo A, et al Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving
anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational
study.
Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
XU S, Yu H, Cheng X, Wu J, et al Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of
Graves' disease: An observational cohort study.
Vaccine. 2023 Aug 4:S0264-410X(23)00884-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
AUVIGNE V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, et al Protection against symptomatic SARS-CoV-2 infection conferred by the
Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original
monovalent vaccines - A matched cohort study in France.
Vaccine. 2023 Aug 2:S0264-410X(23)00917-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MO J, Spackman E, Swayne DE Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by
comparison of in vitro and in vivo data: A meta-analysis and systematic review.
Vaccine. 2023 Aug 1:S0264-410X(23)00922-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
July 2023
HONDA-OKUBO Y, Sakala IG, Andre G, Tarbet EB, et al An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity
against H7N9 influenza in adult and neonatal mice.
Vaccine. 2023 Jul 31:S0264-410X(23)00892-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WALLACE M, Rosenblum HG, Moulia DL, Broder KR, et al A summary of the Advisory Committee for Immunization Practices (ACIP) use of a
benefit-risk assessment framework during the first year of COVID-19 vaccine
administration in the United States.
Vaccine. 2023 Jul 30:S0264-410X(23)00868-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LIU B, Stepien S, Qian J, Gidding H, et al Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273,
ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
Vaccine. 2023 Jul 29:S0264-410X(23)00881-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
AMANI A, Njoh AA, Atuhebwe P, Ndoula S, et al Beyond the numbers: An in-depth look at Cameroon's fifth national COVID-19
vaccination campaign through geographical and gender lenses.
Vaccine. 2023 Jul 29:S0264-410X(23)00905-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GREEN-MCKENZIE J, Shofer FS, Kruse G, Momplaisir F, et al COVID-19 vaccine uptake before and after a vaccine mandate at a major academic
hospital: Trends by race/ethnicity and level of patient contact.
Vaccine. 2023 Jul 28:S0264-410X(23)00853-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LAVENDER B, Hooker C, Frampton C, Williams M, et al Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron
variant in a naive New Zealand cohort.
Vaccine. 2023 Jul 27:S0264-410X(23)00882-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ROSA RG, Falavigna M, Manfio JL, de Araujo CLP, et al BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass
vaccination campaign in southern Brazil: A prospective test-negative design
study.
Vaccine. 2023 Jul 26:S0264-410X(23)00869-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KIM DH, Lee J, Youk S, Jeong JH, et al Intramuscular administration of recombinant Newcastle disease virus expressing
SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
Vaccine. 2023;41:4787-4797. PubMedAbstract available
TAMADA Y, Takeuchi K, Kusama T, Maeda M, et al Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative
study from the VENUS study.
Vaccine. 2023 Jul 22:S0264-410X(23)00856-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GHAZY RM, Ibrahim SA, Taha SHN, Elshabrawy A, et al Attitudes of parents towards influenza vaccine in the Eastern Mediterranean
Region: A multilevel analysis.
Vaccine. 2023 Jul 20:S0264-410X(23)00808-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ARAUJO-CHAVERON L, Sicsic J, Moffroid H, Diaz Luevano C, et al Impact of a COVID-19 certificate requirement on vaccine uptake pattern and
intention for future vaccination. A cross-sectional study among French adults.
Vaccine. 2023 Jul 20:S0264-410X(23)00805-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al Computational design of mRNA vaccines.
Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al Safety signal identification for COVID-19 bivalent booster vaccination using
tree-based scan statistics in the Vaccine Safety Datalink.
Vaccine. 2023 Jul 19:S0264-410X(23)00823-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ZIMMERMAN RK, Patricia Nowalk M, Dauer K, Clarke L, et al Vaccine effectiveness of recombinant and standard dose influenza vaccines against
influenza related hospitalization using a retrospective test-negative design.
Vaccine. 2023 Jul 18:S0264-410X(23)00741-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SABAT I, Neumann-Bohme S, Barros PP, Torbica A, et al Vaccine hesitancy comes in waves: Longitudinal evidence on willingness to
vaccinate against COVID-19 from seven European countries.
Vaccine. 2023 Jul 15:S0264-410X(23)00829-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MOROS A, Prenafeta A, Barreiro A, Perozo E, et al Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer
vaccine candidate.
Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CLOUSTON SAP, Hanes DW, Link BG Social inequalities and the early provision and dispersal of COVID-19
vaccinations in the United States: A population trends study.
Vaccine. 2023 Jul 15:S0264-410X(23)00833-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
TALOTTA R COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in
silico analysis, considerations and perspectives.
Vaccine. 2023 Jul 13:S0264-410X(23)00819-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ALABANZA C, Gavrilov V, Scott T, Yang RS, et al Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent
influenza nanoparticle vaccine by ELISA.
Vaccine. 2023 Jul 12:S0264-410X(23)00821-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BEYERS KCL, Rbeihat MNM, S Vasconcelos D, Pasmans D, et al Preclinical evaluation of performance, safety and usability of VAX-ID(R), a novel
intradermal injection device.
Vaccine. 2023;41:4609-4615. PubMedAbstract available
AGRAWAL P, Damania D, Cseh A, Grab J, et al Impact of COVID vaccine and comorbidities in patients receiving
casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta)
surge: A real-world study.
Vaccine. 2023 Jul 12:S0264-410X(23)00822-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MINCHIN J, Harris GH, Baumann S, Smith ER, et al Exclusion of pregnant people from emergency vaccine clinical trials: A systematic
review of clinical trial protocols and reporting from 2009 to 2019.
Vaccine. 2023 Jul 11:S0264-410X(23)00776-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al Social processes, practical issues, and COVID-19 vaccination among hesitant
adults.
Vaccine. 2023 Jul 7:S0264-410X(23)00809-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FLEMING JA, Baral R, Higgins D, Khan S, et al Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
Vaccine. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022. PubMedAbstract available
ZHANG X, Shen P, Liu J, Ji X, et al Evaluating the effectiveness and cost-effectiveness of free influenza vaccination
policy for older adults in Yinzhou, China: Study protocol of a real-world
analyses.
Vaccine. 2023 Jul 5:S0264-410X(23)00790-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WAGNER A, Juvalta S, Speranza C, Suggs LS, et al Let's talk about COVID-19 vaccination: Relevance of conversations about COVID-19
vaccination and information sources on vaccination intention in Switzerland.
Vaccine. 2023 Jul 5:S0264-410X(23)00807-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LE H, de Klerk N, Blyth CC, Gidding H, et al Non-specific benefit of seasonal influenza vaccine on respiratory syncytial
virus-hospitalisations in children: An instrumental variable approach using
population-based data.
Vaccine. 2023 Jul 3:S0264-410X(23)00788-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PATEL UC, Schultz T, Schmidt J Veteran influenza vaccination acceptance rates after completion of the COVID-19
vaccination series among historical influenza vaccine refusers.
Vaccine. 2023 Jul 3:S0264-410X(23)00803-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ROSHCHINA Y, Rozhkova K, Roshchin S Between nudges and mandates: The drivers of COVID-19 vaccination intentions and
subsequent uptake in Russia.
Vaccine. 2023 Jul 3:S0264-410X(23)00756-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
TUCKERMAN J, Kaufman J, Overmars I, Holland P, et al Barriers to COVID-19 vaccination of migrant populations: A qualitative interview
study of immunisation providers in Victoria, Australia.
Vaccine. 2023 Jul 3:S0264-410X(23)00804-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
TROGSTAD L, Laake I, Robertson AH, Mjaaland S, et al Heavy bleeding and other menstrual disturbances in young women after COVID-19
vaccination.
Vaccine. 2023 Jul 3:S0264-410X(23)00801-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
June 2023
LIU Z, Pang C, Deng Y, Guo C, et al Humoral immune response following the inactivated quadrivalent influenza
vaccination among HIV-infected and HIV-uninfected adults.
Vaccine. 2023 Jun 30:S0264-410X(23)00616-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SHINJOH M, Furuichi M, Tsuzuki S, Iqbal A, et al Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized
children in 2022/23 season in Japan - The first season of co-circulation of
influenza and COVID-19.
Vaccine. 2023 Jun 30:S0264-410X(23)00785-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LIU Y, Zhang A, Wang Y, Yang J, et al Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in
mice and rhesus macaques.
Vaccine. 2023 Jun 30:S0264-410X(23)00789-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KU JH, Sy LS, Qian L, Ackerson BK, et al Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults
in the United States: Interim results from an observational cohort study.
Vaccine. 2023;41:4212-4219. PubMedAbstract available
VAN DER BOOR SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, et al Spontaneously reported adverse events following COVID-19 basic and booster
immunizations in the Netherlands.
Vaccine. 2023;41:4319-4326. PubMedAbstract available
ALVES K, Plested JS, Galbiati S, Chau G, et al Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Vaccine. 2023;41:4280-4286. PubMedAbstract available
ISHIKAWA K, Nascimento MC, Asano M, Hirata H, et al One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis
of a randomized, placebo-controlled phase 1/2 trial in Japan.
Vaccine. 2023;41:4199-4205. PubMedAbstract available
LEE KS, Rader NA, Miller-Stump OA, Cooper M, et al Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta
SARS-CoV-2 challenge in K18-hACE2-mice.
Vaccine. 2023 Jun 28:S0264-410X(23)00783-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SHENG Y, Li Z, Lin X, Ma Y, et al The position of Spy Tag/Catcher system in hepatitis B core protein particles
affects the immunogenicity and stability of the synthetic vaccine.
Vaccine. 2023 Jun 28:S0264-410X(23)00759-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DOMNICH A, Orsi A, Ogliastro M, Trombetta CS, et al Influenza vaccine effectiveness in preventing hospital encounters for
laboratory-confirmed infection among Italian adults, 2022/23 season.
Vaccine. 2023 Jun 27:S0264-410X(23)00775-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KIM S, Ko M, Heo Y, Lee YK, et al Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged
18 years and over.
Vaccine. 2023 Jun 27:S0264-410X(23)00780-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BARRIENTOS M, Vasquez-Lavin F, Rosales C, Bratti L, et al Understanding the role of personal experiences and contextual variables in
shaping risk reduction preferences.
Vaccine. 2023;41:4092-4105. PubMedAbstract available
TORP HANSEN K, Kusk Povlsen F, Hammer Bech B, Nygaard Hansen S, et al Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old
Danish citizens.
Vaccine. 2023 Jun 23:S0264-410X(23)00758-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
TURLEY CB, Tables L, Fuller T, Sanders LJ, et al Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention
network efficacy trials.
Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SALEH SN, McDonald SA, Basit MA, Kumar S, et al Public perception of COVID-19 vaccines through analysis of Twitter content and
users.
Vaccine. 2023 Jun 23:S0264-410X(23)00743-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HOWARD MC Integrating the person-centered approach with the study of vaccine hesitancy:
Applying latent profile analysis to identify vaccine hesitancy subpopulations and
assess their relations with correlates and vaccination outcomes.
Vaccine. 2023 Jun 23:S0264-410X(23)00742-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHAUDHARY A, Madhavan R, Babji S, Raju R, et al Characterization of immune responses to two and three doses of the adenoviral
vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152
in a mix-and-match study in India.
Vaccine. 2023 Jun 23:S0264-410X(23)00744-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
AUGUSTYNIAK A, Szymanski T, Porzucek F, Mieloch AA, et al A cohort study reveals different dynamics of SARS-CoV-2-specific antibody
formation after Comirnaty and Vaxzevria vaccination.
Vaccine. 2023 Jun 21:S0264-410X(23)00665-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LUANGASANATIP N, Painter C, Pan-Ngum W, Saralamba S, et al How to model the impact of vaccines for policymaking when the characteristics are
uncertain: A case study in Thailand prior to the vaccine rollout during the
COVID-19 pandemic.
Vaccine. 2023 Jun 20:S0264-410X(23)00740-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHEN X, Lin Y, Yue S, Yang Y, et al PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.
Vaccine. 2023 Jun 20:S0264-410X(23)00737-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
EKIMOV A, Arunachalam AB, Blake T, Bodle J, et al Assessing the stability-indicating properties of alternative potency assays for
inactivated influenza vaccine.
Vaccine. 2023 Jun 19:S0264-410X(23)00726-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HONDA-OKUBO Y, Li L, Andre G, Leong KH, et al An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects
cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
UDA K, Okubo Y, Tsuge M, Tsukahara H, et al Impacts of routine varicella vaccination program and COVID-19 pandemic on
varicella and herpes zoster incidence and health resource use among children in
Japan.
Vaccine. 2023 Jun 19:S0264-410X(23)00739-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
TZENG R, Huang FY, Lee J Compliance, procrastination and refusal: American COVID-19 vaccination trust and
value orientation.
Vaccine. 2023 Jun 19:S0264-410X(23)00745-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MASOUD D, Pierz A, Rauh L, Cruz AK, et al Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine
trust.
Vaccine. 2023 Jun 17:S0264-410X(23)00690-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DOYON-PLOURDE P, Przepiorkowski J, Young K, Zhao L, et al Intraseasonal waning immunity of seasonal influenza vaccine - A systematic review
and meta-analysis.
Vaccine. 2023 Jun 16:S0264-410X(23)00713-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DUNN DT, Gilson R, McCormack S, McCoy LE, et al Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the
early-phase, dose-finding trials.
Vaccine. 2023 Jun 16:S0264-410X(23)00712-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BISWAS RK, Afiaz A, Huq S, Farzana M, et al Public opinion on COVID-19 vaccine prioritization in Bangladesh: Who gets the
vaccine and whom do you leave out?
Vaccine. 2023 Jun 16:S0264-410X(23)00725-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NISHIYAMA A, Adachi Y, Tonouchi K, Moriyama S, et al Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous
protection via Th1-polarized, non-neutralizing antibody responses.
Vaccine. 2023 Jun 15:S0264-410X(23)00685-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PIGNATTI P, Ramirez GA, Russo M, Marraccini P, et al Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to
excipients.
Vaccine. 2023 Jun 15:S0264-410X(23)00714-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MUANGNOICHAROEN S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, et al Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against
SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Vaccine. 2023 Jun 15:S0264-410X(23)00718-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KENIGSBERG TA, Hanson KE, Klein NP, Zerbo O, et al Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety
Datalink.
Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PUTHANAKIT T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, et al A phase 2 randomized controlled dose-ranging trial of recombinant pertussis
booster vaccines containing genetically inactivated pertussis toxin in pregnant
women.
Vaccine. 2023 Jun 15:S0264-410X(23)00657-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SHOAIBI A, Lloyd PC, Wong HL, Clarke TC, et al Evaluation of potential adverse events following COVID-19 mRNA vaccination among
adults aged 65 years and older: Two self-controlled studies in the U.S.
Vaccine. 2023 Jun 14:S0264-410X(23)00682-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CIEMINS EL, Gillen A, Tallam M RSV: A vaccine is coming, time to educate providers.
Vaccine. 2023 Jun 14:S0264-410X(23)00695-3. doi: 10.1016/j.vaccine.2023. PubMed
SAADATIAN-ELAHI M, Henaff L, Elias C, Nunes MC, et al Patient influenza vaccination reduces the risk of hospital-acquired influenza: An
incident test negative-case control study in Lyon university hospital, France
(2004-2020).
Vaccine. 2023 Jun 13:S0264-410X(23)00621-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SALMANTON-GARCIA J, Wipfler P, Valle-Simon P, Merakou C, et al VACCELERATE Site Network: Real-time definition of clinical study capacity in
Europe.
Vaccine. 2023;41:3915-3922. PubMedAbstract available
WOO EJ, Gee J, Marquez P, Baggs J, et al Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the
Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al COVID-19 booster vaccination during pregnancy enhances maternal binding and
neutralizing antibody responses and transplacental antibody transfer to the
newborn.
Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WATESKA AR, Nowalk MP, Lin CJ, Harrison LH, et al Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in
older US adults.
Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MA D, Tian S, Qin Q, Yu Y, et al Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis
spores-based vaccine and evaluation of its protection efficacy against influenza
in a mouse model.
Vaccine. 2023 Jun 10:S0264-410X(23)00655-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MADRAN B, Kayi I, Beser A, Ergonul O, et al Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging
interventions: A mixed methods study.
Vaccine. 2023 Jun 9:S0264-410X(23)00688-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
UI M, Hirama T, Akiba M, Honda M, et al Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA
vaccine in lung transplant recipients in Japan.
Vaccine. 2023 Jun 9:S0264-410X(23)00663-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MARTINEZ MR, Gao J, Wan H, Kang H, et al Inactivated influenza virions are a flexible vaccine platform for eliciting
protective antibody responses against neuraminidase.
Vaccine. 2023 Jun 8:S0264-410X(23)00629-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NOGAREDA F, Gharpure R, Contreras M, Velandia M, et al Seasonal influenza vaccination in the Americas: Progress and challenges during
the COVID-19 pandemic.
Vaccine. 2023 Jun 8:S0264-410X(23)00689-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DE GIER B, van Asten L, Boere TM, van Roon A, et al Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other
causes, the Netherlands, January 2021-January 2022.
Vaccine. 2023 Jun 8:S0264-410X(23)00660-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ROY A, Polazzi S, Ploin D, Gillet Y, et al The increasing age of respiratory syncytial virus-related hospitalisation during
COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
Vaccine. 2023;41:3796-3800. PubMedAbstract available
SHAW RJ, Doyle AJ, Millen EA, Stowe J, et al Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination
using haematological criteria.
Vaccine. 2023 Jun 7:S0264-410X(23)00662-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KATO H, Hozawa T, Fukushima W, Nobusawa E, et al Influenza vaccine viruses and the development of seasonal vaccines: A Japanese
perspective.
Vaccine. 2023 Jun 6:S0264-410X(23)00640-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KIM DELUCA E, Gebremariam A, Rose A, Biggerstaff M, et al Cost-effectiveness of routine annual influenza vaccination by age and risk
status.
Vaccine. 2023 Jun 6:S0264-410X(23)00495-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KIM WJ, Roberts CC, Song JY, Yoon JG, et al Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2
followed by administration of an mRNA vaccine heterologous boost.
Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PELLETIER C, Labbe F, Bettinger JA, Curran J, et al From high hopes to disenchantment: A qualitative analysis of editorial cartoons
on COVID-19 vaccines in Canadian newspapers.
Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ELDER E, Bangalore Revanna C, Johansson C, Wallin RPA, et al Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine.
Vaccine. 2023 Jun 6:S0264-410X(23)00684-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MAKANUT S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, et al Immunological responses and adverse reactions of the heterologous second booster
dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare
workers of Faculty of Medicine, Naresuan University.
Vaccine. 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WESSELINK AK, Lovett SM, Weinberg J, Geller RJ, et al COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort
study.
Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KOZMA GT, Meszaros T, Berenyi P, Facsko R, et al Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to
PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
Vaccine. 2023 Jun 5:S0264-410X(23)00667-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ERGUN T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, et al Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA
vaccines in patients with psoriasis receiving systemic therapies: A prospective
cohort study.
Vaccine. 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FEDDEMA JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM, et al Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.
Vaccine. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
May 2023
WANG LJ, Tsai CS, Chou WJ, Li CJ, et al Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2
vaccination: A six-month follow-up study.
Vaccine. 2023 May 29:S0264-410X(23)00628-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ARROSPIDE A, Sagardui MG, Larizgoitia I, Iturralde A, et al Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country
during the sixth wave: A nationwide cohort study.
Vaccine. 2023 May 29:S0264-410X(23)00622-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HU S, Xiong C, Zhao Y, Yuan X, et al Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison
before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
Vaccine. 2023 May 29:S0264-410X(23)00617-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MILLER ER, Moro PL, Shimabukuro TT, Carlock G, et al COVID-19 vaccine safety inquiries to the centers for disease control and
prevention immunization safety office.
Vaccine. 2023 May 24:S0264-410X(23)00613-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HORI D, Keneda Y, Ozaki A, Tabuchi T, et al Sexual orientation was associated with intention to be vaccinated with a smallpox
vaccine against mpox: A cross-sectional preliminary survey in Japan.
Vaccine. 2023 May 24:S0264-410X(23)00611-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NUGENT C, Abul Y, White EM, Shehadeh F, et al Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing
activity in both nursing home residents and health care workers.
Vaccine. 2023;41:3403-3409. PubMedAbstract available
JOUDEH AI, Lutf AQ, Mahdi S, Tran G, et al Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with
autoimmune rheumatic diseases: A systematic review.
Vaccine. 2023 May 22:S0264-410X(23)00609-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ALICANDRO G, Orena BS, Rosazza C, Cariani L, et al Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2
in people with cystic fibrosis.
Vaccine. 2023 May 22:S0264-410X(23)00590-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GHAZNAVI C, Eguchi A, Suu Lwin K, Yoneoka D, et al Estimating global changes in routine childhood vaccination coverage during the
COVID-19 pandemic, 2020-2021.
Vaccine. 2023 May 22:S0264-410X(23)00583-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GUO BQ, Li HB, Yang LQ Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis
with focus on adolescents aged 12-17 years.
Vaccine. 2023 May 22:S0264-410X(23)00610-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BOLSEWICZ KT, Steffens MS, King C, Abdi I, et al A qualitative study on COVID-19 pandemic impacts on parental attitudes and
intentions for routine adolescent vaccinations: The role of trust.
Vaccine. 2023 May 22:S0264-410X(23)00586-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
EGER J, Kaplan LC, Sternberg H How to reduce vaccination hesitancy? The relevance of evidence and its
communicator.
Vaccine. 2023 May 22:S0264-410X(23)00298-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
EMBI PJ, Levy ME, Patel P, DeSilva MB, et al Effectiveness of COVID-19 vaccines at preventing emergency department or urgent
care encounters and hospitalizations among immunocompromised adults: An
observational study of real-world data across 10 US states from August-December
2021.
Vaccine. 2023 May 22:S0264-410X(23)00588-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BOING AF, Boing AC, Barberia L, Borges ME, et al Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in
Brazil: A multilevel study of 2021-2022 data.
Vaccine. 2023 May 17:S0264-410X(23)00569-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ZHOU ZH, Cortese MM, Fang JL, Wood R, et al Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA
COVID-19 vaccination.
Vaccine. 2023 May 16:S0264-410X(23)00568-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BLACK SB, Chandler RE, Edwards KM, Sturkenboom MCJM, et al Assessing vaccine safety during a pandemic: Recent experience and lessons learned
for the future.
Vaccine. 2023 May 15:S0264-410X(23)00468-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LIMAYE RJ, Singh P, Paul A, Fesshaye B, et al COVID-19 vaccine decision-making among pregnant and lactating women in
Bangladesh.
Vaccine. 2023 May 15:S0264-410X(23)00551-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SURIE D, Bonnell LN, DeCuir J, Gaglani M, et al Comparison of mRNA vaccine effectiveness against COVID-19-associated
hospitalization by vaccination source: Immunization information systems,
electronic medical records, and self-report-IVY Network, February 1-August 31,
2022.
Vaccine. 2023 May 15:S0264-410X(23)00567-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GEORGE TK, Nair NP, Singh AK, Dilesh Kumar A, et al Development of a Choice-framework for Covid vaccines in India using a
multi-criteria decision analysis approach.
Vaccine. 2023 May 12:S0264-410X(23)00486-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KEHAGIA E, Papakyriakopoulou P, Valsami G Advances in intranasal vaccine delivery: A promising non-invasive route of
immunization.
Vaccine. 2023 May 11:S0264-410X(23)00529-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ROBERTS-MCCARTHY E, Buck PO, Smith-Ray RL, Van de Velde N, et al Factors associated with receipt of mRNA-1273 vaccine at a United States national
retail pharmacy during the COVID-19 pandemic.
Vaccine. 2023 May 11:S0264-410X(23)00383-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LANGLETE P, Tesli M, Veneti L, Starrfelt J, et al Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections
among health care workers and the general adult population in Norway, August 2021
- January 2022.
Vaccine. 2023 May 10:S0264-410X(23)00549-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SMITH K, Hegazy K, Cai MR, McKnight I, et al Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled
clinical trials.
Vaccine. 2023 May 10:S0264-410X(23)00543-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
VAN IERSEL SCJL, McDonald SA, de Gier B, Knol MJ, et al Number of COVID-19 hospitalisations averted by vaccination: Estimates for the
Netherlands, January 6, 2021 through August 30, 2022.
Vaccine. 2023 May 10:S0264-410X(23)00545-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
RUBIN THOMPSON LJ, Grubo M, Veller M, Badenhorst RH, et al Building global vaccine manufacturing capacity: Spotlight on Africa.
Vaccine. 2023 May 10:S0264-410X(23)00527-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CHIAVENNA C, Leone LP, Melegaro A, Rotesi T, et al Personal risk or societal benefit? Investigating adults' support for COVID-19
childhood vaccination.
Vaccine. 2023 May 9:S0264-410X(23)00544-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KURIYAMA K, Murakami K, Masuda T, Sugiura K, et al Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in
healthy Japanese adults who had previously received a primary series of COVID-19
mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
Vaccine. 2023 May 8:S0264-410X(23)00519-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SUTTON WJH, Branham PJ, Williamson YM, Cooper HC, et al Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using
isotope dilution mass spectrometry.
Vaccine. 2023 May 8:S0264-410X(23)00458-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BORDALO FERREIRA F, Rafael MA, Coimbra L, Boavida N, et al Anti-tumor necrosis factor therapy is associated with attenuated humoral response
to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
Vaccine. 2023 May 8:S0264-410X(23)00530-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FITZ-PATRICK D, Young M, Yacisin K, McElwee K, et al Randomized trial to evaluate the safety, tolerability, and immunogenicity of a
booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent
pneumococcal conjugate vaccine in adults >/=65 years old.
Vaccine. 2023 May 8:S0264-410X(23)00520-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KPOZEHOUEN EB, Heywood AE, Menzies R, Seale H, et al Informing the design of a whole of life immunisation register for Australia.
Vaccine. 2023;41:3011-3018. PubMedAbstract available
RODRIGUEZ DM, Major CG, Sanchez-Gonzalez L, Jones E, et al Dengue vaccine acceptability before and after the availability of COVID-19
vaccines in Puerto Rico.
Vaccine. 2023 May 5:S0264-410X(23)00516-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KU JH, Sy LS, Qian L, Ackerson BK, et al Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in
an immunocompromised population: A prospective observational cohort study.
Vaccine. 2023 May 3:S0264-410X(23)00498-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FUKUNAGA R, Kaplan ZE, Rodriguez T, Hagan L, et al Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal
Bureau of Prisons, June-July 2021.
Vaccine. 2023 May 2:S0264-410X(23)00512-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LEFFERTS B, Bruden D, Plumb ID, Hodges E, et al Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2
infections and hospitalizations in Southwestern Alaska, January-December 2021.
Vaccine. 2023 May 1:S0264-410X(23)00496-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MESINA FZ, Sapinoso FAD, De Castro JAV, Vaswani PPM, et al Hematologic adverse events reported after COVID-19 vaccination in the
Philippines: A national database study.
Vaccine. 2023 May 1:S0264-410X(23)00490-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HUSSAINI L, Labberton AS, Winje BA, Kraft KB, et al COVID-19 vaccination rates among adolescents (12-17 years) by immigrant
background and sociodemographic factors: A nationwide registry study in Norway.
Vaccine. 2023 May 1:S0264-410X(23)00514-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KUHLBRANDT C, McGowan CR, Stuart R, Grenfell P, et al COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A
qualitative study moving beyond "vaccine hesitancy".
Vaccine. 2023 May 1:S0264-410X(23)00515-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
April 2023
MARCHESE AM, Zhou X, Kinol J, Underwood E, et al NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the
PREVENT-19 phase 3, randomized, placebo-controlled trial.
Vaccine. 2023 Apr 29:S0264-410X(23)00467-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
VANNI T, da Graca Salomao M, Viscondi JYK, Braga PE, et al A randomized, double-blind, non-inferiority trial comparing the immunogenicity
and safety of two seasonal inactivated influenza vaccines in adults.
Vaccine. 2023 Apr 28:S0264-410X(23)00464-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KOEN AL, Izu A, Baillie V, Kwatra G, et al Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against
SARS-CoV-2 variants of concern: Final analysis of a randomized,
placebo-controlled, phase 1b/2 study in South African adults (COV005).
Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KIM C, Aminawung JA, Brinkley-Rubinstein L, Wang EA, et al COVID-19 vaccine deliberation in individuals directly impacted by incarceration.
Vaccine. 2023 Apr 26:S0264-410X(23)00492-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ALSUHEBANY N, Alowais SA, Aldairem A, Almohareb SN, et al Identifying gaps in vaccination perception after mandating the COVID-19 vaccine
in Saudi Arabia.
Vaccine. 2023 Apr 26:S0264-410X(23)00481-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LU X, Masuda S, Horlad H, Katoh T, et al Safety and adverse effects of the coronavirus disease 2019 vaccine among the
general Japanese adult population.
Vaccine. 2023 Apr 26:S0264-410X(23)00469-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KIM SJ, Kwon SL, Lee JY, Oh J, et al Why school is crucial to increase vaccination coverage for children: Evaluation
of school vaccination check program in South Korea 2021-2022.
Vaccine. 2023 Apr 25:S0264-410X(23)00430-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
JIANG M, Vaisanen E, Kolehmainen P, Huttunen M, et al COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory
responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
Vaccine. 2023 Apr 25:S0264-410X(23)00463-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WALTER D, Ophir Y, Ye H Conspiracies, misinformation and resistance to public health measures during
COVID-19 in white nationalist online communication.
Vaccine. 2023;41:2868-2877. PubMedAbstract available
TAMANDJOU C, Auvigne V, Schaeffer J, Vaux S, et al Effectiveness of second booster compared to first booster and protection
conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and
BA.4/5 in France.
Vaccine. 2023;41:2754-2760. PubMedAbstract available
MA L, Brecher M, Soufal A, Gaiotto T, et al Structural interrogation of a trimeric prefusion RSV fusion protein vaccine
candidate by a camelid nanobody.
Vaccine. 2023 Apr 19:S0264-410X(23)00413-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BAO Y, He L, Miao B, Zhong Z, et al BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous
Omicron infection: A retrospective observation study in Shanghai.
Vaccine. 2023 Apr 19:S0264-410X(23)00377-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PILLSBURY A, Phillips A, Deng L, Quinn H, et al Background incidence rates of selected adverse events of special interest (AESI)
to monitor the safety of COVID-19 vaccines.
Vaccine. 2023 Apr 18:S0264-410X(23)00441-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MAO Z, Li X, Dacosta-Urbieta A, Billard MN, et al Economic burden and health-related quality-of-life among infants with respiratory
syncytial virus infection: A multi-country prospective cohort study in Europe.
Vaccine. 2023;41:2707-2715. PubMedAbstract available
HOUTSMA C, Raines AM, Reggio A, Rushing LK, et al COVID-19 vaccine distribution: A high reliability organization approach.
Vaccine. 2023 Apr 17:S0264-410X(23)00423-1. doi: 10.1016/j.vaccine.2023. PubMed
GORDON SF, Lam J, Vasquez JT, Cercone R, et al A tailored COVID-19 vaccination pathway for children 5-11 years in Victoria,
Australia.
Vaccine. 2023 Apr 17:S0264-410X(23)00424-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Biela M, et al COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of
paediatric multisystem inflammatory syndrome temporally associated with COVID-19
(PIMS-TS).
Vaccine. 2023 Apr 14:S0264-410X(23)00427-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FREITAG TL, Fagerlund R, Karam NL, Leppanen VM, et al Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike
protein improves vaccine immunity in mouse models.
Vaccine. 2023 Apr 14:S0264-410X(23)00403-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ANDRAUD M, Herve S, Gorin S, Barbier N, et al Evaluation of early single dose vaccination on swine influenza A virus
transmission in piglets: From experimental data to mechanistic modelling.
Vaccine. 2023 Apr 13:S0264-410X(23)00401-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ESTEPHAN L, Lin YC, Lin YT, Chen YH, et al Safety and immunogenicity of homologous versus heterologous booster dose with
AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An
observer-blinded, multi-center, phase 2 randomized trial.
Vaccine. 2023 Apr 12:S0264-410X(23)00421-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
UEMURA K, Ono S, Michihata N, Yamana H, et al Duration of influenza vaccine effectiveness in the elderly in Japan: A
retrospective cohort study using large-scale population-based registry data.
Vaccine. 2023 Apr 10:S0264-410X(23)00373-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
RATHORE APS, St John AL Promises and challenges of mucosal COVID-19 vaccines.
Vaccine. 2023 Apr 10:S0264-410X(23)00396-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HARRIS C, Cottrell S, Perry M, Meaden R, et al A pilot intervention to improve uptake and equality of childhood influenza
vaccination in an area of Wales, through the introduction of a mixed delivery
model including nursery school immunisation sessions.
Vaccine. 2023 Apr 8:S0264-410X(23)00382-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LEIGH HOBBS J, Paul LA, Buchan SA, Harris T, et al Methodological changes implemented over time to support accurate and timely
COVID-19 vaccine coverage estimates: Ontario, Canada.
Vaccine. 2023 Apr 7:S0264-410X(23)00389-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HARRIS JN, Mauro CM, Morgan TL, de Roche A, et al Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages
5-17.
Vaccine. 2023 Apr 7:S0264-410X(23)00384-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ALMAHASIS SO, Fox B, Ha D, Qian J, et al Pharmacy-based immunization in rural USA during the COVID-19 pandemic: A survey
of community pharmacists from five southeastern states.
Vaccine. 2023;41:2503-2513. PubMedAbstract available
SMITS PD, Gratzl S, Simonov M, Nachimuthu SK, et al Risk of COVID-19 breakthrough infection and hospitalization in individuals with
comorbidities.
Vaccine. 2023;41:2447-2455. PubMedAbstract available
GOLD MS, Amarasinghe A, Greenhawt M, Kelso JM, et al Anaphylaxis: Revision of the Brighton collaboration case definition.
Vaccine. 2023;41:2605-2614. PubMedAbstract available
BURKHOLDER B, Wadood Z, Kassem AM, Ehrhardt D, et al The immediate impact of the COVID-19 pandemic on polio immunization and
surveillance activities.
Vaccine. 2023;41 Suppl 1:A2-A11. PubMedAbstract available
KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of
delaying outbreak response.
Vaccine. 2023;41 Suppl 1:A136-A141. PubMedAbstract available
KALKOWSKA DA, Voorman A, Pallansch MA, Wassilak SGF, et al The impact of disruptions caused by the COVID-19 pandemic on global polio
eradication.
Vaccine. 2023;41 Suppl 1:A12-A18. PubMedAbstract available
PAYNE JR, Bose S, Kubiak RW, Nolen LD, et al Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
Vaccine. 2023 Apr 5:S0264-410X(23)00380-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al Vaccine effectiveness against transmission of alpha, delta and omicron
SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
Vaccine. 2023 Apr 5:S0264-410X(23)00376-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KIM H, Cho HK, Kang YM, Sagong M, et al Protective efficacy of a bivalent H5 influenza vaccine candidate against both
clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF
chickens.
Vaccine. 2023 Apr 4:S0264-410X(23)00311-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PRADA E, Langbecker A, Catalan-Matamoros D Public discourse and debate about vaccines in the midst of the covid-19 pandemic:
A qualitative content analysis of Twitter.
Vaccine. 2023 Apr 4:S0264-410X(23)00375-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FRODLUND M, Nived P, Chatzidionysiou A, Sodergren A, et al The impact of immunomodulating treatment on the immunogenicity of COVID-19
vaccines in patients with immune-mediated inflammatory rheumatic diseases
compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
Vaccine. 2023 Apr 4:S0264-410X(23)00372-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
TOSHKOV D What accounts for the variation in COVID-19 vaccine hesitancy in Eastern,
Southern and Western Europe?
Vaccine. 2023 Apr 4:S0264-410X(23)00314-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ALI Y, Piche-Renaud PP, Karimi-Shahrbabak E, Farrar DS, et al Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine
for children: A cross-sectional survey in Ontario, Canada.
Vaccine. 2023 Apr 3:S0264-410X(23)00335-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
URQUIDI C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, et al The added effect of non-pharmaceutical interventions and lifestyle behaviors on
vaccine effectiveness against severe COVID-19 in Chile: A matched case-double
control study.
Vaccine. 2023 Apr 3:S0264-410X(23)00354-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MAQUILING A, Jeevakanthan A, Ho Mi Fane B The effect of vaccine mandate announcements on vaccine uptake in Canada: An
interrupted time series analysis.
Vaccine. 2023 Apr 3:S0264-410X(23)00334-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CRIADO MF, Kassa A, Bertran K, Kwon JH, et al Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high
pathogenicity avian influenza, infectious bursal disease, and Newcastle disease
viruses.
Vaccine. 2023 Apr 1:S0264-410X(23)00349-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al Lack of association between vaccination rates and excess mortality in Cyprus
during the COVID-19 pandemic.
Vaccine. 2023 Apr 1:S0264-410X(23)00316-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
March 2023
XU S, Zhang B, Yao J, Ruan W, et al A new H9 influenza virus mRNA vaccine elicits robust protective immunity against
infection.
Vaccine. 2023 Mar 31:S0264-410X(23)00343-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DATAR RS, Fette LM, Hinkelman AN, Hammershaimb EA, et al Factors associated with COVID-19 vaccination during June-October 2021: A
multi-site prospective study.
Vaccine. 2023 Mar 31:S0264-410X(23)00352-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HU Y, Wang Y, Shao T, Tang W, et al Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2
vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
Vaccine. 2023 Mar 30:S0264-410X(23)00350-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FUKUDA H, Maeda M, Murata F Development of a COVID-19 vaccine effectiveness and safety assessment system in
Japan: The VENUS study.
Vaccine. 2023 Mar 29:S0264-410X(23)00353-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SU WJ, Arnold Chan K, Chuang JH, Wang TA, et al Acute reactions after a homologous primary COVID-19 vaccination series: Analysis
of Taiwan V-Watch data.
Vaccine. 2023 Mar 28:S0264-410X(23)00336-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SANTI LAURINI G, Montanaro N, Broccoli M, Bonaldo G, et al Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS
database.
Vaccine. 2023 Mar 28:S0264-410X(23)00348-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GIDENGIL CA, Parker AM, Markowitz LE, Gedlinske AM, et al Health care provider knowledge around shared clinical decision-making regarding
HPV vaccination of adults aged 27-45 years in the United States.
Vaccine. 2023 Mar 27:S0264-410X(23)00186-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HU B, Yang W, Bouanchaud P, Chongo Y, et al Determinants of COVID-19 vaccine acceptance in Mozambique: The role of
institutional trust.
Vaccine. 2023 Mar 27:S0264-410X(23)00347-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KANG SW, Park H, Yeun Kim J, Bae JY, et al Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron
variant in regard to vaccination status: A prospective cohort study.
Vaccine. 2023 Mar 27:S0264-410X(23)00339-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CESUR F, Atasever Z, Ozoran Y Impact of vitamin D3 supplementation on COVID-19 vaccine response and
immunoglobulin G antibodies in deficient women: A randomized controlled trial.
Vaccine. 2023 Mar 27:S0264-410X(23)00341-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DUGOVICH AM, Cox TH, Weeda ER, Garner SS, et al First hepatitis B vaccine uptake in neonates prior to and during the COVID-19
pandemic.
Vaccine. 2023 Mar 27:S0264-410X(23)00333-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PANNUS P, Depickere S, Kemlin D, Georges D, et al Third dose of COVID-19 mRNA vaccine closes the gap in immune response between
naive nursing home residents and healthy adults.
Vaccine. 2023 Mar 27:S0264-410X(23)00340-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CIAPPONI A, Berrueta M, P K Parker E, Bardach A, et al Safety of COVID-19 vaccines during pregnancy: A systematic review and
meta-analysis.
Vaccine. 2023 Mar 27:S0264-410X(23)00332-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
VAN KESSEL R, Forman R, Milstein R, Mastylak A, et al Divergent COVID-19 vaccine policies: Policy mapping of ten European countries.
Vaccine. 2023 Mar 22:S0264-410X(23)00320-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
YANG J, Huo X, Jiang Q, Liao Y, et al Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero
cells) administration in macaques.
Vaccine. 2023 Mar 21:S0264-410X(23)00317-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PHOOLCHAROEN W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, et al Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant
plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
Vaccine. 2023 Mar 21:S0264-410X(23)00312-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SATO R Vaccine hesitancy against COVID-19 vaccine over time in Nigeria.
Vaccine. 2023 Mar 21:S0264-410X(23)00313-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ATMAR RL, Bernstein DI, Winokur P, Frey SE, et al Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal
quadrivalent inactivated influenza vaccine in young adults - A randomized
clinical trial.
Vaccine. 2023 Mar 18:S0264-410X(23)00285-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SHEN AK, Browne S, Srivastava T, Kornides ML, et al Trusted messengers and trusted messages: The role for community-based
organizations in promoting COVID-19 and routine immunizations.
Vaccine. 2023;41:1994-2002. PubMedAbstract available
PEREZ MA, Hsiao HM, Chen X, Kunkel A, et al Serologic responses to COVID-19 vaccination in children with history of
multisystem inflammatory syndrome (MIS-C).
Vaccine. 2023 Mar 15:S0264-410X(23)00283-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LIN JH, Huang YT, Yu JC, Chan KA, et al Mediation and instrumental variable analyses for vaccine-induced antibody titer
against influenza B.
Vaccine. 2023 Mar 14:S0264-410X(23)00261-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LAMUDA PA, Azar A, Taylor BG, Balawajder EF, et al Latent class analysis of medical mistrust and COVID-19 vaccine hesitancy among
adults in the United States just prior to FDA emergency use authorization.
Vaccine. 2023 Mar 13:S0264-410X(23)00263-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KELLY D, O'Donnell K, Marron L, Dwyer R, et al Immunocompromise among vaccinated versus unvaccinated COVID-19 cases admitted to
critical care in Ireland, July to October 2021.
Vaccine. 2023 Mar 13:S0264-410X(23)00258-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KWAK HW, Park HJ, Jung SY, Oh EY, et al Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently
induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
Vaccine. 2023;41:1892-1901. PubMedAbstract available
LIU YC, Munoz FM, Izurieta HS, Tamborska AA, et al Anosmia: Brighton Collaboration case definition and guidelines for data
collection, analysis, and presentation of immunization safety data.
Vaccine. 2023;41:1902-1910. PubMedAbstract available
SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al Prevalence of influenza-specific vaccination hesitancy among adults in the United
States, 2018.
Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SANCHEZ L, Nakama T, Nagai H, Matsuoka O, et al Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine
versus Standard-Dose vaccine in Japanese Adults >/= 60 years of age: Results from a
phase III, randomized clinical trial.
Vaccine. 2023 Mar 9:S0264-410X(23)00225-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PLUMB ID, Fette LM, Tjaden AH, Feldstein L, et al Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2
Infection, March-October, 2021.
Vaccine. 2023 Mar 9:S0264-410X(23)00253-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
IKEWAKI N, Kurosawa G, Levy GA, Preethy S, et al Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta
glucans as a safer strategy in management.
Vaccine. 2023 Mar 8:S0264-410X(23)00252-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HART RJ, Baumer-Mouradian S, Bone JN, Olson P, et al Factors associated with US caregivers' uptake of pediatric COVID-19 vaccine by
race and ethnicity.
Vaccine. 2023 Mar 6:S0264-410X(23)00242-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BAEK YJ, Kim WJ, Ko JH, Lee YJ, et al A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently
elicits neutralizing antibodies, but not memory T cells, than the homologous
BNT162b2 regimen.
Vaccine. 2023;41:1694-1702. PubMedAbstract available
GRIGNOLIO CORSINI A, Zagarella RM, Adamo M, Caporale C, et al From COVID-19 vaccine candidates to compulsory vaccination: The attitudes of
Italian citizens in the key 7-month of vaccination campaign.
Vaccine. 2023 Mar 3:S0264-410X(23)00243-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ESTEPHAN L, Liu LT, Lien CE, Smith ER, et al A Brighton Collaboration standardized template with key considerations for a
benefit/risk assessment for the Medigen COVID-19 protein vaccine.
Vaccine. 2023 Mar 3:S0264-410X(23)00245-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
XIE S, Monteiro K, Gjelsvik A The association between maternal influenza vaccination during pregnancy and
adverse birth outcomes in the United States: Pregnancy risk Assessment Monitoring
System (PRAMS).
Vaccine. 2023 Mar 2:S0264-410X(23)00228-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Olbromski MJ, et al COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among
children with a history of paediatric multisystem inflammatory syndrome
temporally associated with COVID-19 (PIMS-TS) - preliminary study.
Vaccine. 2023 Mar 2:S0264-410X(23)00227-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HURSTAK EE, Paasche-Orlow MK, Hahn EA, Henault LE, et al The mediating effect of health literacy on COVID-19 vaccine confidence among a
diverse sample of urban adults in Boston and Chicago.
Vaccine. 2023 Mar 2:S0264-410X(23)00202-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al Willingness to vaccinate children against COVID-19 declined during the pandemic.
Vaccine. 2023 Mar 2:S0264-410X(23)00223-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
NA L, Banks S, Wang PP Racial and ethnic disparities in COVID-19 vaccine uptake: A mediation framework.
Vaccine. 2023 Mar 1:S0264-410X(23)00241-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
February 2023
MALTEZOU HC, Hatziantoniou S, Theodoridou K, Vasileiou K, et al Anaphylaxis rates following mRNA COVID-19 vaccination in children and
adolescents: Analysis of data reported to EudraVigilance.
Vaccine. 2023 Feb 27:S0264-410X(23)00221-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
TAMANDJOU TCHUEM CR, Auvigne V, Vaux S, Montagnat C, et al Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines
against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults
aged 50 years and over in France.
Vaccine. 2023 Feb 27:S0264-410X(23)00216-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
O'KENNEDY MM, Abolnik C, Smith T, Motlou T, et al Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in
New Zealand white rabbits.
Vaccine. 2023 Feb 27:S0264-410X(23)00185-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ITAMOCHI M, Yazawa S, Inasaki N, Saga Y, et al Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19
mRNA vaccine in a Japanese nursing home cohort.
Vaccine. 2023 Feb 27:S0264-410X(23)00222-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GETANEH AM, Li X, Mao Z, Johannesen CK, et al Cost-effectiveness of monoclonal antibody and maternal immunization against
respiratory syncytial virus (RSV) in infants: Evaluation for six European
countries.
Vaccine. 2023;41:1623-1631. PubMedAbstract available
FEITSMA EA, Janssen YF, Boersma HH, van Sleen Y, et al A randomized phase I/II safety and immunogenicity study of the
Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
Vaccine. 2023 Feb 23:S0264-410X(23)00200-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al COVID-19 vaccine hesitancy among people living with HIV in a low-resource
setting: A multi-center study of prevalence, correlates and reasons.
Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CANNON K, Cardona JF, Yacisin K, Thompson A, et al Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine
coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
Vaccine. 2023 Feb 22:S0264-410X(22)01459-1. doi: 10.1016/j.vaccine.2022. PubMedAbstract available
MOORE KA, Leighton T, Ostrowsky JT, Anderson CJ, et al A research and development (R&D) roadmap for broadly protective coronavirus
vaccines: A pandemic preparedness strategy.
Vaccine. 2023 Feb 21:S0264-410X(23)00167-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ZHANG H, Chen L, Huang Z, Li D, et al The effects of parent's health literacy and health beliefs on vaccine hesitancy.
Vaccine. 2023 Feb 21:S0264-410X(23)00161-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HAMBURG M, Poland GA The time is now for committed and comprehensive action to attain more broadly
protective coronavirus vaccines: The coronavirus vaccines R&D roadmap.
Vaccine. 2023 Feb 21:S0264-410X(23)00196-2. doi: 10.1016/j.vaccine.2023. PubMed
MOTTA M, Callaghan T, Lunz-Trujillo K, Lockman A, et al Erroneous Consonance. How inaccurate beliefs about physician opinion influence
COVID-19 vaccine hesitancy.
Vaccine. 2023 Feb 20:S0264-410X(23)00195-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GEOGHEGAN S, Acosta F, Stephens LC, Gillan H, et al Maternity care provider acceptance of a future Group B Streptococcus vaccine - A
qualitative study in three countries.
Vaccine. 2023 Feb 18:S0264-410X(23)00172-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FORD A, Hwang A, Mo AX, Baqar S, et al Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DUDLEY MZ, Gerber JE, Budigan Ni H, Blunt M, et al Vaccinomics: A scoping review.
Vaccine. 2023 Feb 18:S0264-410X(23)00135-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
RANADE D, Jena R, Patil K, Dogar V, et al A novel high throughput plate-based method for 2-PE quantification in novel
multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines
(Hexavalent).
Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
PARODI A, Martini M History of vaccine and immunization: Vaccine-hesitancy discussion in Germany in
XIX century.
Vaccine. 2023 Feb 17:S0264-410X(23)00164-0. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MEYER C, Goffe L, Antonopoulou V, Graham F, et al Using the precaution adoption process model to understand decision-making about
the COVID-19 booster vaccine in England.
Vaccine. 2023 Feb 17:S0264-410X(23)00182-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MORAIS A, Morais J, Felix M, Neto Z, et al Genetic and epidemiological description of an outbreak of circulating
vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
Vaccine. 2023 Feb 17:S0264-410X(23)00170-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ZIMMERMANN BM, Paul KT, Araujo ER, Buyx A, et al The social and socio-political embeddedness of COVID-19 vaccination
decision-making: A five-country qualitative interview study from Europe.
Vaccine. 2023 Feb 16:S0264-410X(23)00139-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic
groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the
HELIUS study.
Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BARNES K, Faasse K, Colagiuri B The impact of side effect framing on COVID-19 booster vaccine intentions in an
Australian sample.
Vaccine. 2023 Feb 13:S0264-410X(23)00158-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SAELEE R, Chandra Murthy N, Patel Murthy B, Zell E, et al Minority Health Social Vulnerability Index and COVID-19 vaccination coverage -
The United States, December 14, 2020-January 31, 2022.
Vaccine. 2023 Feb 13:S0264-410X(23)00157-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WANKHEDE D, Grover S, Hofman P Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer
patients: A systematic review and meta-analysis.
Vaccine. 2023 Feb 13:S0264-410X(23)00115-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
AFREH OK, Angwaawie P, Attivor E, Boateng LA, et al Examining confidence and hesitancy towards COVID-19 vaccines: A cross-sectional
survey using in-person data collection in rural Ghana.
Vaccine. 2023 Feb 13:S0264-410X(23)00159-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DE VRIES M, Claassen L, Lambooij MS, Timen A, et al Did the temporary suspension of Vaxzveria vaccinations influence COVID-19
vaccination intentions, vaccination perceptions and trust in the vaccination
campaign? A repeated survey study in the Netherlands.
Vaccine. 2023 Feb 10:S0264-410X(23)00138-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HOSAIN R, Aquino P, Baccarini C, Smolenov I, et al Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit
vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
Vaccine. 2023 Feb 10:S0264-410X(23)00144-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SHEN AK, Browne S, Srivastava T, Kornides ML, et al Persuading the "Movable Middle": Characteristics of effective messages to promote
routine and COVID-19 vaccinations for adults and children - The impact of
COVID-19 on beliefs and attitudes.
Vaccine. 2023 Feb 9:S0264-410X(23)00141-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
SILVA VASCONCELOS G, da Conceicao Rodrigues Fernandes M, Cardoso Matsui T, Claudia Dos Santos Luciano M, et al Persistent SARS-COV-2 infection in vaccinated individual with three doses of
COVID-19 vaccine.
Vaccine. 2023 Feb 9:S0264-410X(23)00145-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BUNTINX E, Brochado L, Borja-Tabora C, Yu CY, et al Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine
(SCB-2019) in SARS-CoV-2-naive and exposed individuals in a phase 2/3,
double-blind, randomized study.
Vaccine. 2023 Feb 9:S0264-410X(23)00143-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FEIKIN DR, Higdon MM, Andrews N, Collie S, et al Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from
a meeting of the World Health Organization.
Vaccine. 2023 Feb 9:S0264-410X(23)00146-9. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BUGHIN J, Cincera M, Peters K, Reykowska D, et al Make it or break it: On-time vaccination intent at the time of Covid-19.
Vaccine. 2023 Feb 8:S0264-410X(23)00140-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
WATANABE A, Iwagami M, Yasuhara J, Takagi H, et al Protective effect of COVID-19 vaccination against long COVID syndrome: A
systematic review and meta-analysis.
Vaccine. 2023 Feb 8:S0264-410X(23)00134-2. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FELL DB, Torok E, Sprague AE, Regan AK, et al Temporal trends and determinants of COVID-19 vaccine coverage and series
initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: A
population-based retrospective cohort study.
Vaccine. 2023 Feb 3:S0264-410X(23)00114-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HASSAN RAZA S, Yousaf M, Zaman U, Waheed Khan S, et al Unlocking infodemics and mysteries in COVID-19 vaccine hesitancy: Nexus of
conspiracy beliefs, digital informational support, psychological Well-being, and
religious fatalism.
Vaccine. 2023 Feb 3:S0264-410X(23)00079-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LI R, Liu H, Fairley CK, Ong JJ, et al mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in
Australia.
Vaccine. 2023 Feb 3:S0264-410X(23)00126-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MALTEZOU HC, Basoulis D, Bonelis K, Gamaletsou MN, et al Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and
work absenteeism in hospitalized patients with COVID-19 during the Delta and
Omicron waves in Greece.
Vaccine. 2023 Feb 2:S0264-410X(23)00109-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HAMADA H, Futamura M, Ito H, Yamamoto R, et al Association of a third vaccination with antibody levels and side reactions in
essential workers: A prospective cohort study.
Vaccine. 2023 Feb 1:S0264-410X(23)00082-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
JOHNSON R, Djaafara B, Haw D, Doohan P, et al The societal value of SARS-CoV-2 booster vaccination in Indonesia.
Vaccine. 2023 Feb 1:S0264-410X(23)00110-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
ANDREJKO KL, Myers JF, Fukui N, Nelson L, et al Real-world uptake of COVID-19 vaccination among individuals expressing vaccine
hesitancy: A registry-linkage study.
Vaccine. 2023 Feb 1:S0264-410X(23)00108-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
January 2023
UWAMINO Y, Yokoyama T, Sato Y, Shibata A, et al Humoral and cellular immune response dynamics in Japanese healthcare workers up
to six months after receiving a third dose of BNT162b2 monovalent vaccine.
Vaccine. 2023 Jan 31:S0264-410X(23)00081-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GRESSENS SB, Wiedemann A, Dechenaud M, Dupuis J, et al Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in
lymphoma patients receiving anti-CD20 antibodies.
Vaccine. 2023 Jan 30:S0264-410X(23)00095-6. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HARBIN A, Laventhal N, Navin M Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of
COVID-19.
Vaccine. 2023 Jan 27:S0264-410X(23)00087-7. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GROSSMAN-GIRON A, Tzur Bitan D, Shemesh S, Mayer Y, et al COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine
uptake in Israel.
Vaccine. 2023 Jan 23:S0264-410X(23)00065-8. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
MALLAH SI, Alawadhi A, Jawad J, Wasif P, et al Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV
versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
Vaccine. 2023 Jan 23:S0264-410X(23)00053-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al Predictors of COVID-19 vaccine uptake among people who inject drugs.
Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
KALRA S, Kalra D, Grafova I, Rubin JS, et al Association of death or illness from COVID-19 among family and friends on vaccine
uptake within four months of the Emergency Use Authorization. Findings from a
national survey in the United States.
Vaccine. 2023 Jan 13:S0264-410X(23)00035-X. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
TSUCHIYA Y, Tamura H, Fujii K, Numaguchi H, et al Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1,
randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.
Vaccine. 2023 Jan 5:S0264-410X(23)00006-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
FORD JS, Rouleau SG, Wagner JL, Adams CB, et al Assessment of a COVID-19 vaccination protocol for unhoused patients in the
emergency department.
Vaccine. 2023 Jan 2:S0264-410X(22)01598-5. doi: 10.1016/j.vaccine.2022. PubMedAbstract available
December 2022
SONOYAMA T, Iwata S, Shinkai M, Iwata-Yoshikawa N, et al Results from a preclinical study in rodents and a Phase 1/2, randomized,
double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine
S-268019-a in Japanese adults.
Vaccine. 2022 Dec 16:S0264-410X(22)01540-7. doi: 10.1016/j.vaccine.2022. PubMedAbstract available
OLAYINKA F, Sauer M, Menning L, Summers D, et al Building and sustaining public and political commitment to the value of
vaccination: Recommendations for the Immunization Agenda 2030 (Strategic Priority
Area 2).
Vaccine. 2022 Dec 15:S0264-410X(22)01451-7. doi: 10.1016/j.vaccine.2022. PubMedAbstract available
SALVATORE PP, Lee CC, Sleweon S, McCormick DW, et al Transmission potential of vaccinated and unvaccinated persons infected with the
SARS-CoV-2 Delta variant in a federal prison, July-August 2021.
Vaccine. 2022 Dec 13:S0264-410X(22)01458-X. doi: 10.1016/j.vaccine.2022. PubMedAbstract available
HALL PA, Meng G, Boudreau C, Hudson A, et al Social cognitive predictors of vaccination status, uptake and mitigation
behaviors in the Canadian COVID-19 Experiences survey.
Vaccine. 2022 Dec 12:S0264-410X(22)01526-2. doi: 10.1016/j.vaccine.2022. PubMedAbstract available
WALLACE AS, Ryman TK, Privor-Dumm L, Morgan C, et al Leaving no one behind: Defining and implementing an integrated life course
approach to vaccination across the next decade as part of the immunization Agenda
2030.
Vaccine. 2022 Dec 8:S0264-410X(22)01452-9. doi: 10.1016/j.vaccine.2022. PubMedAbstract available
November 2022
MCCORMICK DW, Hagan LM, Salvatore PP, Magleby R, et al SARS-CoV-2 viral shedding in vaccinated and unvaccinated persons: A case series.
Vaccine. 2022 Nov 18:S0264-410X(22)01428-1. doi: 10.1016/j.vaccine.2022. PubMedAbstract available
October 2022
HALL PA, Meng G, Sakib MN, Quah ACK, et al Do the vaccinated perform less distancing, mask wearing and hand hygiene? A test
of the risk compensation hypothesis in a representative sample during the
COVID-19 pandemic.
Vaccine. 2022 Oct 20. pii: S0264-410X(22)01289. PubMedAbstract available
HUDSON A, Hall PA, Hitchman SC, Meng G, et al Cognitive predictors of COVID-19 mitigation behaviors in vaccinated and
unvaccinated general population members.
Vaccine. 2022 Oct 13. pii: S0264-410X(22)01242. PubMedAbstract available
March 2022
SNIDER CJ, Boualam L, Tallis G, Takashima Y, et al Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2
affecting the Republic of the Philippines and Malaysia, 2019-2021.
Vaccine. 2022 Mar 22. pii: S0264-410X(22)00145. PubMedAbstract available
October 2021
BOZORGI A, Fahimnia B Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A
cost/benefit analysis.
Vaccine. 2021;39:6166-6173. PubMedAbstract available
BOZORGI A, Fahimnia B Transforming the vaccine supply chain in Australia: Opportunities and challenges.
Vaccine. 2021;39:6157-6165. PubMedAbstract available
September 2021
MOLODECKY NA, Jafari H, Safdar RM, Ahmed JA, et al Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in
Pakistan and Afghanistan to inform outbreak control strategies in the context of
the COVID-19 pandemic.
Vaccine. 2021 Sep 25. pii: S0264-410X(21)01228. PubMedAbstract available
LIU D, Leung K, Jit M, Wu JT, et al Cost-effectiveness of strategies for preventing paediatric lower respiratory
infections associated with respiratory syncytial virus in eight Chinese cities.
Vaccine. 2021;39:5490-5498. PubMedAbstract available
KOHL-HECKL WK, Schroter M, Dobos G, Cramer H, et al Complementary medicine use and flu vaccination - A nationally representative
survey of US adults.
Vaccine. 2021;39:5635-5640. PubMedAbstract available